Improving Hadron Therapy: Design of the Beam Transport System for a Biomedical Research Facility and PET Isotope Production by Amin, Tanjilul
University of Huddersfield Repository
Amin, Tanjilul
Improving Hadron Therapy: Design of the Beam Transport System for a Biomedical Research 
Facility and PET Isotope Production
Original Citation
Amin, Tanjilul (2019) Improving Hadron Therapy: Design of the Beam Transport System for a 
Biomedical Research Facility and PET Isotope Production. Doctoral thesis, University of 
Huddersfield. 
This version is available at http://eprints.hud.ac.uk/id/eprint/34882/
The University Repository is a digital collection of the research output of the
University, available on Open Access. Copyright and Moral Rights for the items
on this site are retained by the individual author and/or other copyright owners.
Users may access full items free of charge; copies of full text items generally
can be reproduced, displayed or performed and given to third parties in any
format or medium for personal research or study, educational or not­for­profit
purposes without prior permission or charge, provided:
• The authors, title and full bibliographic details is credited in any copy;
• A hyperlink and/or URL is included for the original metadata page; and
• The content is not changed in any way.
For more information, including our policy and submission procedure, please
contact the Repository Team at: E.mailbox@hud.ac.uk.
http://eprints.hud.ac.uk/
Improving Hadron Therapy: Design of
the Beam Transport System for a
Biomedical Research Facility and PET
Isotope Production
Tanjilul Amin
International Institute for Accelerator Applications
The University of Huddersfield
This dissertation is submitted for the degree of
Doctor of Philosophy
The University of Huddersfield in collaboration with CERN and TRIUMF
January 2019

To my mother for her ongoing support and to my father who could not see this thesis
completed.

Declaration
I hereby declare that except where specific reference is made to the work of others, the
contents of this dissertation are original and have not been submitted in whole or in part
for consideration for any other degree or qualification in this, or any other University. This
dissertation is the result of my own work, and the outcome of work done in collaboration
is indicated in the text. This dissertation contains fewer than 65,000 words including
appendices, bibliography, footnotes, tables and equations and has fewer than 150 figures.
Tanjilul Amin
January 2019

Acknowledgements
I would like to thank my supervisor Prof. Roger Barlow for his guidance during the last few
years. He has granted me the freedom to choose my own topics for research and introduced
me to R which accelerated my work flow. I would also like to acknowledge the IIAA
and the University of Huddersfield for providing funding towards this work, without which
this work would not have been possible. I have been very privileged in being part of the
EPSRC Centre for Doctoral Training in Applications of Next Generation Accelerators. It
has provided opportunities to meet many talented researchers in diverse training programs
thus giving me a broad perspective on hadron therapy.
A large number of in-depth discussions contributed to this work. I wish to thank Daniel
Abler for patiently answering all my questions throughout the years, Ghislain Roy for his
assistance with the LEIR lattice in MAD-X, Manjit Dosanjh and Silvia Schuh-Erhard for
numerous discussions on BioLEIR.
I would also like to thank Prof. Cornelia Hoehr for her supervision and introduction
to the proton therapy facility as well as the TR13 cyclotron at TRIUMF. Her hands-on
approach, even from the other side of the globe, sped up the research carried out and allowed
me to dodge problems that are typical with postgraduate research. I would like to thank
Clay Lindsay for his PT simulations and countless hours of assistance with WestGrid, and
Angelo Infantino for discussions on simulating the TR13 cyclotron. For their assistance
with Geant4 on many occasions, I would like to thank Cristian Bungau, John Allison and
Vladimir Ivanchenko.
I also wish to thank Bruce Mehrdadi for helping me discover my passion for coding
many years ago. Our therapeutic talks have always motivated me to work harder and acted
as the final push towards the completion of this journey. From the IIAA, my thanks goes
to Prof. Robert Cywinski, for his advice on applying for the Research Development Fund
which enabled me to travel to Vancouver, and Prof. Rebecca Seviour, for her advice on how
viii
to survive the competitive world of postgraduate research.
Finally, I wish to acknowledge the friendship of my house mates. During the past 4.5
years we have shared many stories and musical sessions which I will always cherish. Last
but not least, my whole hearted thanks goes to my wife, Kashfah Khan Chowdhury, for her
unlimited patience, love and support during our difficult times.
Abstract
Recently there have been great advancements in the development of hadron therapy (HT)
in Europe to treat cancer with external beam therapy. However, the relative superiority and
especially cost effectiveness of HT over existing photon based forms of therapy have not yet
been generally proven. Furthermore, the biological effect of particle radiation is a major
source of uncertainty in HT. As a result there is a strong interest from the biomedical research
community to have more access to clinically relevant beams. Unfortunately, beamtime
for pre-clinical studies is currently very limited and a new dedicated facility would allow
extensive research into the radiobiological mechanisms of ion beam radiation. A very
important tool in treatment planning in HT are Monte-Carlo simulations. These can also
be used as a tool to improve beam delivery and explore dose deposition verification, one
of the uncertainties in HT. This basic research would support the current clinical efforts of
the new treatment centres in Europe (for example HIT in Heidelberg, CNAO in Pavia, and
MedAustron in Vienna).
This thesis presents three research projects. The first part presents a feasibility study
of an experimental biomedical facility based on the CERN Low Energy Ion Ring (LEIR)
accelerator and suggests possible optics improvements to that design using MAD-X. This
new facility would use CERN’s existing infrastructure and thus provide ion beams (from
protons to neon ions) in a cost effective way with the aim of establishing an accessible
facility to establish the development and implementation of best treatment practices. A
slow extraction scheme has been proposed for extracting ions from LEIR into the designed
experimental beamline that separates into two horizontal beamlines suitable for clinical
beam energies and a low-energy vertical beamline for radiobiological experiments. The first
horizontal beamline and the vertical beamline are intended for biomedical experiments on
cells and the second horizontal beamline is reserved for phantom work, (micro-)dosimetry
and detector development.
xThe second part of the thesis utilizes the Monte-Carlo package Geant4 to explore the
production of radioisotopes during proton bombardment in a phantom or patient at a proton
therapy facility. The possibility of depth dose verification during proton therapy at the
TRIUMF proton therapy centre treating ocular melanomas was explored. Currently, work
has been done at TRIUMF to simulate the interactions of particle beams with a phantoms,
using the Monte Carlo particle transport and interaction code FLUKA. However, due to the
lack of reliable cross-section data for the relevant therapeutic energy range, there are great
uncertainties about the isotope production, and consequently the axial isotope activity profile
inside the phantom. Simulation programs Geant4 and FLUKA are being used to validate
data from PET scans thus improving patient care through validation after each treatment
fraction.
This technique has also been utilized in the third and final part of the thesis. It explores
the production of PET isotopes on the TR13 cyclotron, a medical cyclotron at TRIUMF.
Again, both Geant4 and FLUKA are used to compare to experimental yield measurements
and to validate the Monte-Carlo simulations at these low proton energies.
Preface
The preface of this thesis summarizes and explains the contents of the papers published or
submitted as well as mentioning the contributions of the co-authors in the papers.
• T.Amin, R. Barlow, S.Ghithan, G.Roy and S. Schuh,Formation of a uniform ion beam
using octupole magnets for BioLEIR facility at CERN, Journal of Instrumentation,
vol. 13, no. 04, p. 04016, 2018.
This paper mentions the preliminary beamline optics design for generating a pencil
beam and a homogeneous broad beam in the horizontal beamline (H1) for a potential
biomedical research facility at CERN. The beamline optics were simulated using
MAD-X and PTC, the data analysis was done using Pyaccel and R by T. Amin.
Calculations on dipole and octupole strengths were carried out by S. Ghithan and
hence are not mentioned in the thesis. This project was supervised by R. Barlow and
G. Roy. Useful discussions were had with S. Schuh. Further details are mentioned in
the opening paragraph of Chapter 2.
• T. Amin, A. Infantino, C. Lindsay, R. Barlow and C. Hoehr,Modelling PET radionu-
clide production in tissue and external targets using Geant4, Journal of Physics:
Conference Series, vol. 874, no. 1, p. 012109, 2017.
This paper mentions the finalized results about PET radionuclides produced in tissue
during proton therapy. It also mentions the preliminary findings of PET isotopes
produced using TR13, a small medical cyclotron at TRIUMF. Comparisons have been
made between Monte Carlo codes Geant4 and FLUKAwere compared to experiments
carried out at TRIUMF. All Geant4 simulations and data analysis using Rwere carried
out by T. Amin. All results obtained using FLUKA was contributed by C. Lindsay
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and A. Infantino. This project was supervised by R. Barlow and C. Hoehr. Further
details are mentioned in the opening paragraph of Chapter 3.
• T. Amin, A. Infantino, R. Barlow, C. Hoehr, Validating Production of PET Radionu-
clides in Solid and Liquid Targets: Comparing Geant4 predictions with FLUKA and
Measurements, Applied Radiation and Isotopes, vol. 133, p. 61– 67, 2018.
This paper expands on the TR13 work presented in the second paper and presents
the final set of results. This project was supervised by R. Barlow and C. Hoehr. All
Geant4 simulations and data analysis using R were done by T. Amin. T. Amin found
that Geant4 was able to better calculate the production yield of radio isotopes than
FLUKA for most isotopes investigated. Further details are mentioned in the opening
paragraph of Chapter 4.
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Chapter 1
Introduction
This chapter provides the background for the rest of the thesis. After an introduction into
hadron therapy (HT) and its current situation/advantages over radiotherapy in Section 1.1,
Section 1.2 discusses the challenges of HT and how some of them are addressed in this
thesis.
1.1. Hadron Therapy
Hadron Therapy (HT) is a form of radiation therapy using beams of hadrons to kill cancer
cells. The use of hadrons for radiation therapy was first suggested by Robert Wilson in
1946 [1]. At that time accelerators were not capable of producing heavier charged particle
beams to energies sufficient for medical applications. Such energies became possible with
the development of the 184 inch cyclotron at the Lawrence Berkeley Laboratory and allowed
radio-biological investigation. In 1954, the first patient was treated with proton beams,
followed by helium ions in 1957. Figure 1.1 illustrates the history of HT in greater depth. It
summarizes from the very first proposal for HT to the very first patients being treated in the
various countries such as US, Japan and EU and the ions used.
1.1.1. Cancer
Cancer is the term used for diseases in which cell division occurs uncontrollably and are
able to invade other tissues. They may form tumours, invade nearby organs and spread to
other parts of the body through the blood and lymphatic systems forming secondary cancer
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Fig. 1.1 The evolution of HT over the last century [2, 3].
metastases.
Cancer is responsible for 25% of all deaths in Europe and it is the largest cause of
death of people aged between 45-64. In 2018, the most frequent cases of cancer were
colorectal (13.6%), breast (13.1%), lung (12.2%) and prostate cancers (11.9%) [4, 5]. 5%
of all mortality and 20% of all deaths from cancer are caused by lung cancer. It has been
estimated that over 45% of all cancer patients can be treated successfully [6]. With improved
health conditions and an overall increasing life expectancy, deaths from cancer in the EU
are expected to rise from 7.8 million in 2008 [7] to over 13 million per year by 2030 [8].
Radiation therapy is used in approximately 50% of the curative cases. In about 60% of
those cases, solely radiation therapy was used, the remaining cases were a combination of
radiation therapy with surgery and chemotherapy. Cancer imposes a great economic cost.
Accounting for not only the healthcare system but also factors such as productivity losses
through time off work and mortality and relatives foregoing work to care for cancer patients
costs the European Union 124 billion euros each year [9].
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1.1.2. Photon based Radiation Therapy vs. Hadron Therapy
Radiation therapy uses ionizing radiation to kill tumour cells. This biological effect results
from a series of physical, physio-chemical and finally biological mechanisms that are trig-
gered from the energy deposited as the radiation penetrates through the body. The absorbed
dose, measured in Gray (Gy) corresponds to the deposition of amount of energy [Joule (J)],
per unit mass of medium [kg]. The equivalent dose, in Sievert (Sv), is equal to the absorbed
dose times a weighting factor 1 [10]. Ionizing radiation affects both healthy cells and tu-
mours. The relative damage to the tumour tissue compared to the damage in nearby healthy
tissue is known as a therapeutic ratio. All improvements in radiation therapy are aimed at
improving the therapeutic ratio i.e. achieve high tumour control with low probability for
normal tissue complication. The two main treatment techniques followed are:
(a) optimization of beam paths through critical anatomical structures, minimizing the dose
to healthy tissue.
(b) splitting the total required dose (usually 60 Gy) for tumour eradication into multiple
smaller dose fractions (2 Gy), delivered over several days or weeks [11].
The second option, fractionation, utilizes differences in cell cycles and damage repair
mechanisms between tumour and healthy cells. Thismaymake tumour cellsmore susceptible
to radiation damage. However, in clinical practice, normal tissue complication limits the
maximum dose prescribed.
1.1.2.1. Physical Dose Distribution
To optimize the therapeutic ratio, the depth-dose relationship has to be considered. Figure 1.2
shows the relative dose deposited by different kinds of radiation as a function of penetration
depth into human tissue. Radiation therapies are based on high energy photons produced
using a LINAC between energy levels of 6 MV to 20 MV [12]. Within this energy range,
the most dominating energy transfer mechanism between photons and tissue is Compton
scattering. The number of scattered electrons decreases exponentially with depth, this
results in a decreasing dose with depth as illustrated with the black line in Figure 1.2. A
1The weighting factor is a dimensionless factor dependent on the absorbed radiation type.
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significant portion of the dose is absorbed by the healthy tissue both before and after the
tumour. This is true irrespective of the location of the tumour.
The blue curves illustrate the dose-depth relationship for charged hadrons at different
energy levels. These particles interact with the orbital electrons of the atoms in the tissue
through the Coulomb force via inelastic scattering. Energy is transferred to the electrons
and the velocity of incident particles decreases. The amount of energy lost per distance
travelled is approximately inversely proportional to the square of the particles’ velocity. As
the particles slow down, towards the end of their range in medium, the energy loss increases.
The resulting shape is called a Bragg Peak, the penetration depth of this peak increases
with particle energy. The interaction of protons with matter is discussed in greater depth in
Section 3.3.1.
Fig. 1.2 The dose deposition at different depths of a photon beam (black), a single Bragg peak (blue) and a
spread-out Bragg peak (SOBP) (red) formed from multiple Bragg Peaks.It illustrates the greater absence of
dose from protons over photons after the tumour [13].
Irradiating a tumour volume with particles of multiple energies corresponding to the
superposition of multiple Bragg Peaks allows the full volume of a tumour to be covered with
high ionization density [1]. The superposition of multiple Bragg Peaks results in a spread-
out Bragg Peak (SOBP) which is illustrated by the red line in Figure 1.2. This illustrates that
in contrast with photons, ions have the advantage to stop at a given depth and to deliver a
maximum dose in the distal part, called the Bragg-peak, where the tumour is located. Figure
1.3 illustrates this is more clearly. The figure presents a patient scenario where the patient has
a tumour in the central nervous system. Using photon therapy, exposure of healthy tissues to
exit dose is unavoidable. Such unwanted exposure to radiation leads to long term radiation
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effects such as bone deformities, heart or lung damage and even secondary malignancies.
Fig. 1.3 A dosimetric comparison of photon (center) and proton treatment (left) plans for a patient treated with
craniospinal radiation and the excess dose from photon treatment shown on the right [14].
On the other hand, with proton therapy it is possible to deliver the required dose to the
spine, sparing healthy tissue and organs. Studies with prototypical patients have found that
the percentage of the heart receiving at least 10 Gy (RBE) was 65% with photons and 0%
with protons [15]. Moreover, high-LET2 ions have enhanced radio-biological properties,
which allow the treatment of radio resistant tumours. More details about the LET concept
are discussed in Section 1.1.2.2.
1.1.2.2. Relative Biological Effect
The Radio-biological Effectiveness (RBE) measures the molecular damage caused to bio-
logical cells. It is defined as the ratio between a reference and a test radiation required to
achieve the same biological effect under identical conditions. Predominantly, 60Co γ rays
are taken as the reference radiation. RBE depends on type of radiation, the energy, dose,
dose rate, number of fractions, the biological system and the endpoint3 [6].
The energy absorbed per unit length, also known as the Linear Energy Transfer (LET),
provides a measure for quality of radiation. High LET radiation such as heavy charged
2LET stands for Linear Energy Transfer
3An observed or measured outcome in a clinical trial to indicate or reflect the effect of the treatment being tested. A clinical endpoint
is when a particular disease, sign or symptom is reached, such as cell survival or DNA damage.
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particles or slow protons, cause a high proportion of irreparable DNA damage. On the
other hand, low-LET radiation such as photons or fast protons, induces DNA damage as
a mainly secondary effect resulting from the creation of OH and radicals. Therefore the
effectiveness of low-LET radiation can be increased by the partial presence of oxygen in the
tissue. Oxygen deficient or hypoxic tumours are thus less sensitive to low-LET radiation,
leading to a low therapeutic ratio [16].
1.1.3. Rationale For Hadron therapy
The use of charged ions rather than photons allows the dose to the surrounding tissues to be
reduced by factors of 2-10 [17]. It has also been demonstrated that compared to Intensity
Modulated Radiotherapy (IMRT), proton therapy deposits 50% less energy in healthy tissue
[18]. High LET particles such as carbon ions produce a higher Bragg peak within the tumour
in comparison to the entrance dose and also allow the treatment of tumours that are resistant
to low-LET photons and protons. The superiority of protons has been proven for the case
of small children at late toxicities. For pediatric tumours, photons tend to have an overall
greater total body exposure which leads to a greater risk of radiation induced secondary
cancers [19]. Survival rate improvement has been recently demonstrated by the National
Institute of Radiological Science (NIRS) in Japan. As of March 2013, nearly 8000 patients
with various solid tumours had been treated. The study is based on greater than 6000 patients
treated between 1994 and August 2011 using carbon ions [20].
Treatment comparisons made in this section are for the most frequently treated cancers:
Head and Neck, Bone and Soft Tissue and Prostate. Figure 1.4 illustrates that carbon ion
therapy has been more effective, it has lower rates of local recurrence than X-ray or surgery
and the overall survival is comparable to surgery. In the NIRS subgroup the tumour size was
limited to 100 ml and carbon ion treatment gave a better survival rate. Hadron therapy, (in
this case carbon ions), was a safe and effective treatment for mucosal malignant melanoma4
of the head and neck in terms of high local control and acceptable toxicities. Next, treatments
for chordomas of bone and tissue are compared. Medically inoperable sacral chordomas5
are thought of as incurable. Therefore the 5-year survival of 86% achieved at NIRS is the
best outcome compared to alternatives presented in Figure 1.5. Only patients not responsive
4A melanoma is a type of cancer that develops from the pigment-containing cells known as melanocytes. Melanomas may occur in
the skin, eye or other areas [21].
5A chordoma is a type of bone cancer that usually starts in the lower spinal column or at the base of the skull [21].
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to surgery or with inoperable tumours were involved in the study and the use of HT resulted
in better local control than surgery alone, and the best option proved to be treatment with
carbon ions exclusively.
Skull Base Chordoma treatment results are shown in Figure 1.6. Treatment with protons,
combined with or without photons, had better local control rates than photon only treatments.
Data from heavier particles, carbon at the Gesellschaft fur Schwerionenforschung (GSI) and
helium from Lawrence Berkeley National Laboratory (LBNL) both show similar or better
control than X-ray only treatments. The data contains two groups from NIRS, the first group
includes a dose escalation phase from 63% to 83% of the normalized dose, and the subgroup
dose was 83% (60.8 GyE). This can be an indication that optimized dose delivery is essential
for tumour control. The results for Prostate cancer are shown in Figure 1.7. In this case
protons had better results from 3-D CRT (conformal radiotherapy) in terms of morbidity and
had comparable success rate to IMRT, but carbon ions proved to be most effective in terms
of lowest morbidity rate, lowest dose required and highest rate for no biochemical evidence
of disease (bNED).
Fig. 1.4 Local recurrence and overall survival comparison for different Mucosal Malignant Melanoma treat-
ments. Comparisons are made using data from ILO (Inst. of Laryngology and Otology) [22], MSKCC
(Memorial Sloan-Kettering Cancer Center) [23], MDACC (M. D. Anderson Cancer Center) [24], NJRTOG
(Northern Japan Radiation Therapy Oncology Group) [25], Christie (Christie Hospital, UK) [26] and NIRS
[27].
In summary, even though the results have been greatly simplified, the data presented in
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Fig. 1.5 Local recurrence and overall survival comparison for Chordoma of Bone and Tissue. Data has
been obtained from Mayo (Mayo Clinic, Minnesota) [28], Sweden (Univ. Hosp. Goeteborg) [29], MGH
(Massachusetts General Hospital) [30], LBL (Lawrence Berkeley National Laboratory) [31] and NIRS [32].
* This group contains a dose escalation phase, average value shown on plot.
Fig. 1.6 Chordoma in the skull base and paracervical Spine therapy comparison. Dose normalized to 73 GyE.
Data has been obtained from the Princess Margaret Hospital and The UofT (CA) [33], Mayo Clinic (FO) [34],
The Florence Radiotherapy Department (MA) [35], Puerta de Hierro Hospital (RO) [36], MGH [37], Centre
de Protonthérapie d’Orsay (CPO) [38], Tsukuba [39], PSI (Paul Scherrer Institut) [40], LBL [41] and GSI [42].
When a source has been cited multiple times, the year of publication has been mentioned.
Figures 1.4 - 1.76 has shown that HT using protons and carbon ions can significantly improve
patient outcomes for specific tumours. HT has a dose sparing effect compared to photon
6 Further information about each of the cases can be found in the individual references provided in the figure captions.
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Fig. 1.7 Prostate tumour radiation therapy comparison with dose normalized to 76 GyE. Data has been obtained
from M. D. Anderson (MDACC) [43], Fox Chase Cancer Centre [44], Cleveland [45], Loma Linda University
Medical Center (LLUMC) [46, 47] and NIRS [48].
treatments, and reduces late side effects such as secondary cancers or deterioration of organ
function. The high LET characteristics of carbon ions lead to higher RBE in the cancers
allowing the treatment of tumours resistant to low-LET radiations. Research over the past
20 years has made it possible to reduce the cost of and increase the reliability of HT systems
[20]. In Europe, HT could benefit approximately 13.5-16% of all radiotherapy patients [49],
on the other hand a separate study by the NHS has estimated the number to be 1% for the
UK [50–52]. Despite the benefits of HT it is limited in terms of higher entrance dose (refer
to Figure 1.2), range uncertainties and a variable RBE. The next section discusses some of
the challenges of HT into greater depth.
1.2. Challenges of Hadron Therapy
Currently hadron therapy is a growing market in numerous countries such as China, the
Netherlands and the UK with multiple centres currently under commission in 2018. Despite
the growth there are numerous areas of cancer therapy that require more research to improve
patient care. This thesis investigates three main areas: (i) the need for a dedicated facility
to better understand the biological effect of different ions on human cells, (ii) dose depth
verification of proton therapy for ocular melanoma and finally (iii) the feasibility of using
Monte Carlo techniques to calculate yields of radionuclides used mainly for diagnostic PET
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imaging.
The first topic discusses the need for a dedicated research facility for radiobiology of
charged particle beams. Chapter 2 presents the feasibility design study of a biomedical
research facility at the European Organization for Nuclear Research (CERN). Currently
certain aspects of HT are well-understood, such beam beam production, acceleration and
delivery. However the optimization of treatment still remains a major challenge as further
research is needed to understand the complex mechanism of DNA damage and repair. The
most popular charged particle used in therapy is protons, followed by carbon ions. However,
there is increasing interest for using other ions in clinical treatments. In the past patients have
been treated with helium ions, and even pions [53]. The use of ions heavier than protons
but lighter than carbon is motivated by lesser lateral spreading of the beam inside the target,
higher RBE in the Bragg Peak and lower RBE at the entrance compared to protons and a
more rapid fall-off of the distal edge of the Bragg Peak. Despite the experience with carbon
ion treatment, inaccuracy in the estimates of RBE still represents the main source of dose
uncertainty in therapy [54]. Most RBE estimates for lighter ions date back to radiobiological
experiments performed in the early years of HT. Also systematic studies of RBE for different
cell lines, radiation types and energies, further in-vitro and in-vivo radiobiological research
are needed [54]. Probably the most important challenge for HT at the moment lies in
the identification of clinical situations in which its theoretical advantages translate into
improved clinical outcomes compared to other treatment strategies. The adaptation of the
LEIR synchrotron at CERN to deliver clinical beams of a wide range of ions species would
greatly increase research beam time available to perform such difficult experiments. It would
allow more rapid progress in several biomedical areas, such as in charged hadron therapy of
cancer, radioisotope production and radioprotection.
Chapter 3 addresses the feasibility of using the Monte-Carlo toolkit Geant4 at proton
energies below 70 MeV. This work was carried out as a collaboration with Tri-University
Meson Facility (TRIUMF) located in Vancouver, Canada. This chapter investigates the
performance of the toolkit to calculate the production of PET isotopes from a typical proton
irradiation for an ocular melanoma treatment. Using PET immediately after proton therapy
allows the treated volume to be verified by the clinicians without the need for a radionuclide.
This approach provides immediate results. Models for the Monte Carlo codes Geant4 and
FLUKA have been developed for ocular melanoma patients for exploring the feasibility of
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implementing this technique.
Chapter 4 validates production of PET radionuclides from a 13 MeV cyclotron, TR13,
at TRIUMF. TR13 is a medical cyclotron with both liquid and solid target assemblies.
The isotopes under investigation are 13N, 18F, 44Sc, 52Mn, 55Co 61Cu, 68Ga, 86Y, 89Zr and
94mTc. Measured saturation yields are compared with Monte Carlo simulations FLUKA and
Geant4. Comparisons have also been made between experimental (EXFOR) and theoretical
(TENDL) cross sections to account for differences in theoretical estimations of isotopic
yield.

Chapter 2
Design for the BioLEIR Beam Transport
System at CERN
This chapter presents a beamline transfer system design for a biomedical research facility
based on theLowEnergy IonRing (LEIR) at CERN.The use of charged particles for ion beam
radiotherapy aims at reducing collateral dose to healthy tissues and organs neighbouring a
tumour. This allows one in principle to increase the dose delivered to the tumour. Around
the world there are an ever increasing number of treatment facilities. A vast majority of these
treatments are with protons, but ‘heavy’ ion therapy (Carbon, Helium, Boron, Lithium) is
expected to be superior to proton therapy for specific tumour types. This is verified by the
findings from various treatment centres in the US (MGH), Japan (NIRs), Germany (GSI,
HIT) and Italy (CNAO) [27, 30, 42, 55]. The superior treatment capabilities of heavy ions
come from their increased radiobiological effectiveness and their smaller lateral penumbra.
With more treatment centres opening up around the world, more fundamental research is
needed in this field to help understand the full potential of ion beam therapy and improve the
treatment outcomes for patients. Therefore it has been proposed that a dedicated biomedical
experimental facility be setup at CERN based on the existing synchrotron, LEIR. The reasons
supporting this are detailed in the following sub-sections of this chapter.
This work has been carried out as part of the BioLEIR collaboration and is a continuation
of previous work done. Slow extraction studies were carried out by A. Garonna et al. and
a preliminary proof of concept beam line design was done by D. Abler et al. [56, 57].
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Optimization of the vertical and horizontal (V1, H1) beamline, along with the design of a
new 2nd horizontal (H2) beamline was done by myself using MAD-X and PTC, the data
analysis was done using Pyaccel and R. Publications from this work are available in [58,
Chapter 9] and [59].
2.1. Motivation for an Ion Beam Facility
Despite increased numbers of clinical ion beam centres in Europe, beamtime for pre-clinical
radiation biology, chemistry and physics studies remains insufficient. While clinical studies
are carried out at existing clinical facilities (such as HIT), proton and carbon beams at
such centres are used for patient treatment and related quality assurance purposes. Nuclear
physics research centres are also capable of providing a wide variety of ion beams in terms of
species and characteristics, to suit the needs of the experimenter. However, their beamtime
available for biomedical applications is limited as physics experiments have priority at these
centres [60]. Biological experiments performed at different accelerators, with different
beam delivery systems, are difficult to compare, and a dedicated beam line accessible to
many would eliminate this uncertainty.
It has been proposed to upgrade the LEIR synchrotron to host a dedicated biomedical
research facility. This is due to the capability of LEIR to produce beams at therapeutic
energies, the existence of significant parts of the required accelerator infrastructure, the
guaranteed maintenance throughout the life of the LHC, and the space available for the
installation of the infrastructure in the South Hall. Figure 2.1 illustrates the layout of LEIR
and the South Hall of the Meyrin Site at CERN.
2.1.1. Requirements for biomedical experiments
In 2012 a review of applications and existing facilities was conducted in collaboration with
members of the Particle TherapyCancer Research institute (PTCRi), and requirements for the
proposed biomedical ion beam facility were determined [62, 63]. In 2016 a second meeting
was held between CERN, the medical and the users’ community where the requirement
parameters for the was confirmed again [64].
From the range of applications of ion beams, radio-biological research poses the strictest
requirements on beam characteristics and facility infrastructure. Interest in radio-biological
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Fig. 2.1 The CERN accelerator chain. Linear Accelerator 3 (LINAC3) and LEIR in LHC injection chain shown
in the blue outline [61].
Table 2.1 Beam requirements for Hadron Therapy research [65].
Clinical Radiobiology
Ions mainly p, 126C p to 2010Ne
Energies 60 - 440 MeV/n 10-75 MeV/n and higher
Dose rates 2 - 10 Gy/min
Field size 5−10 mm FWHM to 5×5cm2
Field uniformity Better than ±5% across irradiation field
studies is led by two fields; Radiation protection, the effect of ionizing radiation on cells
and their environment for various absolute doses and dose rates, and medicine, the use of
radiation for therapeutic purposes, as well as its adverse side effects. Table 2.1 summarizes
the beam requirements. Apart from the required beam, suitable infrastructure must also be
available for a successful biomedical facility. The following subsections review the beam
requirements for medical applications of ion beams.
2.1.1.1. Ion Species
Particles from proton, p, to neon nuclei, 2010Ne, have been proposed for radio-biological
experiments at this facility [56]. Protons and carbon ions are required as a reference for
existing particle treatment practice. Other ions which might be advantageous in certain
situations from a ballistic and biological point of view are helium, 42He, and
3
2He, lithium,
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3Li, boron,
10
5B, and oxygen,
16
8O. Compared to protons the heavier ions produce a relatively
higher Bragg peak, and reduced lateral scattering but also increased fragmentation. Thus
advantages are expected for having several ions to choose from, for the treatment of tumours
close to critical organs or those residing in deeper tissue. Finally, nitrogen, 147N, and neon,
20
10Ne, are also interesting elements from a purely radio-biological point of view as reference
to already existing radio-biological data [66]. The use of a deuterium, D, source will lead to
neutron irradiation from the beam and is likely to be restricted to radio-biological uses. 1On
the other hand, beams of lithium, 63Li, and boron,
10
5B, may be of clinical interest; however
both are difficult to produce and handle [66].
The ion species available for biomedical applications are determined by the ion source
and the pre-acceleration stages of LEIR. The current Electron Cyclotron Resonance (ECR)
ion source is capable of producing the required species, however, the front end is suitable
for heavy ions only. The Electron Cyclotron Resonance Ion Source (ECRIS) is a plasma
device designed to provide highly-charged ions at low velocities. It has a volume with a low
pressure gas. This volume is within a solenoidal magnetic field that provides longitudinal
confinement and a hexapole array of permanent magnets that gives radial confinement of
electrons and ions. The ions within the trap region are bombarded by electrons excited by
injected microwaves. When the energized free electrons collide with the gas in the volume
they cause ionization if their kinetic energy is larger than the ionization energy of the atoms
or molecules of the gas.
Fig. 2.2 The Supernanogan ECRIS by Pantech-
nik [61]. The SUPERNANOGAN is a type of
ECRIS that is used in research laboratories and
is also the reference source for Hadrontherapy.
It is suitable for LINACs, Synchrotrons, and
Cyclotrons.
The Radio Frequency Quadrupole is a linear accelerator which focuses, bunches and
accelerates a continuous beam of charged particles with high efficiency and preserving the
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emittance. The focusing as well as the bunching, and acceleration are performed by a Radio
Frequency (RF) electric field. The existing RFQ is suitable for charge-over-mass ratios
Q/A≈1/8 which is below the required 1/2 for light ions. In order to have the full range of ion
species, a new RFQ is required. Previously, a potential design was proposed in [67], where
a new dedicated front end was foreseen. The front end would have its own ECR source and
RFQ, allowing faster switching times for ion species.
However, more recently, there have been discussions about developing a new Linear
Accelerator (LINAC), LINAC5, at CERN [58, Chapter 5]. LINAC5 would focus on light
ions, complementing the capabilities of LINAC3 (refer to Figure 2.3) thus making a full
range of light to heavy ions available to the facility [61]. Table 2.2 lists different ion species
that could be available at BioLEIR, with predicted dose rates.
Table 2.2 Ion species available with LEIR and respective dose rates. Ions from H to O are proposed whereas
the rest are already accelerated using LINAC3.
Ion Mass Charge Energy Energy Ions per Energy per Dose per Dose in
species (MeV/n) (×10−11J/n) cycle (×109) cycle (J) cycle (Gy) 10 secs (Gy)
Pb 207 54 72.25 1.16 60 144 143.77 599.05
Xe 131 39 108.85 1.74 10 22.8 22.85 95.19
In 115 37 124.36 1.99 10 22.9 22.91 95.47
Kr 84 29 80.67 1.29 10 10.9 10.86 45.24
Ar 40 11 124.36 1.99 23 18.3 18.33 76.38
O 16 8 440 7.05 1.1 1.24 1.24 5.17
C 12 6 440 7.05 1.4 1.18 1.18 4.93
He 4 2 440 7.05 85 24 23.97 99.87
H 2 1 250 4.01 85 3.4 3.40 14.19
2.1.1.2. Energy Range
In the proposed facility, measurements of Relative Biological Effectiveness (RBE), as a
function of Linear Energy Transfer (LET) and nucleon charge at various points on the Bragg
curve are components of the research objectives. This requires in-vitro cell experiments,
with measurement points on the rising slope of the Bragg curve, the plateau region and on the
peak. The experimental setup determines theminimumuseful beam energy. For experiments
close to the Bragg peak, the energy has to be sufficiently high for particles to reach and
penetrate the sample. Taking into consideration the thickness of the vacuum window, beam
instrumentation and flask for cell culture, a minimum thickness of approximately 1 mm
water equivalent length needs to be penetrated. This requires beam energies of 10 MeV/n
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for protons and 15 - 20 MeV/n for carbon ions. However, the maximum energy should reach
up to 75 MeV/n for carbon ions to allow measurements in the plateau of the Bragg Curve.
Higher energies would be preferable to allowmeasurements sufficiently away from the rising
shoulder of the Bragg peak with heavier ions.
To simulate treatments with human phantoms, the beam energy needs to be sufficiently
high to reach typical treatment depths in the range of 3.5 cm to 27.5 cm in human tissue.
This corresponds to a beam energy from 60 - 250 MeV/n for protons and 120 - 440 MeV/n
for carbon ions.
2.1.1.3. Dose Rates
For radio-biological experiments, the irradiation time is kept as low as possible , typically 10
minutes, for practical reasons and to prevent cellular repair mechanisms during irradiation.
The resultant dosage typically lies in the range of 2-10 Gy/min for most mammalian cells.
For clinical applications, the dose rate is typically 2 Gy/min for a volume of up to one litre.
This corresponds to 1010 protons or 108 carbon ions being delivered to the patient per second
[58].
2.1.1.4. Field Size and Uniformity
For clinical phantom studies, in-vivo and in-vitro cell studies, the beam has to be adjustable
between a pencil beam, with a spot size of about 5 mm to 10 mm Full-Width Half Maximum
(FWHM), to broad beamwith fields up to 5 cm× 5 cmwith greater than±5% inhomogeneity
[65]. This requirement has been expressed by the medical community during the meeting
previously mentioned in [62, 63].
2.1.2. LEIR
The Low Energy Ion Ring (LEIR) was proposed for the accumulation of heavy ions up
to Pb-Pb for collisions at the desired luminosity in the Large Hadron Collider (LHC). It
was built from a previous synchrotron, the Low Energy Anti-proton Ring (LEAR), which
decelerated anti-protons [68, 69]. LEIR was commissioned in 2005 and forms part of the
LHC injection chain between LINAC3 and Proton Synchrotron (PS), illustrated at the bottom
centre of Figure 2.3.
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Fig. 2.3 The CERN accelerator chain. Linear Accelerator 3 (LINAC3) and LEIR in LHC injection chain shown
in the blue outline [70].
The function of LEIR is to transform long, low intensity pulses from LINAC3 (25 µA to
50 µA, 200 µs pulse length, 3 × 108 to 6 × 108 Pb54+ per LINAC3 pulse) into short, high
intensity pulses (200 ns, 9 × 108 Pb54+) that are extracted towards the PS. A single pulse
is injected from LINAC3 then accelerated while the magnets are ramped up to Bρ = 4.8
Tm [71]. After the desired acceleration, the beam is extracted by de-bunching the beam
and ramping the extraction elements (magnetic septa and closed orbit bumpers). Figure 2.4
illustrates an extraction spill of 1.2 seconds, which can be increased by the operator. The
main dipoles are ramped down after extraction. The cycle duration is an integer multiple
of the period, which is currently 1.2 seconds. The increase of the extraction energy to 440
MeV/n (6.7 Tm) requires an upgrade of the main dipole power supplies. The relevant magnet
ramping cycle is also shown in Figure 2.4 by the dotted red line.
2.1.3. Local Constraints
Apart from the requirements mentioned in Table 2.1, the proposed beamlines also have a
number of additional constraints due to the current infrastructure consisting of the LEIR lat-
tice, the injection and pre-acceleration chain and the location itself. Finally, the performance
of the LHC for heavy ions must not be affected by any modifications made to LEIR.
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Fig. 2.4 Magnet cycle of LEIR for heavy ion (3.6 second cycle for Pb+54) operation (blue), tentative cycle for
proposed light ion operation (green) [71] and proposed extraction at 440 MeV/n energies (red). Injection of
bunches shown in solid red dots.
(a) Photograph of the LEIR synchrotron [72] (b) LEIR and South Hall [73]
Fig. 2.5 Current LEIR lattice with new extraction from SS30 towards the South Hall. The approximate positions
for the extraction line and end stations are indicated in (b). The dipole bending magnets are shown in orange
in (a) and green in (b).
2.1.3.1. Location and Space Availability
LEIR, illustrated in Figure 2.5a, is located next to the PS ring in the CERNMeyrin site. The
adjacent area to LEIR, the ‘South Hall’ is currently being used as storage space. Clearing that
area should provide approximately 1500 m2 for proposed beamlines, experimental stations
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and required offices. Figure 2.5b shows the floor plan for LEIR and the South Hall with the
proposed new extraction beamlines and experimental end stations.
2.1.3.2. Extraction Method
Beams are extracted from synchrotrons by what is known as fast extraction, based on fast
kickers deflecting the beam, or slow extraction, based on resonant amplitude growth of the
circulating beam. Extraction of the beam towards the new experimental stations needs to
take place in section SS30 and is illustrated in Figure 2.5b.
Due to space constraints in the LEIR lattice, it is not possible to implement another
fast extraction in SS30. This is because it requires the placement of kicker magnets in the
preceding section SS20, which is not possible. Therefore, slow extraction of the beam has
been investigated. Such a method of extraction is currently being used at other synchrotron
based ion beam therapeutic centres [74]. For slow extraction process the sextupole magnets
are at first excited. Next the horizontal tune is moved to a value near the third order resonance
(5/3) and the vertical tune of 2.735 by changing currents of the quadrupole magnets. Beams
which have deviated to the distance more than 10.2 mm from the central orbit at the entrance
of the ES are deflected outward by 56 mrad by the static high voltage of the ES [67].
2.1.3.3. Extraction Energies
The maximum magnetic rigidity of the circulating beam Bρ is determined by the magnetic
strength |B | and the bending radius ρ of the lattice dipoles. The current power supplies
of the magnets limit the maximum beam rigidity to Bρ = 4.8 Tm, however the magnets
are rated for a much higher rigidity of Bρ = 6.67 Tm. At Q/A = 1/2 this corresponds to a
maximum extraction energy of 240 MeV/n and 440 MeV/n respectively. Using knowledge
from the experience of operating LEAR, the minimum and maximum extraction energies
can be translated into magnetic rigidities of (Bρ)min = 0.34 Tm and (Bρ)max = 6.67 Tm. For
12
6C
+6 the corresponding energy range is 1.5 MeV/n to 440 MeV/n. Finally the extraction
energy from the LEIR ring is also affected by the stability of the power supplies in the
proposed operation regimes.
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2.2. Accelerator Physics Concepts
This section details the accelerator physics concepts that are required for the remainder of
this chapter.
2.2.1. Linear Particle Motion
Accelerators use electric and magnetic fields E and B to manipulate beams of charged
particles. The trajectory of a particle with charge and velocity q and v is determined by the
Lorentz force as shown in Equation 2.1.
FL = q(E+v×B) (2.1)
A lattice of an accelerator consists of various elements for various functions such as
diagnostics, beam manipulation, etc., aligned along the reference orbit. The reference orbit
is that followed by a particle at the designed momentum p= p0 and with the nominal position
and direction x, y, x′ and y′ assuming all elements are perfectly aligned [75]. The circulating
particles experience centrifugal force due to its circular acceleration:
|Fcf | = p
2
m · ρ (2.2)
To keep a particle on the reference orbit, the Lorentz force, Equation 2.1 must counteract
the centrifugal which gives Equation 2.3. This equilibrium condition defines the magnetic
rigidity Bρ of the beam [76]:
Bρ =
p
q
=
10
2.9979
βrelE (2.3)
where βrel and E are given by the following equations:
βrel =
√
1− 1
γ2rel
(2.4)
E = γrelm0c2 (2.5)
where E is the particle energy in GeV and m0 is the invariant mass in GeV/c2. Figure
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2.6 illustrates the coordinate system (xˆ, yˆ, zˆ). s is the distance along the orbit, the z-axis is
the tangent to the reference orbit. xˆ, yˆ are the horizontal and vertical components of the
displacement from the reference orbit [75].
Fig. 2.6 Local reference system along zˆ [75].
2.2.2. Magnetic Fields
A transverse two dimensional magnetic field can be expressed as [77]:
B = Bx(x,y)xˆ+By(x,y)yˆ (2.6)
By(x,y = 0)=
∞Õ
n=0
1
n!
{
∂nB
∂xn
}
xn = B0+
(
∂By
∂x
)
x=0
x+
1
2!
(
∂2By
∂x2
)
x=0
x2+
1
3!
(
∂3By
∂x3
)
x=0
x3+ ...,
(2.7)
where the constant B0 corresponds to a dipole field component, the linear term to a
quadrupole field, the quadratic term to a sextupole and the cubic term to an octupole field.
Magnets are characterized by their coefficients in the Taylor expansion Bn =
∂nBy
∂xn , where n
is the order of the pole. In order to characterize magnetic elements independent of beam
momentum, their coefficients are normalized with the magnetic rigidity B0ρ. Therefore the
24 Design for the BioLEIR Beam Transport System at CERN
normalized coefficient kn for a 2(n+1) pole can be written as:
kn =
1
|B0ρ|
∂nBy
∂xn
(2.8)
2.2.3. Hill’s Equation and Twiss Functions
High energy accelerators employ alternating gradient focusing provided by quadrupole
magnetic fields. The linearized equations of motion of a particle undergoing oscillations
with respect to the design trajectory are [78]:
x′′+Kxx = 0,
Kx ≡ ep
∂B
∂x
+
1
ρ2
(2.9)
y′′+Kyy = 0,
Ky ≡ − ep
∂B
∂x
(2.10)
where the magnetic field B(z) acts only in the y direction and contains only dipole and
quadrupole terms. The radius of curvature due to the field on the reference orbit is ρ; p
and e are the particle’s momentum and charge respectively. The prime denotes d/dz. Both
Equations 2.9 and 2.10 can be written in the general form
x′′+K(z)x = 0 (2.11)
The term K is a function of the independent variable z. Due to the fact that many
accelerators are periodic, there is a distance C such that
K(z+C) = K(z) (2.12)
The general solution can be written in the following form:
x = Aw(z)cos[ψ(z)+ δ] (2.13)
where A and δ are the two constants of integration reflecting the initial conditions and
w(z) is a periodic function with periodicity C. Substitution of 2.13 into 2.11 gives:
x′′+Kxx = A(2w′ψ′+wψ′′)sin(ψ+ δ)+ A(w′′−wψ′2+Kxw)cos(ψ+ δ) = 0. (2.14)
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as this is required to be true for all values of ψ, equating the sine term to zero and
multiplying by w gives:
2ww′ψ′+w2ψ′′ = (w2ψ′)′ = 0, (2.15)
Hence after integration:
ψ′ =
k
w(z)2 , (2.16)
where k is a constant of integration. Equating the coefficient of the cosine term to zero
gives:
w3(w′′+Kxw) = k2. (2.17)
w(z) needs to be a solution of Equation 2.17 and for a periodic accelerator w(z) has to
be periodic. Hence the solution of the equation is restricted with periodicity C [78]. If
Equation 2.13 is rewritten as:
x = w(A1cosψ+ A2sinψ) (2.18)
and
x′ =
(
A1w′+
A2k
w
)
cosψ+
(
A2w′− A1k
w
)
sinψ (2.19)
At boundary conditions at ψ = 0, that x = x0 and x′ = x′0, the constants A1 and A2 are:
A1 =
x0
w0
, (2.20)
A2 =
x′0w0− x0w′0
k
. (2.21)
Since w is periodic over the distance C, the matrix equation describing the motion for
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propagation from z0 to z0+C is

x
x′
 z0+C =

cos∆ψC − ww′k sin∆ψC w
2
k sin∆ψC
−1+(ww′/k)2
w2/k sin∆ψC cos∆ψC +
ww′
k sin∆ψC


x
x′
 z0 (2.22)
The phase advance of the particle’s oscillation through the repeat period C is given by
∆ψ(z0→z0+C) =
zo+C∫
zo
kdz
w2 (z) (2.23)
This integral is known as the tune and is independent of z0 as w(z) is periodic [78].
2.2.4. Courant-Snyder Parameters
Inspection of the matrix in Equation 2.22 reveals that the function w2(z) and its derivative
both scale independent of constant k. Since w2(z) and its derivatives are more fundamental
quantities of the problem, the following substitutions are made.
β(z) = w
2(z)
k
, (2.24)
α(z) = −1
2
dβ(z)
dz
= −1
2
d
dz
(
w2(z)
k
)
, (2.25)
γ =
1+α2
β
. (2.26)
α, β and γ are known as the Courant-Snyder parameters. Equation 2.22 can be rewritten for
a single passage through the repeat period as:

x
x′
 z0+C =

cos∆ψc +αsin∆ψC βsin∆ψC
−γsin∆ψC cos∆ψC −αsin∆ψC


x
x′
 z0
(2.27)
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Here the phase advance is:
∆ψC =
zo+C∫
zo
dz
β (z), (2.28)
A particle with initial condition (x0,x′0) follows an ellipse in phase space (xˆ, xˆ′), Figure 2.7,
described by the Courant-Snyder invariant [78]:
β(s)x′2(z)+2α(z)x(z)x′(z)+γ(z)x2(z) = ϵ (2.29)
The area enclosed by this motion in phase space is given by piϵ , its shape and orientation
is given by the Courant-Snyder parameters and thus depend on the position z in the lattice.
The emittance of a beam decreases with increase in energy due to adiabatic damping.
The normalized emittance ϵ∗ remains invariant to changes in the beam energy as shown in
Equation 2.30.
Fig. 2.7 Phase-space trajectory of single particle undergoing betatron oscillation around its equilibrium orbit
in real phase-space [79]. The Courant Snyder parameters are also shown.
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ϵ∗ = βrelγrelϵ (2.30)
where βrel and γrel are the relativistic parameters. This describes the motion of a single
particle in many turns around the machine, it can also be applied to a single instance of many
particles. In most cases the bunch will be described by a 2 dimensional Gaussian. If the
ellipse is selected containing 39% of the beam, that can be used to describe the root mean
squared (r.m.s.) emittance.
2.2.5. Beam Envelopes and Apertures
The beam envelope is the physical size of the beam in the x and y axes and is given by:
Beam Envelope = ±
(
∆+
∆pp0 D
 ) (2.31)
where the beamhalfwidth ∆ in the vertical plane is given by ∆y =2.5σ = 2.5
√
βyϵ
′
rms,y and
ϵ′rms,y = 4pi mm mrad, the maximum vertical emittance at low energy for LEIR. Horizontal
beam size, before scattering is given by ∆x = 2.5σ = 2.5
√
βxϵ′ and using the emittance ϵ′rms,x
= 2 pi mm mrad overestimates the horizontal beam size at most locations. From previous
studies, 2.5σ was chosen as the measure of beam envelope as it is good approximation to
the beam size.
The thickness of the scattering foil and ratio of horizontal and vertical betatron amplitudes
are assumed to be adjustable, so that the same emittance of ϵ′rms,y = ϵ′rms,x = 4.5pi mm mrad
can be achieved in both planes after scattering irrespective of beam energy [80]. The
momentum spread ∆p/p0 of the extracted beam is determined by LINAC3 at the injection
of LEIR and a value of ±2×10−4 has been used in simulations [71].
2.3. LEIR-specific constraints for Slow Extraction
For completeness a brief discussion of the main components in the LEIR facility is given in
this section. Although this is not the main focus of this thesis, each of the components of the
LEIR facility needs to be studied in detail in order for the project to proceed from conceptual
design to engineering design. Various members of the BioLEIR collaboration have been
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involved in developing ideas for the various components. References to the most recent
publications or conference proceedings are given for those items which are not the work of
this author. LEIR was chosen to be operated with a lattice configuration with horizontal
tuneQH = 5/3 as the beam has zero dispersion in the extraction section SS30. The following
subsection discusses this in greater details.
2.3.1. Lattice and Beams parameters
As mentioned previously, LEIR is a square lattice with perimeter of 79 m. It consists of four
straight sections (SS10, SS20, SS30, SS40) each measuring 12.8 m in length and four 90°
bending magnets (ARC10, ARC20, ARC30, ARC40), see Figure 2.8.
Several low intensity ion pulses are injected from LINAC3 into SS10. The injection is
alternated with phase space cooling for ion accumulation, using the electron cooler situated
in SS20 [60]. After the required accumulation and acceleration, fast kicker magnets in
SS30 are used to extract a short, high intensity ion pulse from SS40. The beam is focused
using quadrupole doublets in the ejection section SS10 and the opposite side SS30 and
using triplets in the cooling section SS20 and the extraction section SS40. For chromaticity
correction, sextupoles are installed in SS10 and SS30. Additionally two weaker sextupoles
are present in SS40 and the bending magnets contain entrance and exit Pole Face Windings
(PFW) producing dipole and sextupole magnetic fields. Table 2.3 details the field strength
of the listed sextupole magnets. Also present in SS30 are several orbit correction magnets
(DWHV21, DWHV32,DEHV22, DWHV22, DWHV31, DHV31).
Table 2.3 Properties of sextupole magnets in LEIR. XFN (focusing) and XDN (defocusing) are used for
chromaticity adjustment. XFLS and PFW can be used for resonance excitation. All magnets XFN, XDN,
XFLS have a length of 33.5 cm.
Type Number Position Max. Integrated Strength [Tm−1]
XDN 4 SS10 5.23
XFN 4 SS30 5.23
XFLS 2 SS40 2.17
PFW 8 ARCs 5.4
For Pb ion operation, the typical working point was found to beQH = 1.82,QV = 2.72. In
order to achieve slow extraction, the lattice is required to be tuned to the third order resonance.
This configuration is similar to the previously existing LEAR which implemented a slow
extraction scheme based on a horizontal tune QH = 7/3. Figure 2.9 illustrates the lower
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Fig. 2.8 Detailed view of the LEIR lattice [56]. Charged ions are currently injected into LEIR via the injection
line connected to SS10 and extracted via SS40 after required acceleration. On SS30 the proposed new extraction
line is shown by the orange arrow and two magnetic septa are positioned after KFH31.
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betatron oscillation and dispersion that are possible in this ‘LEAR-like’ configuration. On
the other hand the ‘LEIR-like’ configuration is similar to the current Pb-ion operation with
a horizontal tune QH = 5/3, and SS20 and SS40 being zero dispersion regions. This is
illustrated in Figure 2.10. The optical functions of these configurations are summarized in
Table 2.4.
LEAR slow extraction was not used because the sextupoles are not positioned in dis-
persion free regions, thus being unable to avoid introducing added chromaticity. The beam
parameters at injection and potential extraction energies for LEIR are listed in Table 2.5.
Table 2.4 Lattice Parameters for LEAR and LEIR configurations
Configuration QH QV Q′H ,nat Q′V ,nat βx,max βy,max dx,max d ′x,max
LEAR 7/3 2.73 -2.71 -6.95 11.02 21.97 -3.85 -2.09
LEIR 5/3 2.72 -3.49 -4.54 30.34 21.34 -10.22 -4.46
Fig. 2.9 Optical functions in the LEAR-like lattice at third-integer resonance Q=7/3. The four straight segments
are marked with arrows showing that SS20 and SS40 are not dispersion free regions.
The geometric emittance is the measured emittance of the beam at 2.5σ. According to
Section 35.13 of [71], beam emittances for 20853Pb at 4.2 MeV/n are based on the geometric
emittances, ϵH,geom = 60pi mm rad and ϵV,geom = 40pi mm rad at injection energy after phase
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Fig. 2.10 Optical functions in the LEIR-like lattice at third-integer resonance Q=5/3. SS20 and SS40 are
dispersion free regions.
stacking and before cooling. Unlike the case for Pb-ion injection, biomedical beams will
not require longitudinal phase space stacking. Therefore the beam momentum spread can be
assumed to be equal to momentum spread of the beam from LINAC3, ∆p/p0(1σ)=±2 ·10−4
[60].
2.4. Fundamentals of the Tracking code: MAD
For this study, the MAD-X (Methodical Accelerator Design, version X) program was used
for beam optics calculations and particle tracking studies. MAD-X is the successor of MAD-
8, a tool for charged particle optics design in accelerators and beamlines. Its source code is
written in C, C++, Fortran90 and Fortran77 [81]. Results generated using MAD-X are used
by the Polymorphic Tracking Code (PTC) for particle tracking [82]. Both MAD-X and PTC
are commonly used for accelerator design projects at CERN.
Particle tracking was done using ptc_track, based on the PTC libraries, and integrated
intoMAD-X. Particles were specified by their starting parameters in 4-D phase space (X, PX,
Y, PY) and tracked individually starting from the first element in the beamline. Simulations
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Table 2.5 Beam parameters for injection at 4.2 MeV/n and various extraction energies. Configurations P6 to
P3 correspond to energies from 10 MeV/n to 40 MeV/n. Configurations P2 and P1 correspond to maximum
extraction energies with current power supplies (240 MeV/n) and after the power supply upgrade (440 MeV/n)
[60, 71].
Parameters Injection Extraction
P6 P5 P4 P3 P2 P1
E [MeV/n] 4.2 10 20 30 40 240 440
Bρ (Q/A=1/2) [T/m] 0.59 0.92 1.3 1.6 1.85 4.75 6.64
ϵH ,rms [pi mm mrad] 9.61 6.22 4.38 3.57 3.08 1.2 0.86
ϵH ,geom(2.5σ) [pi mm mrad] 60.04 38.85 27.4 22.31 19.27 7.49 5.36
ϵV ,rms [pi mm mrad] 6.44 4.17 2.94 2.39 2.07 0.8 0.57
ϵV ,geom(2.5σ) [pi mm mrad] 40.25 26.04 18.37 14.96 12.92 5.02 3.59
(∆p/p0)(1σ) [10−3] ±0.2
were based on optical models of LEIR7 provided and maintained by CERN. MAD-X was
mainly used to model the different accelerators in the form of Twiss tables, which contains
the optics functions. PTC on the other hand was used for tracking bunches of particles. Data
analysis scripts were implemented in Python [83] based on Pyaccel [84, 85], an existing
library for accelerator design. The statistical computing package, R [86], was also used.
In the following paragraphs the linear transformation matrices for some typical beamline
elements are introduced.
Drift Space
In a length s of the beamlinewhere nomagnetic elements are installed, the focusing parameter
is zero and the transfer function can be written as [78]:

x
x′
 zout =

1 s
0 1


x
x′
 zin (2.32)
where x stands for the vertical or horizontal position.
7LEIR, lattice files are available from http://project-leir-optics.web.cern.ch/project-LEIR-optics/2012/
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Dipole
In the case of a dipole magnet, the transfer function can be written as:

x
x′
 zout =

cosθ ρsinθ
− 1ρ sinθ cosθ


x
x′
 zin
(2.33)
where θ = sρ is a angle and ρ is the bending radius.
Quadrupole
For a quadrupole the field gradient or quadrupole strength K(s) can be either positive, for
horizontally focusing, or negative, for horizontally defocussing. If K is positive the transfer
function for a focusing quadrupole is expressed as:

x
x′
 zout =

cos
√
K 1√
K
sin
√
K
−√Ksin√K cos√K


x
x′
 zin (2.34)
and for the other plane with negative K the transfer matrix is:

x
x′
 zout =

cosh
√|K | 1√|K | sinh√|K |
−√|K |sinh√|K | cosh√|K |


x
x′
 zin (2.35)
If α, β and γ are known for the initial particle bunch, they can be tracked along the
beamline using 3 × 3 matrices built from these 2 × 2 matrices.
Particle travelling though a beamline
The tracking of a particle through a beamline containing drift spaces, bending magnets
and/or quadrupoles is rather straightforward. All elements are assumed aligned on the ideal
path. A particle following this trajectory through a magnet experiences a uniform field which
begins and ends abruptly at the entrance and exit faces of the magnet. The transfer matrix
for the entire beamline is equal to the product of the individual matrices. For the example
beamline illustrated in Figure 2.11 the transfer matrix can be expressed as Equation 2.36:
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Fig. 2.11 Example beamline with 7 elements.
M(s |s0) = M7...M3M2M1 (2.36)
The position and phase of the particle at the exit of the example beamline are then easily
found by:

x
x′
 zout = M(s |s0)

x
x′
 zin (2.37)
2.5. Particle Tracking Study
For accurate calculations of spot sizes and dose homogeneity, particle tracking studies were
done for beamline H1. Two scenarios were investigated, a (5 cm × 5 cm) broad beam and a
(5 mm × 5 mm FWHM) pencil beam, presented in Sections 2.5.1 and 2.5.2 respectively.
2.5.1. Broad Beam
Many biomedical applications of accelerated ions, especially treatments of tumours, require
large areas or volumes to be uniformly irradiated, typically 5 cm × 5 cm with ±5% dose
variation. For slow extraction from LEIR, the beam parameters at the exit from the syn-
chrotron and entry into the extraction line are unique in that the beam has the shape of a
horizontal bar in the horizontal phase space rather than the typical ellipse. This particular
beam shape is often referred to as a “bar-of-charge”. More details are mentioned in Section
2.6.3. Under the present assumptions, the bar of charge has been assumed to be Gaussian in
both the x and y axes. This results in a significant irradiation inhomogeneity at the isocenter.
Two different technologies to achieve homogeneous dose distribution are discussed below:
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2.5.1.1. Scattering
In the previous solution for BioLEIR [65], it was proposed that upon the beam arriving
at the experimental stations, the final quadrupoles strongly defocus it in order to achieve a
uniform transverse distribution. With the use of collimators, any residual tails were excluded
and a dose inhomogeneity of better than ±5% was achieved. This technique is a variation
of the commonly known passive scattering and consists of transporting a tightly focused
beam through one or more scattering foils, see Figure 2.12. A single foil broadens the beam
sufficiently for the small areas, whereas for larger areas a second scatterer is used to ensure
uniform dose distribution. The first foil would reshape the bar-of-charge into a Gaussian-
like distribution as mentioned in Section 2.6.3, this can either be followed by collimators
and a compensator, or a second scatterer to ensure a uniform dose profile [87, 88]. For
BioLEIR instead of a second scatterer, defocusing quadrupole magnets have been suggested.
These are illustrated in Figure 2.13. The limitation of using a scatterer is that the scattering
material shortens the usable range of the particles. The scatterers become radioactive after
prolonged bombardment of protons and need to be replaced regularly. Scatterers present
another challenge by producing neutrons during operation, increasing the integrated dose
delivered at the experimental station [87]. Despite its limitations, scattering is still in use
in many treatment facilities around the world but is being phased out gradually. Using this
approach for the BioLEIR facility, particle losses of greater than 93.5% would be needed
to achieve sufficient dose homogeneity for a broad beam. Figure 2.14 illustrates that for a
dose homogeneity of ±5%, i.e. I/I0=0.9, 6.5% of the particles would reach the isocenter.
This would not be satisfactory so an alternative approach, non-linear focusing, was sought,
presented in the next section.
2.5.1.2. Non Linear Focusing
Non-linear or third order focusing is another approach that can be used to produce a broad
homogeneous beam. The trade-off between uniform irradiation and beam efficiency can be
resolved by using what is called a beam expander. Such an expander consists of multipole
magnets to reshape the beam for uniform dose distribution. The transverse intensity dis-
tribution of the beam can be transformed from a Gaussian distribution to a more uniform
one using non linear focusing produced by octupoles such that beam spills outside the target
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Fig. 2.12 Illustration of a scattering system [89]. The modulator wheel is responsible for creating the spread
out Bragg peak, the two scatterers widen the beam to cover the treatment volume. The collimator stops the
diverging protons from reaching the patient/target area and finally the compensator shapes the beam to match
the deepest edge of the tumour.
Fig. 2.13 Survey of the LEIR facility along with the space available in the South Hall. The top left corner
indicates the position where the injection from LINAC3 and extraction to PS take place. The brown rectangle
indicates the area with maximum vertical height for placement of the vertical beamline. The two final
quadrupoles of the horizontal beamline are located between the blue arrows [80].
are avoided. A single octupole focuses in the horizontal or vertical planes and defocuses
on the diagonals. An octupole doublet can focus in both horizontal and vertical directions.
An octupole magnet inserted before the target will cause a direction change of the particle
in the beam proportional to the cubic power of the distance of the particle from the z axis.
Leaving the magnetic field of the octupole, the particle will travel in a straight line onto the
target station. Assuming the phase space distribution to be Gaussian, in effect there will be
a folding of the tails of the distribution toward the center of the axis.
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Fig. 2.14 Required rms beam half widthσ (left scale) and beam utilisation (right scale) in function of maximum
intensity variation I/I0 across 5 cm × 5 cm irradiation field [80, 90].
Fig. 2.15 A beam distribution at the target location of the NSRL line. The octupoles of the line are turned ON
to generate a uniformly irradiated area within a large portion of the rectangular area of this distribution at the
target. The inner and outer markings correspond to distances of 10 cm and 20 cm respectively. The horizontal
and vertical projections of the distribution (beam profiles) are shown on the bottom and the right side of the
figure by the red and green lines respectively [91].
This technique has been implemented at NSRL and JAEA [92, 93]. A typical broad
beam from the NSRL is shown in Figure 2.15. The field size is 20 cm × 20 cm with a
±2.5% dose variation in the inner region. At the edges of the rectangle the beam intensity is
higher. There was no loss of particles along the beamline by collimation or other means. The
folding of Gaussian tails confines the beamwithin the target area so there is minimum loss of
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beam and also the beam intensity in the target is much more uniform than that possible with
scattering foils. Unlike other facilities, decoupling of the x and y dimensions of the broad
beam was given low priority, whereas the minimum beam divergence (the Courant-Snyder
parameter, α) was given higher priority. This resulted in a broad beam that is very parallel
approaching the target, thus minimizing dose inhomogeneities in thick targets/phantoms.
2.5.2. Pencil beam
Treatment of cancer cells with modern active beam delivery systems, see Figure 2.16,
requires very small beams or ‘pencil beams’ for very precise beam delivery to the target
area. To control such narrow beams, a technique known as ‘Pencil Beam Scanning’ is used.
The method involves very precise control of the position of the pencil beam to cover the
target in 3 dimensions. The beam is adjusted in the x and y planes using a pair of scanning
magnets and in the z plane by a degrader upstream of the beamline [94]. The use of Pencil
Beam Scanning is typical for all new treatment facilities and treatment beamlines allow the
scanning surface to be parallel to the body with the use of a gantry. For the BioLEIR transfer
line, this may be possible for small targets with the use of the quadrupole triplets downstream
of the octupoles.
Fig. 2.16 Illustration of an active scanning system [89]. A pair of kicker magnets steer the beam in the x and
y direction to ‘paint’ the treatment volume. Adjustment in the z direction is done upstream by altering LEIR
extraction parameters and is not relevant in this study.
40 Design for the BioLEIR Beam Transport System at CERN
2.6. Design of Beam Lines for the Experimental Areas
This section presents the space constraints within the South Hall, Section 2.6.1, the parame-
ters of the beam extracted from LEIR, Section 2.6.2, and the technique proposed for making
the beam suitable for biomedical irradiations in Section 2.6.3.
2.6.1. Space Constraints for Beamlines
The schematic shown in Figure 2.13 shows the storage area adjacent to the LEIR hall.
It has ample space for the installation of transport beamlines, experimental stations and
biological laboratories. While no specific constraints are imposed on the position and length
of the horizontal beamline, the length of the vertical beamline is limited by the transport
crane installed above the site. The location assumed for the vertical beamline in this study,
indicated in Figure 2.13, maximizes the height available to approximately 7.95 m, whereas
in other locations in the hall the height is limited to 5.5 m. The maximum height available
was calculated assuming that the beam line is 1.5 m above ground level.
2.6.2. Starting Parameters of the Extracted Beam
In order to use the Courant Snyder formulae, the beam parameters ϵ , α, and β have to be
determined for the extracted beam. Table 2.6 summarizes the initial parameters for the
beamline design study. Particle tracking starts within the LEIR ring and values have been
used to represent the maximum possible beam width in the beamline.
Table 2.6 Starting parameters for the beam transport line, values taken from circulating beam in LEIR [65].
ϵgeo β ∆ xmax D D
′ α
[pi mm mrad] [m] [mm] [m]
Vertical Phasespace 0.6-4.2 15 - 0 0 -2.8
Horizontal Phasespace 2 15 11 -4 -1 0
2.6.3. Reshaping the Extracted Beam
For biomedical irradiations, such as ion beam therapy, it is generally ideal to deliver a
beam with circular profile and a Gaussian distribution. However the slow extraction method
proposed for LEIR will yield an asymmetric beam in the horizontal and vertical phase space.
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In the vertical plane, the beam occupies an elliptical area, whereas, in the horizontal plane,
it is a narrow ‘bar’, often referred to as a ‘bar of charge’. In order to compensate for such an
asymmetric distribution in phase space and the difference between the horizontal and vertical
emittance, a technique employing a thin foil scatterer has been proposed for BioLIER. Ions
extracted from LEIR would undergo multiple scattering while passing through the foil
resulting in a distribution that can be approximated to be Gaussian in both x and y planes.
This principle has been proven in clinical settings and further discussed in [74].
Thin scattering foils made of copper may be used to re-shape a slow extracted beam
in a beam transfer line into a near Gaussian form from the ‘bar of charge’ extracted. The
horizontal emittance of the beam after a thin scattering foil would be dominated by the
emittance increment given in Equation 2.38a and the vertical emittance be composed of the
initial and incremental r.m.s. emittances:
ϵ′rms,x = ∆ϵrms,x (2.38a)
ϵ′rms,y = ϵrms,y + ∆ϵrms,y (2.38b)
By adjusting parameters βx and βy at the scattering foil, the r.m.s. scattering angle can
be adjusted to obtain a beam with similar beam emittances in both the horizontal and vertical
planes.
(ϵ′rms,x = ϵ′rms,y = ϵ′rms) & (2.38) →
βx
βy
=
∆ϵrms,x
∆ϵrms,y
=
ϵ′rms
ϵ′rms − ϵrms,y (2.39)
The emittance of the beam in the transfer line is dependent on the extraction energy at
LEIR. By controlling the ratio of βx vs βy at the position of the scatterer and using different
foils of varying thickness, the emittance blow up of the beam due to scattering can be
controlled [90]. In this study, the value for emittance after scattering was limited to 4.5pi mm
mrad in calculations. This value is comparable to the maximum vertical emittance of the
beam when extracted from LEIR at 10 MeV/n (previously mentioned in Table 2.5). Multiple
scattering foils up to 12.5 × 10−3 radiation lengths would be required for Q/A = 1/2 ions,
such as 126C
6+. For Cu as a scattering material, this corresponds to a thickness of 181 µm.
It must noted that different foils will result in different levels of energy loss. The process of
obtaining these values is discussed in greater depth in [80, Section 1.4.1.3].
42 Design for the BioLEIR Beam Transport System at CERN
2.7. Results
The beam transport system for the facility is divided into several parts: An Extraction
line from LEIR and Common Horizontal bend towards the South Hall, Section 2.7.1, two
Horizontal beamlines, Section 2.7.2 and 2.7.3 and a Vertical beamline, Section 2.7.4. The
extraction line and horizontal bend are common among the vertical and horizontal beamlines.
The vertical beamline consists of an additional vertical bend and focusing structures, the
horizontal beamlines consist of an additional bending and focusing structures only. All
horizontal dipoles in the beam transfer line have a bending angle of 44° and length of 3.41
m.
2.7.1. Common Horizontal Bend
The extraction line starts at the Electrostatic septum (ESS) and is identical to the first part
of LEIR’s SS30 until kicker tank KFH31. Therefore, LEIR quadrupoles (QDN31, QFN31)
determine the initial beam parameters in this part of the extraction line. The extracted beam
is deflected sufficiently to enter KFH3234 by two magnetic septa, MS1* and MS2, that are
positioned downstream fromKFH31. The common horizontal bending line contains the first
focusing quadrupoles and bends the beam towards the South Hall. The first quadrupole was
originally placed 3.75 m downstream ofKFH3234, next to a beammonitor installed between
the last quadrupole in SS30 and the beginning of ARC30, shown previously in Figure 2.8.
Figure 2.17 shows the survey plots of the existing LEIR ring together with the simulated
beam transport system in x-z (2.17a), y-z (2.17b) and y-x (2.17c) plane. LEIR and the
proposed beamlines are positioned in CERN coordinates, based on survey data fromCERN’s
GEODE portal8 and civil infrastructure information from the GIS portal9. A long gap of 6.5
m has been placed inside the quadrupole doublets to keep the elements clear of the shielding
wall. This design has been chosen so that the shielding wall can be altered to incorporate
the beamline with minimum interruptions. Figure 2.17a also illustrates the ‘L-shaped’
modification to the shielding wall between the South Hall and the LEIR which is required
to incorporate the extraction beamline.
After the upgrade of the power supplies, the maximum beam rigidity that can be acceler-
8https://espace.cern.ch/service-geode/geode/default.aspx
9https://gis.cern.ch/gisportal/
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(a) x - z plane
(b) y - z plane
(c) y - x plane
Fig. 2.17 Survey plot of LEIR and beamlines in x - z plane. Vertical and horizontal beam line in (b) y - z and
(c) x - y plane. The position of transport crane rails is indicated by dashed orange lines in (c). The floor level
building walls are indicated by the solid black lines and the top-level walls in dotted black lines. Blues arrows
indicate target planes in the vertical and horizontal beamlines.
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ated by LEIR is Bρ = 6.67 Tm. With conventional bending magnets with Bmax = 1.6 T, the
bending radius obtained is ρ = 4.17 m. The bending angle must be sufficiently large for the
horizontal beamline to clear the walls marked in Figure 2.17a. This must be done taking into
consideration that the vertical beamline must be located within the area of maximum space
availability. The area of the South Hall surrounding the new extraction line is delimited
by the PS wall and the transport crane rails as illustrated in Figure 2.17a. The constraints
that must be fulfilled by the common horizontal beamline are listed in Table 2.7. The total
bending angle in the setup shown is 132°. The horizontal bending structure was modelled
by three identical SBEND10 segments with half gap of 40 mm and flux integral of 0.5.
Table 2.7 Matching constraints for transfer lines. Conditions d ′ = 0 and α = 0 are important for samples with
finite thickness and were therefore considered less critical for the vertical beamline. All estimates are based
on ϵrms = 4.5 pi mm mrad.
Beamline segment Constraint Location
Extraction Line x = -0.42 m, x’= 140 mrad entrance of KFH3234
Common Horizontal Bend dx = d
′
x = 0 b exit of horizontal bend
βx ≫ βy c at scatter foil
Horizontal Line
dx = d ′x = 0 d in target plane
αx = αy = 0 e in target plane
∆x=∆y = 5 mm to 5 cm f in target plane
Vertical Line
dx = d ′x = 0 d in target plane
dy = d ′y = 0 d in target plane
αx = αy = 0 e in target plane
∆x=∆y = 5 mm in target plane
General βx = βy < 55 m g throughout transferlines
bAchromatic beam transport for both horizontal and vertical beamline.
cMinimum impact of scatter foil on vertical emittance; location of the scatter foil chosen for bar of charge to be approximately horizontally oriented
dPosition and momentum of particles uncorrelated in 2-D plane (d = 0) and in 3-D (d0 = 0).
eParallel beams; not critical for thin samples.
f Pencil beams of 5 mm to 10 mm FWHM and broad beams of 5 cm × 5 cm (I/I0 = 0.9) in target plane.
gBeam envelope, smaller ± 40 mm
In order to reduce dispersion after the end of the bendingmagnets, the dispersion function
was focused towards the positive values in the horizontal bend. Due to the presence of the
second pair of bending magnets, further focusing elements were placed at the centre of
the bend to compensate for the increased dispersion. For improved control of the betatron
amplitude functions, the upstream quadrupole was replaced by a quadrupole doublet (QC01,
10SBEND is a sector bending magnet. Its pole faces meet at the centre of curvature.
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QC02). A single focusing quadrupole at the centre of the bend, strong enough to remove
dispersion, would result in over-focusing in the horizontal and defocusing in the vertical
betatron functions.
The use of a single quadrupole would increase both βx and βy values (βx ≈ 150 m and
βy ≈ 100 m) at the exit of the bending magnets. Hence a quadrupole triplet (QCB1, QCB2,
QCB3) is used for dispersion correction and better control of both horizontal and vertical
betatron amplitude functions. This triplet was placed at the centre of the horizontal bending
section. After this triplet was the ideal position for the scattering foil as the phase advance
∆µx was between 1.8pi and 2pi. Other positions were not ideal for the placement of the
thin scatter foil as either ∆µx , n · pi, or βy ≫ βx . The scattering foil causes the beam to
experience immediate increase in r.m.s. emittance and thus growth in the horizontal beam
envelope. Dipole CBED3 is equipped with a ‘Y’ chamber to enable switching between
different experimental stations.
Downstream of the second horizontal bend, a quadrupole doublet (QC03, QC04) was
positioned. In Figure 2.18 the common bending line from the kicker tank (KHF3242) of
LEIR are shown. The topmost subplot in this Figure shows the position and length of the
lattice elements. The second subplot shows β functions and dispersion in the horizontal
and vertical phase space. The third subplot shows the dispersion function (α) followed by
the bottom subplot which shows the change in beam envelope along the beam line using
Equation 2.31 and assumptions made in Section 2.6.3.
2.7.2. Horizontal Transfer Line 1
The horizontal transfer line 1, (H1), extends from the Common Horizontal Bend with a 44°
dipole, H1BED1, two downstream quadrupoles (QH01, QH02), a pair of octupoles (OCT1,
OCT2) and finally a quadrupole triplet (QH3, QH4, QH5). The total length from extraction
to the end of H1 is 46 m and it is required to have capabilities of producing a broad beam
and also a pencil beam. Figures 2.18 illustrates the current design of transfer line H1. It
shows no dispersion in the vertical plane and limited dispersion in the horizontal plane from
extraction that get exaggerated due to dipole magnets. The triplets QH3, QH4 and QH5
near the target station are responsible for eliminating all dispersion. Scattering is assumed to
result in immediate increase in r.m.s. emittances leading a growth sudden in beam envelope
between QCB3 and CBED3. The dipole properties are summarized in Table 2.8.
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Fig. 2.18 Optical functions in horizontal beamline for broad and pencil beam from kicker tank KFH3234 to
horizontal beamline 1. The first part illustrates the position of the individual elements long the beamline. The
second part shows the variation of beta component and dispersion as a function of position. The third part
shows alpha and the fourth shows variation of the beam envelope along the s axis.
2.7.2.1. Broadbeam
For the horizontal transfer 1 the requirements of beam functions in the target plane are listed
in Table 2.7. Investigations were carried out to see how the particles within the bar of
charge could be altered using octupoles. Figure 2.19a illustrates the 2-D beam distribution
when the octupoles are used. The homogeneity on the focal plane is uniform, the dose
distribution varies less than ±2% in the horizontal and vertical plane. Within the 5 cm × 5
cm boundary, 24% of all particles Such a broad beam satisfies the criteria for biomedical
irradiation. In principle, a smoother distribution could be achieved using higher order
magnets than octupoles, however this proved to be unnecessary as the distribution obtained
with the present technique proved adequate.
Next, the homogeneity of the broad beam in the longitudinal direction was investigated.
This was done in MAD-X by placing observation points to observe the effect the octupole
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has on the particles’ track along the horizontal beamline. The parameters for the particle
bunch at the start of the transfer line were defined using information presented in Section
2.6.2. Due to low priority given to the decoupling of x and y planes of the broad beam,
an extremely simple design is possible for producing uniform beams of 5 cm × 5 cm. An
octupole doublet afterQH2made it possible to fold the tails of the distribution sufficiently for
uniform transverse profile. This pair was followed by a quadrupole triplet to finally control
and focus the beam to have minimum divergence (α ≈ 0). By defining three observation
planes at the target station, the beam parameters were recorded at 0 cm 10 cm and 20 cm
beyond the isocentre and illustrated in Figures 2.19c and 2.19e. The figures show that
20 cm beyond the isocentre the beam profile in horizontal and vertical planes experienced
negligible change, thus relaxing the restrictions of target/sample positioning for broad beam
irradiation. In Figure 2.19a hot spots can be observed at the isocenter. This is due to the
inability of MAD-X to take into account the reshaping of the beam by the scattering foil
located between QCB3 and CBED3.
2.7.2.2. Pencilbeam
Figure 2.19b shows a pencil beam possible with horizontal beamline 1. This beam line has
been designed to be able to incorporate a pencil beam scanning system as a future upgrade.
The spot size is 5 mm FWHM to the nearest millimeter. The triplet QH3, QH4 and QH5
manages to produce pencil beam with |α | = 0.0 and dx <0.5 in the target plane of the first
experimental station. From Figures 2.19d and 2.19f it can be observed that the beam slowly
diverges 10 cm and 20 cm beyond the isocentre in both x and y axes. To achieve a spot
size of 5 mm × 5 mm, the β parameter had to be set to 0.5 m. Such strong focusing of the
beam increases the phase advance of the beam, to keep the phase difference between the
target plane and the kicker magnet at pi/2, the scanning magnet has to be placed towards
the end of the beamline after QH5. As a result space has been allocated in the horizontal
beamline 1 for a scanningmagnet. However, the typical length of this element varies between
manufacturers/vendors11. Therefore 2.5 m of space has been allocated allowing the upgrade
to be possible without having to change the position of the experimental end-station.
11Typical scanning magnet assembly in a Varian system is 2.2 m.
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(a) The uniformity of the 5 cm × 5 cm beam in x and
y plane on the target.
(b) The uniformity of the 5 mm × 5 mm beam in x and
y plane on the target
(c) Horizontal projection of the broad beam. (d) Horizontal projection of the pencil beam.
(e) Vertical projection of the broad beam. (f) Vertical projection of the pencil beam.
Fig. 2.19 The horizontal and vertical projections of the broad beam and pencil beam at the 0 cm, 10 cm and 20
cm after the isocenter. The dashed lines indicate the required beam dimensions for the different beams. The
broad beam has a ±1.3% and ±1.7% dose inhomogeneity in the horizontal and vertical planes respectively
within a 5 cm × 5 cm target area. The pencil beam has a Gaussian distribution with a 5 mm FWHM spot size.
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2.7.3. Horizontal Transfer Line 2
The horizontal transfer line 2, (H2), also extends from the Common Horizontal Bend with a
44° dipole, H2BED1, in the opposite direction to transfer line H1, followed by a quadrupole
triplet QH21, QH22 and QH23. The total length from extraction to the end of H2 is 39 m.
This beamline is required to have capabilities of producing a pencil beam for the targetry and
fragmentation studies. Figure 2.20 illustrate the current setup of transfer lineH2. The triplet
manages to produce beam sizes of 5 mm FWHM in both vertical and horizontal planes, with
|α | <0.5 and dx <0.5 in the target plane as shown in the bottom subplot in Figure 2.20. The
dipole magnet properties are summarized in Table 2.8.
Fig. 2.20 Common line from LEIR and horizontal beamline 2.
2.7.4. Vertical Transfer Line
The vertical transfer line, (V1), is required to be capable of producing only pencil beams for
irradiation of cell cultures from the bottom. Due to space constraints mentioned previously,
50 Design for the BioLEIR Beam Transport System at CERN
the vertical bend has been located directly after doublet QC03, QC04. The total length
from extraction to the end of V1 is 29 m and is envisioned to bend particle beams with
energies up to 75 MeV/n (βρ = 2.55, Q/A=1/2) with a bending radius ρ = 1.69 m. Similar
to the horizontal bending magnets, the vertical magnets have been modelled as two SBEND
segments with a half gap of 40 mm and flux integral of 0.512. The 90° vertical bend contains
two 45° magnets with a quadrupole lens QVB1 in the middle. This is followed by a final
quadrupole triplet QV1, QV2 and QV3 allowing further beam focusing onto the target plane.
The dipole magnet properties are summarized in Table 2.8.
Figure 2.21 illustrates the current design of the transfer line V1. The total height of the
vertical beamline is 6.95m above ground level, leaving<1m for the installation of the vertical
end-station along with beam positioning and measurement instrumentation. Additionally,
the dispersion in the vertical beamline could not be suppressed by the achromatic vertical
bend, hence a quadrupole triplet was added to the design to further reduce beam dispersion.
More space can be accommodated by reducing the number of magnets, however this might
not be preferable as it would sacrifice beam quality through increased dispersion. The main
matching constraints have been previously listed in Table 2.7.
Table 2.8 Properties of dipole magnets. Values for the horizontal bend are based on 440 MeV/n and Q/A =
1/2, value for the vertical bend on 75 MeV/n, Q/A=1/2. 2° has been deducted from the 180° bending angle due
to the inclination of LEIR.
Max Bρ Radius ρ Angle Half Gap
[Tm] [m] [°] [mm]
Horizontal Bend 1 6.67 4.15 178 40
Horizontal Bend 2 6.67 4.15 178 40
Vertical Bend 2.55 1.59 90 40
2.8. Conclusion
Today despite the large number of patients treated, there lies a great deal of uncertainty in the
relative biological effectiveness (RBE) of different ion beams. A dedicated facility would
allow a large systematic collection of relevant data under strictly controlled settings. The
creation of such a facility at CERN is based on the potential for infrastructure savings by
making use the of existing LEIR synchrotron. Designs have been developed for a common
12MAD-X parameters: HGAP=0.04, FINT=0.5
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Fig. 2.21 Common line from LEIR and vertical beamline.
beam transport line from SS30 of LEIR synchrotron to the South Hall onto vertical and
horizontal experimental end stations. This chapter detailed the optical design for the beam
transfer line from LEIR SS30 to future end stations envisioned in the South Hall. The
design consists of a common transport line and three separate beamlines in the vertical and
horizontal direction. The design consists of four bending magnets of 44°, two of 45°, and
20 quadrupoles in total. Using quadrupoles of length 0.52 m (same as those in LEIR),
the maximum quadrupole gradient required was ≈ 39 Tm−1 located in horizontal beamline
1, this along with maximum field strengths and maximum beam envelopes throughout the
designed transfer system are summarized in Table 2.9.
Results of the previous study indicate that the minimum pencil beam sizes (FWHM) of (5
± 1) mm can be achieved in the vertical line and (8 ± 1) mm in the horizontal line 1, as well
as broad beams with inhomogeneities ≤ ±5% across a sample area of 5 cm × 5 cm. However
this was only possible with 93.5% beam loss at the target station. An alternative method of
producing uniform beam distribution based purely on third order magnetic focusing of the
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Table 2.9 Maximum Field gradients k and beam envelope (BE) at the all quadrupoles at the BioLEIR facility.
Both pencil beam and broad beam requirements have been taken into account.
Common Line qc1 qc2 qcb1 qcb2 qcb3 qc3 qc4
k [Tm−1] -3.9 -1.8 -10.6 18 -5.7 8.8 -7.6
BE [mm] ±22 ±21 ±49 ±45 ±60 ±68 ±53
Horizontal line 1 qh1 qh2 qh3 qh4 qh5
k [Tm−1] 6.8 -8.9 36.8 -39.3 18.9
BE [mm] ±64 ±39 ±38 ±60 ±41
Horizontal line 2 qh21 qh22 qh23
k [Tm−1] 2.3 2.6 -8.8
BE [mm] ±34 ±29 ±26
Vertical line qvb1 qv1 qv2 qv3
k [Tm−1] 4.6 -6.2 6.2 9.6
BE [mm] ±51 ±52 ±59 ±26
beam has been investigated here. This method requires little to no collimation of the beam
or any other type of beam interaction with materials to produce a uniformly distributed beam
over a rectangular region normal to the beam direction of travel. With the use of octupoles,
100% of the extracted beam can reach the target station with minimum interaction with any
material upstream. At the isocenter more than 24% of the beam is focused within the 5 cm
× 5 cm spot. This is a factor of 4 improvement on the previous design in [80] where optical
defocussing was investigated. The lack of need for collimators at the nozzle also improves
the beam quality possible in the BioLEIR facility. For the vertical beamline no significant
improvement could be made to the beam due to the shortage of space. The second horizontal
beamline cannot be compared as it is a new addition to the design not present previously.
Pencil beams of FWHM of (5 ± .1) mm are possible with plenty of room for a scanning
system to be installed in order for large target regions to be irradiated.
The maximum beam envelope through out the beamlines was ± 50 mm so an aperture of
100 mm was chosen for the BioLEIR beam transfer system. In neighbouring regions to all
the dipoles, the beam envelope is at times greater than 50 mm and with further improvements
this preliminary design can be improved so that maximum beam envelope is less between
± 40 mm and beta function is less than 100 m. The optics from the kicker tank KFH3234
up to QC4 are independent of the beam parameters required at the target station. The optics
design and PTC study were based on slow extraction from LEIR, the use of the different
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extraction system such as RF knockout, would result in different beam properties and hence
a difference optics design. The PTC study is limited as it cannot take into account the effects
of the scattering foil used to convert the beam into a Gaussian distribution. Therefore, dose
homogeneities presented are conservative estimates of what can actually be achieved. The
scattering foil in reality would increase the dose homogeneity at the target plane.

Chapter 3
PET Scanning of Ocular Melanoma after
Proton Therapy
This chapter reports proton therapy research conducted at TRIUMF - Canada’s National
laboratory for particle and nuclear physics under the supervision of Dr. Cornelia Hoehr.
During proton therapy positron emitting isotopes are generated in patient tissue, which
can be used to deduce where the proton dose was deposited. The proton therapy facility at
TRIUMF has been simulated using theMonte Carlo codes Geant4 and FLUKA to investigate
the feasibility of using this technique for ocular melanoma or similar small tumour sites.
FLUKA calculations were performed by C. Lindsay and data provided by C. Hoehr. The
Geant4 model was developed and data analysis was conducted by myself in version 9.6 and
10.1 using various physics lists. Publications from this work are available in [95] and [96].
3.1. Introduction
Ocular melanoma is a form of cancer that forms as a tumour inside the eye. Although it
is the most common form of intraocular eye cancer, it is a rare form of cancer that affects
approximately 6 out of every million people in the United States and is the most common
form of ocular cancer in adults. This occurrence rate has remained fairly stable over the last
30 years [97]. Ocular melanomas can metastasize and spread to the remainder of the body,
with high accumulation in the liver [98, 99]. Ocular cancer metastates spread mainly to the
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liver. When this occurs, the cancer spread is fatal and untreatable with the death rate at 2
years being extremely high at 85% [100].
Treatment options available for ocular melanomas are enucleation13, brachytherapy and
hadron therapy. Brachytherapy, hadron therapy and enucleation have similar levels of success
in terms of occurrence rate of metastasis after treatment. Hadron therapy or brachytherapy
treatment of smaller tumours offers increased likelihood of vision retention and thus lead to
a better quality of life after treatment [101]. An alternative treatment such as brachytherapy
while proven to be effective, poses risk in terms of coverage for large tumours. Increasing
the activity of the isotope inside the eye results in greater risk of exposure to healthy tissue,
and in the case of tumours near the optic nerve, increases risks of blindness or neuropathy
[102, 103]. Hadron therapy, using protons, is a preferred treatment for medium to large
ocular melanomas with a high success rate of eye preservation and vision retention in treated
patients.
The Proton Therapy Facility at the Tri University Meson Facility (TRIUMF) has been
a joint project between TRIUMF, the British Columbia Cancer Agency (BCCA) and the
University of British Columbia (UBC) Department of Ophthalmology. The facility has
been treating patients with ocular melanoma with 74 MeV protons extracted from the 520
MeV cyclotron. The TRIUMF cyclotron facility is able to provide proton beams between
energies of 65-520 MeV with stable and easily controlled beam intensity and good energy
resolution. The eye treatment equipment is located on beam line 2C1 and has an energy
range of 65-115 MeV. Figure 3.1 illustrates the layout of the Proton Therapy Facility and its
position respective to the TRIUMF cyclotron [104]. From 1995 and 2007, the facility has
treated patients and yielded a 5 year local control rate of 91%, a 5 year survival rate of 82%
and an enucleation rate of 0% for small tumours and 14% for medium sized tumours [102].
The proton therapy facility at TRIUMF continues to treat approximately 10 patients a year
on average and in 2017 just treated its 200th patient. Despite the success, few studies have
been carried out to verify the accuracy of the proton dose deposition in the tumour of the
patient as there has been no direct way to determine the actual proton dose deposition during
patient treatment.
One method being investigated at TRIUMF is the image reconstruction of the isotope
emission in the tumour or any target irradiated with protons using Positron Emission Tomog-
13Enucleation is the removal of the eye that leaves the eye muscles and remaining orbital contents intact.
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Fig. 3.1 Layout of the TRIUMF Proton Therapy Facility in red with respect to the cyclotron facility [104].
raphy (PET). Positron emitting isotopes are produced inside a target after proton irradiation
and the resulting photons can be detected using scintillation detectors [105]. If any errors
are found in dose deposition, future fractions can be adjusted to compensate. The medical
facilities at the nearby UBC Hospital in addition to the expertise available at TRIUMF may
make PET imaging an appropriate method of image reconstruction for dose verification.
3.2. Literature Review
Proton therapy can be an effective treatment modality for certain types of cancer. This is due
to the ability of protons to stop within the patient at controlled depth, sparing healthy tissue
from unwanted damage. This stopping nature of protons causes a very sharp longitudinal
dose fall-off, hence patient alignment with respect to the beam isocenter is extremely impor-
tant to prevent dose delivery to healthy tissue. Unlike a treatment field using photons, a small
positioning error using protons could lead to dose changes of up to 100% [106] resulting in
underdosage of tumour volume and overdosage of the surrounding critical organs. During
fractionated therapy unpredictable range deviations can occur because of minor inaccuracies
in the of the patient or changes in the anatomy with respect to the information of the planning
X-ray CT, typically acquired several days before the treatment. Despite the introduction of
safety margins around the target volume to account for range uncertainties, tools for visu-
alizing dose deposition inside the patient are limited and highly desirable. The widespread
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installation of proton therapy facilities around the world has called for more strict quality
assurance for proton therapy [107].
The application of end of range measurement for a charged particle beam using positron
emission imaging was proposed in 1970s at Berkeley [108]. By irradiating the patient with a
low dose β+-radioactive beam of 19Ne prior to the therapeutic beam of 20Ne, accurate range
verification (<1 mm) was obtained. Such high accuracy could be achieved as the range of
the radioactive and stable ions are almost identical. Despite the success of this test using a γ
camera, the system was never used in a clinical environment due to activation of the detector
from secondaries produced along the beamline due to passive beam shaping devices such
as scatterers [109, 110]. Based on this experience, in 1994 at HIMAC, a commercial PET
scanner was chosen to monitor PET isotopes produced after treatment with a 12C ion beam.
Due to the time interval between treatment and imaging, the activation detected was mainly
from 11C [111, 112]. The range was deduced from the peak of the 11C fragments shortly
before the end point of the 12C ions.
The first in-beampositron camerawas installed atGesellschaft für Schwerionenforschung
(GSI) [113, 114] in 1996. It consisted of a double head system with commercial detectors
which allowed dose monitoring in 3-D from a 12C ion beam, see Figure 3.2. This meant
that not only the beam range, but also the conformal lateral dose deposition from the raster
system could be verified. This on-line solution eliminated time intervals between treatment
and imaging, thus being able to measure more β+ activity from short lived isotopes such
as 15O and 10C without the possibility of patient alignment changes during transport to
the scanner. The applicability of this technique for protons for range monitoring is more
challenging. The small mass of proton and other similar ions (He, Li, Be, B) creates
insufficient amounts of β+-radioactive projectile fragments. Towards the end of the 1970s,
preliminary investigations were carried out on the potential of 2-D online imaging of proton
induced β+-emitting fragments/isotopes (11C, 15O, etc) inside phantoms and animals in
Brookhaven [115, 116].
In the 1996, work was carried out at TRIUMF investigating dose monitoring using
PET activity generated inside a lucite phantom after proton beam irradiation [118]. Beam
energies used were 62 MeV and 110 MeV with doses varying between 16 Gy and 317 Gy.
The phantom was imaged 20 - 40 mins after irradiation. The lateral dose deposition inside
the phantom was identified quite well, however, along the beam axis the correlation between
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Fig. 3.2 The double head positron camera (labelled A and B) at the treatment site at GSI Darmstadt. The
horizontal carbon ion beam escapes the beam pipe through a 20 cm × 20 cm window visible in the centre.
To provide sufficient space for patient positioning, the PET scanner can be moved parallel to the beam. For
irradiating patients the detector heads are fixed below and above the patient couch. In future designs, the
detectors can be rotated around the central beam [117].
dose and activity generated was found to be poor. This study was limited due to the 5 mm to
6 mm resolution of the ECAT 953b scanner used and that the simulation was in 1-D only. As
a result the scanned activity profiles from a RBP and SOBP irradiation were almost identical
to each other.
First attempts at using a commercial full ring PET scanner to verify patient treatment
from a passively scattered proton beam in a clinical setting was made in Hyogo Ion Beam
Medical Center, Japan in 2002. A patient with ethmoid sinus carcinoma was treated with
a proton beam, followed by an emission and transmission scan performed 5 to 20 mins
afterwards. However, there were significant issues with coregistration between treatment
and offline PET imaging [119]. These issues with coregistration were addressed in a pilot
project at Massachusetts General Hospital (MGH), Boston, MA. Imaging was performed
for a duration of 30 min, starting up to 20 min after a treatment fraction was delivered in
one or two fields for a total dose of 1.8–3 GyE up to 10 GyE (ocular melanoma). Using
offline PET/CT imaging combined with novel detailed Monte Carlo modeling (FLUKA) of
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expected tissue activation with biological washout14, it was possible for range verification to
be verified up to 1-2 mm for head and neck patients. Figure 3.3 summarizes the study for a
patient with pituitary adenoma. It can be observed that the Monte Carlo predictions agreed
with the activity measurements and that two separate fields were used for this particular
treatment fraction. However, sites such as lower spine and eye sites required better fixation
and coregistration methods.
Fig. 3.3 Top: Treatment-plan (TP) (left) and Monte Carlo recalculated (right) dose for a patient with pituitary
adenoma receiving two fields at 0.9 GyE/field. Bottom: Measured (left) and Monte Carlo-calculated (right)
PET image. Delay times ∆T1 and ∆T2 to beginning of imaging were about 26 and 18 min from the end of the
first and second field applications, respectively. The PET activity is indicated by the colour scale from blue
(minimum) to red (maximum) [120].
14After being produced in tissue, β+ emitters are not static in the patient. They diffuse beyond the irradiated area due to the circulation
of blood/fluids and metabolism after end of beam.
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Results from the pilot study allowed the strengths and limitations of PET (such as
biological washout and limited resolution of the scanner) as a treatment verification tool for
various tumour sites to be identified [120]. Currently at MGH a mobile PET scanner inside
the treatment room is used to study range verification. In this arrangement, the patient does
not have to be repositioned as the robotic table can be manoeuvred into the scanner thus
greatly reducing time between treatment and imaging. This technique also has the advantage
of being able to detect more β+ activity due to 15O contribution and less time for biological
washout. This leads to a reduced imaging time of 5 mins as opposed to 30 mins for offline
imaging. While in-room PET is a low cost, highly sensitive technique for in vivo range
verification of proton therapy, it is limited to cranial or pediatric cases due to the small bore
opening of the scanner [121]. Most recently at Heidelberg Ion-Beam Therapy Center in
Germany, a PET/CT scanner has been installed close to the treatment rooms [122]. Patients
either walk or are transported to the scanner after a treatment fraction from a scanned proton
or carbon beam. The feasibility of using this technique has been proven and is moving
towards clinical routine at the Center. Recently, two new technologies have emerged in this
field and are discussed below:
3.2.1. Prompt Gamma Ray Imaging
Inelastic interactions of protons and target nuclei occur along almost the whole proton
penetration path, until 2-3 mm before the Bragg-peak, where the reaction cross sections start
dropping with decreasing energy of the projectiles. After an interaction, the target nucleus is
excited to a higher energy state and then emits a gamma cascade to return to its ground state.
The emission of prompt gammas is correlated with the penetration path of the protons in
the tissue, so that measurements of the prompt gammas can be used to draw conclusions on
the proton range [123, 124]. The correlation between photons emitted and dose deposition
is illustrated in Figure 3.4. From the figure the emitted prompt gamma ray activity can be
seen for R80 at 9 g/cm2 for 1010 incident protons.
The main advantage of using prompt gamma imaging is that dose verification can be
performed in real time. However, it is limited due to its spatial resolution, low statistics,
large background, and typically its measurement in only one dimension [123–125]. The
background signal is generated by prompt gammas and neutrons penetrating the collimator,
and secondaries produced by neutrons that are scattered or interact with the collimator.
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Fig. 3.4 Prompt gamma-ray emissions along the path of a proton pencil-beam in water for proton range of 9.0
g/cm2. Shown is the mean and ±1σ statistical uncertainty of five measurements with 1010 incident protons per
measurement point. The dose deposited by the beam is shown by the black solid line [126].
3.2.2. Protoacoustic Technique
A proton beam traversing through a phantom deposits energy and causes localized heating.
The protoacoustic technique (also referred to as ionoacoustics) works by measuring the
created pressure wave inside the phantom. The system consists of an array of transducer-
s/sensors positioned along the z axis of the beam at equal radial distances from the beam
axis. After a pulsed proton beam is incident onto a target, an acoustic signal with two peaks
are generated. The compression peak (know as a α) and the rarefaction peak (known as the
γ) result from the rising edge and the Bragg peak respectively. The distance from the beam
axis (s) and the Bragg peak center can be determined from the arrival times of the α and γ
pulses respectively. This enables the range of the beam to be verified. This phenomenon
is being investigated at the University of Pennsylvania and is illustrated in Figures 3.5a and
3.5b for a RBP and a SOBP respectively. This technique has been successful at verifying
the Bragg peak position to within ≈1 mm. It also has the added comparative advantage in
terms of equipment required such as microphones, amplifiers and oscilloscopes; all of each
are available off the shelf and have a relatively low instrumental cost. More information can
found in [127].
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(a) A RBP (a). A cascade plot where each trace shows the pressure measured at a transducer (s = 35 mm) for a beam spill
time of 1.12 µs (b). The z-position of each transducer corresponds to the z-axis in (a). The two peaks are labelled α and γ.
(c) A characteristic pressure trace from the transducer (s,z)=(35, 64 mm) [127].
(b) A cascade plot of the pressure waves measured for SOBP of width ψ ranging from 1 mm to 30 mm. The pressure
amplitude is magnified by ×5 after the α peaks. The * indicates the γ compression peak [127].
Fig. 3.5 Pressure waves induced by a RBP and SOBP in water.
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3.2.3. Summary
After the excitations of the nuclei in tissue, prompt gammas are emitted within a few
nanoseconds. Thus, this approach is only applicable for on-line range verification during
field delivery. Several dedicated research groups have reported promising results on prompt
gamma detector developments within the last few years. Recently a prototype has been
developed for clinical use [128], but requires further testing. On the other hand, ionoacoustics
have proven to accurately reproduce Bragg peak positions with <1 mm tolerance [129].
However, this accuracy was possible in an ideal homogeneous phantom, more realistic
resolution is <2 mm. At proton energies higher than 100 MeV, the SNR will lower be
due to a higher noise levels. This is because at such energy levels, the Bragg peak fall-off
will be less sharp thus creating signal that is also less sharp in time and space. Finally at
higher energy levels i.e. greater tissue depth, the signal is also attenuated more. Therefore,
improving the SNR is the main challenge for ionoacoustics in clinical applications. When
using PET imaging, the PET signal builds up only during proton irradiation. In order
to achieve a sufficient signal-to-noise ratio, PET range verification is only possible after
completion of each treatment field or fraction. The choice of the probing isotope should
be made with care, since, depending on its half-life and the possible reaction channels, the
measured activity profiles can look very different. If short lived isotopes are used, fast PET
imaging is possible as biological wash-out processes as minimized. If used in off-line mode,
commercially available PET(/CT) scanners can be employed. If aiming for on-line PET
imaging, or imaging immediately after treatment delivery, the solution will depend on the
facility-specific beam delivery system (passive scattering or active beam) [130]. Table 3.1
provides a comparison of the different techniques presented so far.
While there has been significant theoretical and experimental investigations done in this
field over the years using different techniques, most of the work was focused on tumour sites
as such head, head and neck, liver and pelvic tumours. At the start of this project little research
had been carried out for the case of small tumour sites such as ocular melanomas. Previous
work mentioned in [120–122] combined measurements with only FLUKA to perform range
verification. More recently investigations have been carried out in Italy to develop a custom
system capable of capturing β+ activity during beam delivery [131]. This system has the
capability of sustaining the high event rate generated by a beam from a cyclotron. The
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Table 3.1 Comparison of different techniques for range verification.
Technique Pros Cons
Prompt gamma imaging On-line acquisition Large Background
<1 mm resolution Unsuitable for passive scattering systems
Low Statistics
Commercially unavailable
Protoacoustic On-line acquisition Still in early stages of development
<2 mm resolution
Lower hardware cost
PET imaging Commercially available On-line acquisition is challenging
Off-line acquisition Biological washout
1-2 mm resolution
work has reported on measurements performed using this system for a 62 MeV proton beam
and compares these results with predictions obtained from FLUKA. The work presented in
this thesis aims to compare experimental results using a commercial PET scanner during
beam off period and compare with two Monte Carlo packages, FLUKA and Geant4. So
far no literature is available that verifies both Monte Carlo packages with experiments for
range/dose verification of proton therapy. Given that Monte Carlo codes (such as Geant4,
FLUKA, MCNPX, etc) are becoming increasingly popular in the hadron therapy field,
their performance must be assessed with measurements to ensure that clinical accuracy is
maintained across different platforms. It is hoped that investigations carried out in this work
will allow the best suitedMonte Carlo to be identified for proton therapy of ocular melanoma
and other small tumour sites.
3.3. Theory: Interactions of Charged Particles with Matter
When charged particles travel through matter, the incident particle will lose energy or be
deflected from its original path through various interactions such as Multiple Coulomb
scattering. This includes mainly inelastic collisions with electrons and elastic scattering
from the nuclei inside the material. For therapeutic energies other processes which may
occur with far less likelihood for the case of incident protons are emission of Cherenkov
radiation and nuclear reactions[132]. This section lists the theoretical concepts required for
the rest of the this chapter.
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3.3.1. Basics of Proton Stopping
The fluenceΦ is defined as the number of particles N crossing an infinitesimally small area
dA normal to z (beam direction) [133]:
Φ ≡ dN
dA
protons
cm2
(3.1)
The stopping power S is the rate of decrease in kinetic energy E for a single proton. It has
units of energy per unit length and the negative sign signifies loss of energy [133]:
S ≡ −dE
dz
MeV
cm
(3.2)
The mass stopping power is the stopping power corrected for the density ρ of the material
and has units of energy per unit mass over area [133]:
S
ρ
≡ −1
ρ
dE
dz
MeV
g/cm2 (3.3)
The absorbed dose D is the energy absorbed by the material per unit mass. It has units called
Gray or Gy, which is equal to 1 joule per kilogram. Dose is given by the following relation:
D =Φ
S
ρ
(3.4)
Specializing to protons, themass stopping power in an elementarymaterial of atomic number
Z and relative atomic mass A is [133, 134]:
−1
ρ
dE
dz
= 0.3072
Z
A
1
β2
[
ln
Wm
I
− β2
]
MeV
g/cm2 (3.5)
and,
Wm =
2mec2β2
1− β2 (3.6)
where Z, A, and I are the atomic number, mass and mean excitation energy of an
elementary medium, β = vc for the incoming proton and Wm is the largest possible energy
lost during a collision between the proton with a free electron of rest mass me [133]. From
Equation 3.5 it can be seen that when the incoming particle slows down, the rate of energy
loss increases.
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3.3.2. Medical Imaging for treatment verification
During treatment, the proton beam undergoes nuclear interactions with tissue and creates (i)
prompt gammas from excitations of the target nuclei (ii) 511 keV gammas from the positron
annihilation following the decay of the positron emitters produced in beam interactions with
the tissue and (iii) pressure waves after localized heating due to energy deposition from the
proton beam.
Positron Emission Tomography (PET): Isotope Production and Decay
For the production of radioisotopes at a constant rate, the decay rate is given by [135]:
dN
dt
= S′−λN (3.7)
where S′ the source term and λ is the decay constant. Equation 3.7 can be solved using
an integral factor or by standard complementary function/particular integral approach. With
an initial condition N=0 at t=0, the activity of the isotope is given by [136]:
A = λN = S′[1− e−λt] = Asat[1− e−λt] = nφσy[1− e−λt] (3.8)
where n is the number of atoms of the target material, φ is the proton flux rate [cm−2s−1]
and σy is the microscopic cross section [cm2]. In Equation 3.8 the activity increases with
time, converging on a saturation value equal to the rate at which the isotope is being produced
S′ or Asat .
Inside a material, for instance a human body, interactions are determined by the Coulomb
force between the charge of the projectile particle and the charge of the atom. When a beam
of protons pass through human tissue or lucite phantom, short-lived radioisotopes such as
11C, 13N and 15O will be produced due to nuclear reaction processes with half lives of 20,
10 and 2 minutes respectively and decay exponentially. The radioactivity of an isotope is
the rate of its radioactive decay measured in decays per second or Becquerels (Bq). The β+
decay mechanism is shown below:
p+ −→ n0+ e++ ve (3.9)
The decay mechanism illustrates a proton within the isotope nucleus transforming into
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a neutron, forming a positron (β+ particle) and a neutrino to conserve charge and lepton
number. The neutrino will escape into the material without interacting and the positron
after travelling a short distance will annihilate with an electron to produce two 511 keV
photons emitted in approximately opposite directions, conserving energy and momentum as
illustrated in Figure 3.6a and 3.6b [137].
Imaging using PET must be carried out either during the treatment, or within some
minutes after treatment. The time restrictions due to the decay of the short lived PET
isotopes and biological washout. By using this method, the actual dose distribution in the
patient can be deduced, and this can be compared with the predicted dose from the treatment
plan. The unavoidable activation of the patient can thus be utilized without invasion or no
additional dose (except the transmission scan) to the patient as a measure of dose deposition
in the patient’s body. The typical reaction for the production of PET isotopes in human
tissue after proton irradiation are shown in Table 3.2.
(a) Positron annihilation [138]. (b) PET Scan Process [139].
Fig. 3.6 A positron produced via β+ decay from 18F and producing two 511 keV gammas after annihilating
with an electron in the material and image construction.
The gamma pairs are emitted isotropically in a full solid angle of 4pi and can be detected
by detectors on opposite sides operating in coincidence giving lines of response (LORs)
of the system. With appropriate acquisition and reconstruction algorithms it is possible to
retrieve the unknown spatial distribution of β+ activity source. The reconstruction algorithm
in PET relies on two basic assumptions, (i) the nucleus from which the positron originated
is exactly located along the line at which the two photons are emitted and (ii) the two
annihilation photons are emitted at approximately 180° to each other. The limited validity
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Table 3.2 Positron emitter reactions in tissue from proton therapy [140]. The average energy and range of
positron inside tissue is also listed [141].
Nuclear Reactions Threshold Energy Half-life Time Mean Energy Mean Range
(MeV) (min) (MeV) (mm)
16O(p,pn)15O 16.79 2.04 0.73 2.97
16O(p,2p2n)13N 5.66 9.965 0.49 1.73
16O(p,3p3n)11C 59.64 20.39 0.39 1.27
14N(p,pn)13N 11.44 9.97 0.49 1.73
14N(p,2p2n)11C 3.22 20.39 0.39 1.27
12C(p,pn)11C 20.61 20.39 0.39 1.27
of these approximations due to the distance travelled by the positron from the point of
creation and the non-collinearity of photon emission restricts the achievable resolution to
2 mm approximately. Other physical processes affecting the measured data are attenuation
inside the object under investigation due to reduction of detected photon pairs along LORs,
scattered coincidenceswhere photons reach the detector after experiencing angular deflection
due to scattering in the object, and random coincidences where photon pairs not originating
from the same annihilation event are detected in coincidence leading to incorrect assignment
of emission lines [138], see Figure 3.7. The specific details of the scanner installed at UBC
hospital are briefly discussed in Section 3.4.
Fig. 3.7 Representation of true (left), scattered (middle), and random (right) coincidence events. The solid
lines show the real photon pathways, whereas the dashed line is the assigned line of response to the detected
coincident γ-ray pair [138]. A true coincidence consists of a single annihilation and two co incident photons
in opposite directions being detected. A scattered coincidence is where the annihilated photons experience
scattering prior to detection resulting in an artefactual LOR. A random coincidence is where photons from
multiple annihilations are detected simultaneously causing an artefactual LOR.
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Calculation of depth activity profiles
During proton therapy, a target volume composed of different target nuclei AZNT is irradiated
for a time tR with a beam of monoenergetic protons of energy E0. Collapsing the 3-D depth
activity profile onto one axis simplifies the calculation of isotopic activity of the phantom
and allows the proton flux to be measured in Geant4. The probability of transforming a target
nucleus AZNT to a positron emitting isotope
A′
Z ′NI is given by the isotope production cross
section σT I(E) which is a function of the kinetic energy E of protons traversing through the
human tissue or target. PET isotopes are created for energies E larger than the threshold
energy ET I . For most proton induced activations of PET isotopes the threshold energies are
in the range of 3 to 20 MeV as listed in Table 3.2, with the exception of the 16O(p,3p3n)11C
reaction, for which it is 59.64MeV. Therefore the range of the activity of isotopes will always
be less than the range of the protons within the target. The isotope production cross sections
of 11C, 15O and 11N, σT I , are shown in Figure 3.8. The sources of all EXFOR cross sections
are listed in the figure caption. A cubic spline has been performed and the knots position
were adjusted to give reasonable agreements by eye. The energy range of the proton beam
is indicated by the red shaded region. The produced activity per volume aE0I at a depth z is
proportional to the proton fluxΦE0(z), the isotope cross section σT I and the density ρT (r) of
the target nuclei AZNT , i.e., a
E0
I (z) ∝ΦE0(z)ρT (z)σT I(E(z)) [118].
For the time dependence of the induced activity profiles aI(z,t) the loss of isotopes due
to decay has to be taken into account in addition to the production rate as per Equation 3.8.
The decay of the PET isotope A′Z ′NI ′ depends on the decay constant λI . Given that a specific
isotope can be produced from different target nuclei, the 1-D depth activity profile aE0I (z,t)is
given by Equation 3.10 [118]:
aE0I (z,t) =
Õ
T
ρT (z)ΦE0(z,t)σT I(E(z))

(1− e−λI t) if t ≤ tR
(1− e−λI tR)e−λI (t−tR) if t ≥ tR
(3.10)
Throughout this study, it has been assumed that the activated isotopes do not undergo any
dispersion inside the lucite target. This is because biological washout is negligible inside
the human eye as discussed further in [106]. In Equation 3.10 t ≤ tR and t ≥ tR refer to
observation time t during and after the irradiation time respectively.
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(a) 12C(p,pn)11C cross section taken from: [142–146]
(b) 16O(p,3(pn))11C cross section taken from: [147, 148]
(c) 16O(p,2(pn))13N cross section taken from: [149].
(d) 16O(p,pn)15O cross section taken from: [147, 148, 150]
Fig. 3.8 Experimental cross sections of relevant PET isotopes with cubic spline fits are shown. Energy range
used in this work is shown by the red shaded area [151].
3.4. Experiment
At TRIUMF, ocular melanoma patients have been treated with protons since 1995 [102].
Tumours are usually marked with tantalum clips and orthogonal X-rays are used at the
treatment room for accurate patient positioning. The treatment planning software (TPS)
EYEPLAN [152, 153] was used to define the gaze angle, incoming beam energy, energy
spread and the patient collimator. The treatment is delivered over four subsequent days with
the patient receiving 12.5 Gy every fraction. Prior to treatment, the patient is carefully
positioned so that the tantalum clips are aligned with respect to the treatment plan.
For proton therapy, a 74 MeV beam is extracted from TRIUMF’s main cyclotron. The
beam traverses through TRIUMF medical beam line 2C1 and penetrates a 0.8 mm thick
lead scatterer with a collimator cutting away the lateral tails of the beam. The beamline is
illustrated in Figure 3.9. The beam core is unaffected by the collimator and is uniform across
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its width. The beam energy is then degraded to the maximum required using a PMMA
range shifter. The beam energy is then varied using a PMMAmodulator wheel with varying
thickness, producing a series of Bragg peaks of varying energy with different heights to form
an overall Spread-Out Bragg Peak (SOBP) with flat plateau region to cover the entire tumour
volume in the axial direction. For more details see [154].
Fig. 3.9 Arrangement and setup of the equipment for patient treatment [154].
During experiments a Markus ion chamber (PTWModel N23343) was used to measure
the Raw Bragg Peak (RBP) and the SOBP in a water phantom. The waterbox had an external
length 144 mm with wall thickness 2.9 mm. The chamber was fixed to a 3-D stage and
was moved in the axial, horizontal and vertical directions. The experimental error was 200
µm due to the range shifter uncertainty and 300 µm due to the water phantom positioning.
These errors added in quadrature gave a total uncertainty of 360 µm. A PMMA phantom
(C5H8O2) of length 55.55 mm and radius 11.5 mm was irradiated with protons, see Figures
3.10 and 3.11. The phantom was irradiated twice: with a RBP and a 23 mm SOBP. In both
cases the cumulative dose was 50 Gy and the collimator was 25 mm in diameter as shown in
Figure 3.10. The dose was comparable to that delivered during a single treatment fraction
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and the measurement was made in the centre of the plateau of the 23 mm SOBP.
The PET scans were carried out at University of British Columbia (UBC) hospital 11
to 13 minutes after end of beam (EOB). The delay was due to 2.5 km transportation of the
phantom between TRIUMF and UBC PET Suite. Each scan was for 60 minutes and followed
by a transmission scan. The scanner used was a Siemens Focus 120 µPET with a resolution
of (1.8 mm)3 [155]. Data were fully corrected for randoms, attenuation, scatter, and dead
time. After Fourier rebinning, images were reconstructed using 2-D filtered back-projection,
calibrated, and decay corrected. To assess the proton range, the data was projected along the
beam axis.
Figure 3.12 shows the 2-D projections of the PET activity from both 60 mins scans.
The yellow outlines represent the dimensions of the PMMA phantom as determined by the
transmission scan. Figs 3.12a and 3.12c show the scan from the RBP irradiation in the
sagittal and transverse plane respectively. It can be seen that the 25 mm collimator was used
hence the transverse beam width was larger than the PMMA phantom. This resulted in the
phantom being activated entirely along its width. Figures 3.12b and 3.12d show the scan
from SOBP irradiation in the sagittal and transverse plane respectively. The effect of the
irregular collimator in Figure 3.11 can be observed in the different planes. The presence
of a protruding edge can be observed very well from Figure 3.12d. The degraded beam
now has a wide energy spread which leads to different phantom penetration ranges. Due
to having lower kinetic energies the protons produce less PET isotopes after undergoing
inelastic reactions.
Fig. 3.10 Setup of the lucite phantom irradiation in front of the 25 mm collimator [156].
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(a) Sagittal plane. (b) Transverse plane.
Fig. 3.11 Setup of the lucite phantom irradiation in front of the nozzle with the irregular collimator [156].
(a) Sagittal plane RBP. (b) Sagittal plane SOBP.
(c) Transverse Plane RBP. (d) Transverse Plane SOBP.
Fig. 3.12 Activity from a 1 hour PET scan of PMMA phantom for a RBP (25 mm diameter collimator) and a
SOBP (irregular collimator) projected onto the sagittal and transverse plane [156, 157].
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3.5. Monte Carlo Simulations
3.5.1. Geant4
Geant4 is an all particle Monte Carlo toolkit designed for simulating particle interactions
from 100 TeV down to a few eV. Geant4 is implemented in C++ and has great flexibility
and expandability and thus is used in various applications such as space research, Large
Hadron Collider (LHC) experiments, medical physics and microdosimetry applications
[158–160]. Like other Monte Carlo codes, Geant4 uses a statistical approach of deriving
a macroscopic solution to a problem by the use of random numbers. In the simulation,
particles travel in discrete steps and undergo various types of interactions along the way.
The stochastic nature of the particles and their interactions are simulated using a pseudo-
random generator. The step length and the type of interaction are sampled from the cross
section data, with geometrical constraints taken into account. Sampling of the appropriate
differential cross sections determines the energy and direction of the resultant particles.
Data and expertise have been drawn from many sources around the world and stored in a
repository. Geant4 incorporates a large part of that repository whilst determining particle
interactions in simulations.
3.5.1.1. Mean Free Path and Interaction Length
Particle transport in Geant4 is performed step by step. For a physics interaction, a true step
length is randomly sampled using the mean free path of the interaction or by various step
limitations established by other Geant4 components. The length of the track is determined
by the mean free path or interaction length λ of a particle, given by Equation 3.11:
λ(E) = ©­«
Õ
i
[niσ(Zi,E)]ª®¬
−1
(3.11)
where ni is the number of atoms per volume of the ith element, σ(Z,E) is the total cross
section per atom of the process and
Í
i runs over all the elements in the material. Cross
sections per atom and mean free path may be tabulated during initialization.
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3.5.1.2. Global Structure
Geant4 was designed as a software for users from multiple disciplines with diverse require-
ments. Hence it has been made to be flexible and modular by allowing users to select library
classes that are applicable for their own applications. For example the global category cov-
ers the system of units, constants, numerics and random number handling. Materials and
particles implement facilities necessary to describe the physical properties of particles and
materials for the simulation of particle-matter interactions. The geometry module describes
a geometrical structure and propagating particles. Processes implements models of physical
interactions. An overview of all 17 major categories is illustrated in Figure 3.13.
Fig. 3.13 Overview of major class categories of Geant4 [161].
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3.5.1.3. Mandatory User Classes
In the application program, the G4RunManager class controls the overall behaviour of the
program. Registered under this class are three essential base classes: G4UserDetectorConstr-
uction, G4VUserPhysicsList and G4VUserPrimaryGeneratorAction. In the base class
G4User-DetectorConstruction, the dimensions and materials of the geometry are defined.
Other definitions include scoring regions and visualization properties. The required particle
types, related physics processes and production cuts for photons, electrons and positrons are
registered in the base classG4VUserPhysicsList. The classG4VUserPrimaryGeneratorAction
is where the energy, direction, size, particle types are defined for the particle beam.
3.5.1.4. Optional User Classes
Along with the mandatory user classes mentioned previously, Geant4 also provides other
optional user classes for obtaining data at various stages or for more in-depth control of the
simulation. These classes are listed in Table 3.3.
Table 3.3 Optional user action base classes of Geant4 and the times of execution [161].
User action class Time of execution
G4UserRunAction at the beginning and end of each simulation
G4UserEventAction at beginning and end of each particle history
G4UserStackingAction at the start of each history; when a new track is pushed onto the stack
when the Urgent stack becomes empty
G4UserTrackingAction at the beginning and end of each particle trajectory
G4UserSteppingAction at the end of each step
3.5.1.5. Physics List
Multiple physics lists can be used in Geant4 depending on the particular application. The
suitability of a particular physics list depends on numerous variables such as the type of
incident particle, beam energy ranges, required accuracy, etc. For Geant4 version 10.1, three
physics lists were investigated: QGSP-BERT-HP,QGSP-BIC-HP andQGSP-BIC-AllHP.
They were chosen as they have been listed as the most suitable for low energy applications
such amedical application and radio-protection [161]. They are all described in the following
paragraphs.
Bertini Intranuclear Cascade High Precision (QGSP-BERT-HP) [162] solves the
Boltzmann equation. It models a target nucleus by concentric shells of uniform density
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to approximate the continuously changing density distribution of nuclear matter within the
nuclei. An incident particle can produce secondaries which can interact with nucleons or
be absorbed. The cascade is stopped when all particles that are capable, have escaped the
nucleus. When the final state is reached energy conservation is verified. This is implemented
in Geant4 through the creation of virtual photons with energies to balance initial and final
state particle energies. The Bertini Cascade model has been validated extensively between
100 MeV to 10 GeV proton-induced reactions in different targets. The Bertini Intranuclear
Cascade physics list uses a pre-equilibrium model, a simple nucleus explosion model, a
fission model, and an evaporation model. For more information on these models, see [161].
The model is valid for p, n, pi, γs (between 0 and 10 GeV energy) and other particles. All
types of nuclear targets are possible. For the model to be valid, the following condition must
be satisfied:
λB
v
<< τc << ∆t (3.12)
where λB is the deBroglie wavelength, v is the average relative velocity between two
nucleons and ∆t is the time between collisions. At energies below 200 MeV, this condition
is not valid and the pre-equilibrium model has to be implemented. At energy levels greater
than 10 GeV, the intranuclear cascade model breaks down [161].
Binary Intranuclear Cascade High Precision (QGSP-BIC-HP) model uses a new
approach to cascade calculations. It is based on a detailed 3-D model of the nucleus and
based on binary scattering between the incident particle and the nucleons participating in
the collision. Using a straight trajectory, the distance dmini of closest approach to each target
nucleon i and the corresponding time of flight tdi is calculated. It is assumed that the target
nucleus does not move. The interaction cross section σi is determined greatly by the dmini .
If the dmini <
√
σi
pi , the interaction is classified as a collision. The particle is tracked collision
to collision according to its corresponding time step tdi . If secondaries are created, they
are treated like the primary. All possible collisions are calculated similar to the previous
step, with the addition that new primary particles may be short-lived and may decay. A
decay is treated similar to a collision, the collision time being the time until the decay of
the particle. The cascade terminates when the average energy of all participants within the
nuclear boundaries are below the set threshold. The remaining pre-fragment will be treated
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by pre-equilibrium decay and de-excitation models described in [161].
The *-HP variant of physics lists (such as QGSP-BERT-HP and QGSP-BIC-HP) denotes
the use of the NeutronHPmodel for neutron interactions between thermal upto 20MeV ener-
gies. This model uses cross sections from the ENDF/B-VI evaluated library [161]. Neutron
interactions are categorised into four possibilities: radiative capture, elastic scattering, fis-
sion and inelastic scattering and are compliant with other hadronic models within the Geant4
toolkit. For version 9.6 the Electromagnetic Option3 package was used. Bertini cascade and
Binary cascade was applied to protons and neutrons except at low energies where the high
precision G4NeutronHP package was used for neutrons. To describe elastic interactions, the
HadronElastic process was used for all particles. The G4HadronElastic model was applied
for all particles except for low energy neutrons for which the G4NeutronHPElastic model
was preferred. Table 3.4 lists the physics lists that were used in this work.
Table 3.4 Hadronic models used in the Geant4 9.6 simulations and their set energy ranges.
Hadronic Process Particles Geant4 Geant4 Geant4 Energy
processes models datasets range
Elastic scattering All particles except G4HadronElastic G4HadronElastic G4HadronElastic 0–5 GeV
low energy neutrons Process DataSet
Elastic scattering Low energy neutrons G4HadronElastic G4NeutronHPElastic G4NeutronHPElastic 0–20 MeV
Process Data
Inelastic process Protons G4ProtonInelastic G4Bertini G4ProtonInelastic 0–5 GeV
for protons Process Cross Section
Inelastic process GenericIon, Deuteron, G4IonInelastic G4QMDReaction G4IonsShen 0–5 GeV
for ions Triton, 3He, Alpha Process Cross Section
Inelastic scattering Neutron G4NeutronInelastic G4NeutronHPInelastic G4NeutronHP 0–20 MeV
for neutrons Process InelasticData
G4Bertini G4NeutronInelastic 19.9 MeV–
Cross Section 5 Gev
Binary Intranuclear Cascade All High Precision (QGSP-BIC-AllHP) was used to
describe hadronic interactions. It is a new data-driven all particle, high precision physics
model that uses the TALYS-based Evaluated Nuclear Data Library (TENDL). TENDL is
based on experimental and calculation results of the TALYS nuclear model code to produce
a nuclear data library for Alpha, Deuteron, 3He, Proton and Triton particles for energies
below 200 MeV. The proton sub-library contains cross sections of about 2800 isotopes. This
model has been validated against experimental data [163]. In this work TENDL 2015 cross
sections were used with Geant4 10.1 for energies below 200 MeV.
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3.5.1.6. Continuous energy loss
Two parameters inGeant4 simulation are range cut and step length. Range cut is the threshold
energy for producing secondary particles (γ,e, β+) after electromagnetic interactions. Below
the range cut threshold, the energy loss of an ion occurs continuously along the ion track
(at each step), while above the threshold, the loss is caused by the production of secondary
particles [164]. All generated particles are tracked until no energy is left. Information on
the calculation of stopping power is given in [161]. Step length is the distance a particle has
to travel for an interaction to take place. The continuous energy loss of charged particles is
calculated in Geant4 by the Bethe-Bloch formula (Equation 3.5). The continuous energy loss
imposes a limit on the step length, because of the energy dependence of the cross-sections
[164]. The energy deposited is calculated using Equation 3.13.
Continuous energy loss = Steplength × dE
dz
(3.13)
with dEdz the restricted stopping power of the charged particle at the beginning of the step.
In high-energy gradient regions (such as the Bragg-peak), the approximation of constant
cross-sections along the step may lead to an inaccurate dose deposition. In Geant4 the step
length of a particle is inversely proportional to the kinetic energy of the particle i.e. at lower
energies the particles experiences smaller step lengths and vice versa. This feature has been
incorporated to save computation time. The default maximum step-length is 1 mm. For our
investigation this is too high, hence a maximum step-length inside the phantom was limited
to 0.1 mm using the StepLimit function.
3.5.1.7. Radioactive Decay
G4RadioactiveDecay class and others are used to calculate the decay of radioactive nuclei
by emission of α, β+, β− and by electron capture (EC). The information related to half
lives, binding energy levels for parent/daughter nuclide, decay branching ratios and energies
of decay process are obtained from Evaluated Nuclear Structure Data File (ENSDF). More
details can be found in Chapter 44 of [161].
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3.5.2. Materials and Methods
In Geant4 complex volumes and geometries are constructed from combinations of much
simpler shapes (cubes, spheres, cylinders, cones, etc.). Each shape may have its own defined
material. The entire Geant4 experimental geometry was built in a large cube defined as the
“experimental hall”. The Hall was usually constructed of air, but could also be defined
as vacuum or any other material. All materials in Geant4 are generated from user-defined
atomic elements. The elements are defined based on atomic numbers and masses. From
these basic building blocks larger volumes of solids and gases were generated.
The two phantoms have been simulated in this work, a water and a PMMA phantom,
illustrated in Figure 3.14. The first target, a waterbox, was reproduced as two cuboids. The
first layer was PMMA plastic, followed by a second layer of water see Figure 3.14a. The
second was a PMMA cylinder, see Figure 3.14b. PMMA plastic with a density of 1.2 g/cm3
had to be added to thematerials class and water wasG4_water taken from the NIST database.
The entire beamline was simulated in FLUKA and a phase space file was generated at
the nozzle, shown in Figure 3.9. The FLUKA simulation was optimized for RBP, SOBP and
neutron fields typical for the beamline, for further information see [165]. This generated
phase space file was used by both Geant4 and FLUKA to reduce computation time and to
ensure that the beam properties between the two Monte Carlo codes was identical. The
proton beam energy was set to 74.05 MeV and the energy spread was assumed Gaussian
with a FWHM of 1.5 MeV. The file contained the following variables: id number of the
particle, the particle (x, y, z) coordinates, the x direction cosine, y direction cosine and
particle momentum at the collimator of the nozzle. The total number of primaries in the
phase space file was 7 × 106.
3.5.3. FLUKA
FLUKA is a general purpose Monte Carlo toolkit for calculations of particle transport and
interaction with matter. It is applicable for very low keV energy to TeV energy levels such
as shielding, target design, calorimetry, hadron therapy, neutrino physics, cosmic rays, etc
[166]. FLUKA can simulate interactions of approximately 60 particles with a large energy
span and is written in FORTRAN. For this work FLUKA version 2011.2c.4 was used, see
[165] for more details. Isotope production in FLUKA is always handled internally and the
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(a) Waterbox phantom. (b) Lucite phantom.
Fig. 3.14 Two phantoms used in this investigation. Target materials PMMA and water is indicated by the
colours green and blue respectively.
tabulated cross sections used are not accessible to the user for comparison.
3.6. Results
In this section the results of themodel inGeant4 are comparedwith FLUKAand experimental
data. The study was done using two targets: a waterbox for benchmarking the model and a
PMMA cylinder. Two different beams were used on the targets, a RBP and a SOBP, both
with a dose of 50 Gy and a proton energy of 74.05 MeV. Multiple physics lists were used in
Geant4 10.1 in order for the best match with measurements to be chosen. This was done for
the RBP case only.
3.6.1. Dose-Depth Comparison
Figure 3.15a and 3.15b show the raw and spreadout Bragg peaks from different Monte Carlo
models and measurements made with the Markus chamber. The experimental error was due
to uncertainties in the setup and positioning of the Markus chamber along the beam axis.
The axial dose was normalized to 1 at the height of the Bragg peak to compare its shape.
From measurements, the maximum point of the RBP was at 32.39 mm and 80% fall-off
was at 32.96 mm. Compared to this, the range in simulations was underestimated. The
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difference in range at distal 80% fall-off is 40 µm for FLUKA, 60 µm for Geant4 9.6 and 120
µm for 10.1. Compared to the experimental uncertainty of 360 µm the Monte Carlo codes
performed really well. Figure 3.16a illustrates theMonte Carlo deviation frommeasurements
for a RBP throughout the depth of the target. Up to 23 mm depth the three Monte Carlo
codes show small deviations from measurements. Closer to the distal edge of the Bragg
peak, the deviations were larger. The maximum percentage differences were 6.4 ± 0.12%
for FLUKA at 31.5 mm, 3.9 ± 0.3% at 18 mm for Geant4 9.6 and 4.1 ± 0.3% at 18 mm for
Geant4 10.1. These differences are due to the different physics lists implemented in FLUKA
and Geant4.
Figure 3.15b illustrates the dose deposition from a SOBP with a width of 23 mm.
All curves have been normalized to 1 at the centre of the SOBP. From Markus chamber
measurements, the 80% fall-off from the centre of the SOBPwas at 30.51mm approximately.
The difference in range at distal 80% fall-off is underestimated by 50 µm for FLUKA, 20
µm for Geant4 9.6 and 130 µm for 10.1. The largest difference was 1.4 ± 0.8% at 29 mm
depth for FLUKA, 1.2 ± 6% at 30 mm for Geant4 9.6 and 4 ± .8% at 16 mm for Geant4
10.1. Beyond 20 mm depth the Geant4 simulations differ noticeably from measurements
especially near the distal fall off, however they were all able to reliably reproduce the raw
and spread out Bragg peaks similar to [167] and [168].
Figures 3.17a and 3.17b illustrate the dose deposition from a RBP and a SOBP in the
PMMA phantom. As the dose deposition can not be measured with the Markus chamber in
the solid phantom, the Geant4 simulations are being compared the FLUKA results. Figure
3.18a illustrates the simulations deviation from measurements for a RBP throughout the
depth of the target. All three simulations agreed that the RBP was at 31.4 mm, the maximum
percentage difference from FLUKA was -9% at 30 mm for Geant4 9.6 and -6% at 30 mm
depth for version 10.1. For SOBP, figure 3.18b, the maximum deviations from FLUKA for
Geant4 9.6 and 10.1 were both 2% at 29 mm. Overall Geant4 10.1 had better agreement
than 9.6 with FLUKA for dose deposition inside PMMA. Interestingly, the deviation for the
SOBP is smaller in area than for the RBP. This is also observed in the water phantom in the
comparison with experiment.
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(a) Comparison of energy deposition from a 74 MeV proton beam.
(b) Comparison of the SOBPs with 23 mm width and a 80% fall-off at 30.5 mm.
Fig. 3.15 Dose comparison between Geant4, FLUKA and measured data for a proton beam in waterbox. The
error bars take into account experimental uncertainty in energy and position measurement.
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(a) Difference for RBPs.
(b) Difference for SOBPs.
Fig. 3.16 Difference comparison between Geant4, FLUKA and measured data, using Markus chamber, for a
proton beam in waterbox. The error bars take into account experimental uncertainty in energy and position
measurement. For both RBP and SOBP, FLUKA performed worse than Geant4 at estimating entrance dose.
86 PET Scanning of Ocular Melanoma after Proton Therapy
(a) Comparison of the RBPs.
(b) Comparison of the SOBPs.
Fig. 3.17 Dose comparison between Geant4 and FLUKA for a proton beam in lucite.
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(a) Comparison of the RBPs.
(b) Comparison of the SOBPs.
Fig. 3.18 Difference comparison between Geant4 and FLUKA for a proton beam in lucite. For RBP and SOBP
Geant4 10.1 agreed better than 9.6 with FLUKA.
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3.6.2. β+ Activity Decay
As mentioned before, the lucite phantom was scanned at UBC hospital using a µPET
scanner for different beam parameters. Figures 3.19a and 3.19b compares the decay curves
between the three simulations and from the µPET from the RBP and SOBP irradiation, the
distributions have been normalized to 1 at the beginning of the scan. On the other hand,
Figures 3.19c and 3.19d shows the difference between the simulations and measurements
for RBP and SOBP. Both FLUKA and Geant4 9.6 have good agreement with the data, with
a maximum point-to-point percentage difference for the RBP of 0.9% for both. In Figure
3.19d, it can be observed that for the SOBP irradiation, Geant4 9.6 and FLUKA agree
very well with the data. From Figure 3.19c the maximum difference was 1.9% for both
FLUKA and Geant4 9.6. However, the percentage difference for Geant4 10.1 for the RBP
and the SOBP was 14% and 15% respectively; a clear disagreement with the experimental
measurements.
For both irradiations, the overproduction of 13N compared to 11C resulted in the observed
faster decay in Geant4 10.1. This is traced back to a greater fraction of the total PET activity
being comprised of 13N with a short half-life of 10 min. Therefore an overproduction of
13N resulted in the observed faster decay. The production cross section of 13N via the
16O(p,2(pn)) reaction is discussed in Section 3.6.3.
3.6.3. Axial Isotopic Yield
In this work axial isotopic yield is defined as the β+ activity along the z axis integrated across
the radii and for individual isotopes in the lucite phantom at end of beam (EOB). The axial
yield is illustrated in Figure 3.20 from QGSP-BERT-HP and QGSP-BIC-HP and Figure 3.21
from QGSP-BIC-AllHP. Figure 3.20 has been normalized to maximum total activity. On the
other hand Figure 3.21 was normalized to the isotope with maximum activity to keep the
plots legible to the reader by reducing the number of lines present. The calculated isotopic
distributions are illustrated after 0 mins (sub-figure (a), (b)), 15 mins (sub-figure (c), (d))
and 30 mins (sub-figure (e), (f)) from EOB. This shows the decay of the three PET isotopes
over time. As more time progresses the short lived isotope (15O) decays significantly and
contributes less to the total activity inside the phantom. In Figure 3.20 the activity from
QGSP-BIC-HP was found to be most discrepant with FLUKA, whereas QGSP-BERT-HP
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(a) Comparison between simulations and PET scanner
for a RBP.
(b) Comparison between simulations and PET scanner
for a SOBP.
(c) Difference between the experimental data and the MC
simulations for a RBP.
(d) Difference between the experimental data and the MC
simulations for a SOBP.
Fig. 3.19 Comparison of the Activity decay curves for the PMMA target induced by a 23 mm SOBP of 74 MeV
extracted protons. The distributions have been normalized to 1 at the beginning of the scan.
performed slightly better. While the activity peak from QGSP-BIC-HP near the end of the
proton range is discrepant, it is an expected outcome from QGSP-BIC-HP. Similar results
have been shown in previous work presented in [167]. The excessive peak near the end of
the proton range is due to discrepant cross sections of the isotopes. 30 minutes after EOB,
almost all the activity is from the decay of 11C isotope as shown in Figures 3.20e and 3.20f.
In Figure 3.21, for 11C and 15O, there is a good agreement between FLUKA and both
versions of Geant4, but 10.1 is slightly better. For 13N, FLUKA has disagreement with
Geant4 9.6, whereas 10.1 calculates a significant overproduction and is in complete dis-
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agreement. Figure 3.21c shows the PET activity 15 minutes after EOB, the 15O activity
becomes negligible due to its short half life. The over production of 13N in Geant4 10.1
is due to the discrepancy present in TENDL cross sections used. The over production of
13N results in excess total activity. This cross section discrepancy is illustrated in Figure
3.22c. The activity induced from a SOBP is illustrated in Figure 3.21b. The isotopic profiles
agreement are similar to those in the RBP case. In both cases, Geant4 10.1 results were
normalized to the over produced 13N as it had the highest count. Therefore while it may
appear from Figures 3.21c and 3.21d that 11C (blue dotted line) is under produced in 10.1
with respect to FLUKA and Geant4 9.6, that is not the case. After 30 minutes from EOB,
11C contributes to the most activity according to calculations from Geant4 9.6 and FLUKA
only. This is shown in Figures 3.21e and 3.21f.
The measured activity of the phantom in the sagittal plane (Figures 3.12a and 3.12b) has
been projected in 1-D and presented in this section as the measured axial activity of the target
in Figures 3.26 and 3.27 respectively. When comparing the axial activity profile of the lucite
phantom, the simulations agree well with each other as illustrated in Figures 3.26 for the
RBP and 3.27 for the SOBP. However, there is a general smearing effect that takes place due
to the resolution of the scanner. As a result, to make suitable comparisons, the simulation
results were convoluted with a Gaussian function assuming a detector resolution of 1.8 mm
on average [155]. For the RBP, the measured distal 50% fall-off was at 27.9 ± 1.8 mm.
FLUKA and Geant4 9.6 underestimate the 50% range by 2.4 mm and 2.7 mm respectively,
on the other hand Geant4 10.1 overestimates the range by 2.7 mm due to the overestimated
13N production at the end of proton range. For this case, the range was calculated more
accurately by FLUKA than either versions of Geant4. For the SOBP, the measured distal
50% fall-off was at 21.9 ± 1.8 mm. Again, both FLUKA and Geant4 9.6 underestimate the
50% range by 3.5 mm and 2.5 mm respectively, while Geant4 10.1 slightly overestimates
the range by 1.0 mm, within the experimental uncertainty. For this case, Geant4 10.1 was
able to calculate the range within experimental error.
For both cases the type of beam can be easily identified from the scanner data as opposed
to earlier work presented in [118]. Hence the loss of information due to the resolution of
the scanner does not hinder the potential to use PET scanning as a means to verify very
different doses (e.g. RBP versus SOBP) delivered in the cylindrical lucite phantom. On
the other hand, the difference between the simulations (for FLUKA and Geant4 9.6) and the
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(a) Profile at EOB using BERT-HP physics. (b) Profile at EOB using BIC-HP physics.
(c) Profile after 15 mins using BERT-HP physics. (d) Profile after 15 mins using BIC-HP physics.
(e) Profile after 30 mins using BERT-HP physics. (f) Profile after 30 mins using BIC-HP physics.
Fig. 3.20 Axial profile comparison of the cylindrical target between Geant4 and FLUKA for a RBP proton beam
in lucite at EOB, 15 mins and 30 mins after EOB. The dotted lines represent activity from FLUKA and solid
lines Geant4 10.1, either Bertini (BERT-HP) or Binary Cascade (BIC-HP). All plots have been normalized to
maximum total activity.
92 PET Scanning of Ocular Melanoma after Proton Therapy
(a) The axial profile at EOB for a RBP. (b) The axial profile at EOB for a SOBP.
(c) The axial profile after 15 mins for a RBP. (d) The axial profile after 15 mins for a SOBP.
(e) The axial profile after 30 mins for a RBP. (f) The axial profile after 30 mins for a SOBP.
Fig. 3.21 Comparison between Geant4 and FLUKA for a RBP and SOBP proton beam in lucite at EOB, 15
mins and 30 mins after EOB using Binary Cascade all HP physics. The dashed lines represent activity from
FLUKA, solid lines Geant4 9.6 and the dotted lines Geant4 10.1. Version 10.1 has been normalized to 13N to
highlight the shape. If 11C was used, information about the other isotopes would be lost.
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experimental reconstructed activity depth is not within the treatment margin of 2.5 mm. This
means that the application of this technique is limited by the achievable resolution of the
scanner, especially since in a patient, slight diffusion of the isotopes in the eye is observed
[106]. The activity depth deposition from Geant4 10.1 lies within treatment margins despite
errors. Further discussion of this error and its correction are discussed in Section 3.6.4.
3.6.4. Correction factor for TENDL cross section
The prediction accuracy of PET isotope production depend almost entirely on the reaction
cross section used by the Monte Carlo. Figure 3.22 compares the experimental reaction
cross sections (EXFOR) with the TALYS Evaluated libraries (TENDL) used by Geant4
10.1 production of 11C,15O and 13N. The sources of the EXFOR cross sections are identical
to those in Figure 3.8. The red shaded region indicates the energy range of the proton
beam inside the phantom. It can be observed that the two libraries have varying levels
of agreement. For the 12C(p,pn)11C reaction in Figure 3.22a, TENDL overestimates in
one region and underestimates in another leading to a cancellation of the error between 0
MeV to 70 MeV. For the 16O(p,3(pn))11C reaction in Figure 3.22b, TENDL agrees well
with EXFOR between 0 MeV to 50 MeV and underestimates between 51 MeV to 70 MeV.
Therefore TENDL will underestimate 11C production from this reaction. However this
reaction is significantly less likely to occur thus the underestimation from TENDL can be
neglected. For the 16O(p,pn)15O reaction in Figure 3.22d, TENDL overestimates in the 0
MeV to 40 MeV region and underestimates between 41 MeV to 70 MeV. The two errors
cancel each other out thus leading to an acceptable level of agreement in the entire energy
region. For the 16O(p,2(pn))13N reaction in Figure 3.22c, compared to EXFOR, TENDL
overestimates the production yield of 13N throughout the entire region between 0 MeV to
70 MeV. Among all the cross sections investigated for this investigation, this is the most
discrepant one. Therefore a systematic correction or compensation has been attempted for
the overproduction of 13N.
The EXFOR library for the 16O(p,2(pn))13N reaction is made available by the IAEA
and is based on numerous experiments. This cross section is well known and the library
provided is widely accepted by the PET isotope community. Hence the experimental library
is taken as the base and TENDL library has been chosen to be corrected. A compensation or
correction factor can be determined to calculate the correct overall yield of 13N. The factor
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Fig. 3.22 Theoretical and spline fitted experimental cross sections of relevant PET isotopes. Energy range used
in this work in shown by the red shaded area [151].
can be calculated by taking into account the energy spectrum of the incoming beam, Figures
3.23a and 3.24a, then assigning weighting factors to both TENDL and EXFOR cross section
at selective relevant energies ranges, shown in Figures 3.23b and 3.24b. By comparing the
area under both curves, the correction factor can be calculated. Figure 3.25 illustrates the
results from using this method. The discrepancy was reduced from 15% to 3% for RBP;
and from 14% to 02% for the SOBP. The upward trend in the percentage difference was due
to the exponentially decreasing trend in the normalized measured data. When analysing the
axial activities (Figures 3.26 and 3.27), for both RBP and SOBP, it can observed that there is
significant reduction in the overall target activity and the compensated activity agrees much
better with FLUKA.
Figure 3.27a illustrates the axial PET activity from simulations and measurements, with
the RBP indicated with the dotted red line on the secondary y axis. The maximum activity
and peak dose has been normalized to 1. The error bars are obtained from the average
resolution of the scanner. Figure 3.27b illustrates difference between the Monte Carlo
and measurements. For the SOBP, use of the compensation factor caused the maximum
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(a) Proton energy spectrum for RBP.
(b) Weighted cross section for 16O(p,x)13N reaction from a energy spectrum for RBP.
Fig. 3.23 Two peaks are observed in the weighted cross section. The peak between 10 to 30 MeV is due to the
inaccurate resonance from the TENDL cross sections as shown in Figure 3.22c. The second peak at 68 MeV is
due to high number of the protons having that exact energy at the nozzle. The red region indicates the energy
range of the proton inside the target.
normalized PET activity difference between measurements and Geant4 10.1 to decrease
from 14% to 2%. The new distal 50% fall-off also decreased from 23.4 mm to 19.3 mm,
this change was in better agreement with other Monte Carlo codes (18.90 mm from FLUKA
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(a) Proton energy spectrum for SOBP.
(b)Weighted cross section for 16O(p,x)13N reaction from a energy spectrum for SOBP.
Fig. 3.24 The peak between 10 to 30 MeV is due to the inaccurate resonance from the TENDL cross sections
as shown in Figure 3.22c. The rising regime between 35 to 70 MeV is due to the spread of energies present at
the nozzle in order to form the SOBP. The red region indicates the energy range of the proton inside the target.
The individual spikes arise from the individual RBPs.
and 19.9 mm from Geant4 9.6) but more discrepant when compared to the measured 50%
fall-off of 22.4 mm. The maximum difference in the PET activity along the depth of the
phantom also decreased from 4.41 at 31 mm to 0.47 at 25.4 mm depth. Compared to other
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Monte Carlo codes this was the smallest difference compared to 2.72 for FLUKA at 31 mm
and -0.8 at 27.3 mm for Geant4 9.6. These results are compared in Table 3.6. Overall
after the use of the compensation factor all three Monte Carlo codes used agree with each
other to the nearest millimetre for the distal 50% fall-off for both RBP and SOBP. Despite
the less accurate calculation of QGSP-BIC-AllHP of energy deposition, its use of TENDL
cross sections resulted in accurate prediction of 11C and 15O production inside the PMMA
phantom. Unfortunately, the magnitude of error in 13N overproduction was significant
enough to distort the β+ activity beyond the Bragg peak.
(a) Comparison of activity decay for a RBP. (b) Comparison of activity decay for a SOBP.
(c) Difference between the experimental data and the
simulations for a RBP.
(d) Difference between the experimental data and the
simulations for a SOBP.
Fig. 3.25 Comparison of the simulated PET activity with measurements for the PMMA target before and after
13N compensation (notated by 10.1 comp.). The distributions have been normalized to 1 at the beginning of
the scan
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Figure 3.26a illustrates the axial PET activity from simulations and measurements, with
the RBP indicated with the dotted red line on the secondary y axis. The maximum activity
and peak dose has been normalized to 1. The error bars are obtained from the average
resolution of the scanner. Figure 3.26b illustrates difference between the Monte Carlo codes
and measurements. For the RBP, use of the compensation factor caused the maximum
normalized PET activity difference between measurements and Geant4 10.1 to decrease
from 0.15 to 0.03. The new distal 50% fall-off also decreased from 30.5 mm to 24.9 mm,
this change was in better agreement with other Monte Carlo codes (25.5 mm from FLUKA
and 25.2 mm from Geant4 9.6) but more discrepant when compared to the measured 50%
fall-off of 27.8 mm. The maximum difference in the PET activity along the depth of the
phantom also decreased from 5.8 at 33 mm to 0.52 at 28.2 mm depth. Compared to other
Monte Carlo codes this is a small difference compared to 3.1 for FLUKA at 33 mm and -0.83
at 29.5 mm for Geant4 9.6. These results are compared in Table 3.5.
Table 3.5 Parameter comparison between measurements and Monte Carlo for a RBP.
Parameters Measurement FLUKA Geant4 Geant4 Geant49.6 10.1 10.1 Comp.
Max ∆ decay activity NA 2% 2% 14% 2%
Distal 50% fall-off [mm] 27.8 25.5 25.2 30.5 24.9
Max ∆ axial activity NA 3.1 at -0.83 at 5.80 at 0.52 at33 mm 29.5 mm 33 mm 28.2 mm
Table 3.6 Parameter comparison between measurements and Monte Carlo for a SOBP.
Parameters Measurement FLUKA Geant4 Geant4 Geant49.6 10.1 10.1 Comp.
Max ∆ decay activity NA 0.1% 0.1% 15% 3%
Distal 50% fall-off [mm] 22.4 18.90 19.9 23.38 19.30
Max ∆ axial activity NA 2.72 at -0.8 at 4.41 at 0.47 at31 mm 27.3 mm 31 mm 25.4 mm
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(a) PET activity comparison between simulations and PET scanner for a RBP.
(b) Difference between simulations and measurements for a RBP.
Fig. 3.26 Experimental and simulated PET activity for the PMMA phantom. The maximum PET activity has
been normalized to 1 on the primary axis and peak of the dose curves (dashed lines) have been normalized
to 1 on the secondary axis. The use of the correction factor caused the discrepancy between Geant4 10.1 to
decrease substantially.
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(a) PET activity comparison between simulations and PET scanner for a SOBP.
(b) Difference between simulations and measurements for a SOBP.
Fig. 3.27 Experimental and simulated PET activity for the PMMA phantom. The maximum PET activity has
been normalized to 1 on the primary axis and peak of the dose curves (dashed lines) have been normalized to
1 on the secondary axis.
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3.7. Feasibility of using 3-DPrintedPhantoms forClinical ProtonTher-
apy
3.7.1. Introduction
After studies with the lucite cylinder were successful, the investigation moved onto 3-D
printed phantoms of the human eye. 3-D printing can be used to create tissue-equivalent
proton phantom materials and a 3-D printed eye phantom can provide much more realistic
information about the proton depth dose deposition than the previous cylindrical phantom.
Although such phantoms can never absolutely simulate actual patient anatomy, they can
validate, examine, and guide treatment planning under tightly controlled conditions. The
design and experimental work were done by N. Unick, C. Lindsay, C. Dunning and C. Hoehr
[169, 170]. The data analysis and Geant4 simulation was conducted by myself.
In proton therapy uncertainties such as different patient anatomy and presence of hetero-
geneous tissue are quantified and minimized. To test the treatment plan for these uncertain-
ties, a phantom is used to simulate the clinical patient. In our case, a large phantom is not
required. The human eye is a small organ and beam is incident from the front, thus requiring
only a small phantom as shown in Figure 3.10. However, it lacks the anatomical details of a
patient’s eye which can be overcome using 3-D printing technology. A 3-D printed phantom
allows the treatment plan to be tested with the best possible replication of a real life situation.
3.7.2. Materials and Methods
In proton therapy the technologies available for 3-D printing are thermoplastic resin based
Fused filament fabrication (FFF), UV-cured photopolymer PolyJet (PJ) and stereolithography
(SLA) methods. The PJ and SLA methods are of similar costs whereas the FFF is more
expensive at similar density levels. High end PJ machines are capable of higher resolution
than SLA in terms of layer thickness and precision. PJ machines offer layer thickness of 16
µm against SLA’s 50 µm, and lateral precision of 0.1 mm against 0.2 mm [171, 172].
FFF printers print a 3-D object by extruding a stream of heated or melted thermoplastic
material. The semi molten material is positioned layer upon layer from the bottom up. Upon
leaving the heated nozzle, the plastic promptly cools and hardens to form a layer of the
supplied 3-D model. A PJ printer produces a jet of drops of photopolymer that solidify upon
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exposure to UV light. These very thin layers accumulate on the build tray until the part
is complete. This technology can also mix multiple materials together to achieve unique
materials properties and colour. A removable support structure can be printed if required. An
in-depth analysis of the performance of these two approaches for proton therapy application
in presented in [170]. Table 3.7 summarizes the capabilities of FFF and PJ printing methods:
Table 3.7 Comparison of different printing methods [171, 172].
FFF PJ
Manufacturer StrataSys Inc. StrataSys Inc.
Model uPrint SE plus Objet30 Pro
Layer thickness 0.25 mm 0.016 mm
Layer precision 0.9 mm 0.1 mm
Material ABSPlus thermoplastic VeroWhitePlus
Density 1.07 g cm−1 1.17-1.18 g cm−1
Filament diameter 1.75 mm N/A
Cost 1.47 USD/g 0.34 USD/g
The models have been designed in SOLIDWORKS (shown in Figure 3.29a) and printed
from a UV curable resin on a PJ 3-D printer at UBC [170]. The printed phantom tolerances
were based on the resolution of the PolyJet printer. A base diameter of 23 mm in the vertical
axis was chosen to achieve this. More details about the dimensions of the phantom are
illustrated in Figure 3.29b. From Figure 3.29a dimples can be seen on the top, bottom and
side of the phantom. The dimples were added to mount the 3-D printed eye in a gimbal in
front of the beam line and a small hole through the centre of the eye was used to accurately
align it using laser.
3.7.2.1. Experiment
The phantom was irradiated with a broad proton beam incident from the front side at a 45°
angle (Figure 3.28) and then underwent an activity scan for 30 minutes using the MicroPET
scanner, followed by a transmission scan (Figure 3.30b). It was assumed that the scanner had
an average resolution of 1.8 mm [155]. The activity scans are illustrated in two dimensional
projections in Figures 3.30c and 3.30d.
Gamma spectroscopy of VeroWhitePlus was performed immediately after proton irra-
diation and again 1 week later. The first scan indicated activation consistent with PMMA
while the second showed no activity. The material contained no detectable levels of long
lived radioactive isotopes which make them suitable for clinical applications [170].
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Fig. 3.28 Eyeball model in position along the beamline in front of the nozzle. The target has been mounted on
a 3-D printed gimbal used for alignment and positioning.
3.7.2.2. Simulation
To simulate this phantom, the 3-D CADmodel was voxelized and imported in to FLUKA. As
part of the previous work done, a treatment planning program was developed using NumPy,
proton range tables, and the model of the treatment head and eyeball. The output of the
program was the optimal range shifter setting and the modulator wheel plastic size, which
determines the maximum proton range in the eyeball and the width of the clinically useful
proton dose plateau respectively. Using this output, the treatment plan was then verified for
74 MeV protons using FLUKA. The required phase space file was generated and imported
into Geant4 10.1 to determine the beam parameters. The eye phantom geometry has been
generated in Geant4 10.1 usingQGSP-BIC-AllHP physics by combining the following three
geometries: an orb, ellipse and a cylinder. The physics in the simulation was kept the same
as the PMMA cylinder. Two irradiations were done on the eye phantom one with a broad
beam to check for target feasibility for PET analysis; the second irradiation was a narrow
pencil beam similar to that of treatments to investigate axial misalignments.
Simulations were also carried out to investigate whether signal inside the eye phantom
could be used to detect beam alignment with respect to the phantom. The eyeball was
irradiated with a narrow RBP and the PET signal was measured in XYZ planes using voxels
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of (1 mm)3. The beam was moved away from the centre of the phantom in steps of 1 mm
and the resultant PET activity calculated. The final activity was used to investigate whether
the PET signal could be used to determine the isocentre of the beam in the XY plane. All
calculated PET activity from Geant4 has been smeared with a Gaussian function to account
for the (1.8 mm)3 resolution of the MicroPET scanner.
(a) Eyeball model in SOLIDWORKS. (b) Eyeball phantom in Geant4.
Fig. 3.29 The design of the eyeball phantom in SOLIDWORKS and Geant4. In the CADmodel the positioning
dimples can be clearly seen.
3.7.3. Results
The 2-D coronal and sagittal PET activity of the simulated volume is shown in Figure 3.31a
and Figure 3.31b. Data from the transmission scan was first plotted in order to obtain the
exact position of the phantom inside the scanner. The CAD model outline was then placed
and aligned with the transmission scan as shown in Figure 3.30b. Finally the transmission
scan was replaced with the activity measurements on the same axis to give the activity plots
with phantom outline in coronal and sagittal planes.
The 2-D projections are presented as summations of multiple planes, as a single plane
did not show sufficient statistics for analysis. The dose deposited inside the eye phantom
has been successfully calculated as a sum of 11C,15O and 13N isotopes using a scoring mesh
of 0.125 mm3. The Geant4 model was able to reproduce the measured data and exposed
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limitations in the experiment. From Figure 3.30c it can be seen that the PET activity does
not completely align with the phantom outline in the coronal plane. This is because unlike
simulations, there was a mismatch between the phantom irradiation position at TRIUMF and
PET scan position at UBC hospital. From Figure 3.30a it can be observed that the phantom’s
positioning dimple is leaning to the left instead of being at the centre shown by the outlines.
The measured PET activity does not remain well within the boundaries of the phantom
due to the limited resolution of the scanner. Therefore a 1-D projection has been made
for more accurate comparison. Figures 3.31c and 3.31d compare the PET activity from
simulation and measurement in the x and z axis only. It can be seen that when the activity
is projected onto a single axis the results are comparable and Geant4 was able to accurately
reproduce the PET activity within error margins. In the X plane, the measured 50% fall-
off activity was 18.75 mm, Geant4 underestimated the activity by 2.05 mm, shown in
Figure 3.31c. In the Z plane, the measured 50% fall-off activity was 17.45 mm, Geant4
underestimated the activity by 1.2 mm, shown in Figure 3.31d. In both cases the Monte
Carlo results were well within acceptable error margins. Figures 3.31e and 3.31f show
that the percentage difference within the target boundaries in the coronal and sagittal plane
respectively. The phantom boundaries are indicated with the vertical dashed line and the
maximum point to point deviations were -14% and -7% in the coronal plane and sagittal
plane. For both planes error peaks are present near the phantom boundaries due to two main
reasons: limitations in representing the smearing effects of the scanner and the very low
magnitude of the normalized activity near the edges. This provided sufficient evidence of
the model created in Geant4 to investigate the feasibility of calculating the target alignment
using the PET activity in the XY plane of the phantom. This is discussed in the following
paragraph.
Figure 3.32a illustrates the orientation of the beamwith the centre of the eyeball, whereas
figure 3.32b illustrates the PET signal in the transverse plane of the eyeball after several beam
positions in Geant4. From the plot, the beam isocenter can be very easily determined in the
transverse plane upto to 1 mm accuracy. The proton beam position was altered by 1 mm
translations along the X plane and the corresponding β+ emissions recorded. Along the X
plane, the β+ activity was observed to be a Gaussian distribution with a prominent peak,
which correlates with the beam’s centre position. From Figure 3.32b, beam translations
of 1 mm, 2 mm, and 3 mm were easily identifiable from the β+ activity generated inside
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the target. The positive results in this 1-D analysis indicates that further studies should be
carried out with patient collimators of different sizes and a SOBP proton beam. A 3-D
analysis of the PET activity should carried out to investigate the correlation between PET
isotope production and dose-depth deposition.
(a) MicroPET scanner (b) Transmission Scan
(c) Activity scan in coronal plane (d) Activity scan in sagittal plane.
Fig. 3.30 The scan procedure and results of the 3-D printed eye phantom. The phantom outline is from the
CAD model. In Figure 3.30b an artefact from the bed is present near the bottom left corner of the scan. In
transmission scan, warmer colours indicate the greater density of the phantom surrounded by the lower density
air indicated in blue. In activity scan, the warmer colours indicate greater β+ emission activity.
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3.8. Conclusion and Future Work
Proton dose verification with a PET scan after ocular melanoma treatment was simulated
using Geant4. A PMMA phantom was irradiated with a 74 MeV proton RBP and 23 mm
(a) PET activity in the ZX plane. (b) PET activity in the YZ plane.
(c) PET activity comparison in the X plane. (d) PET activity comparison in the Z plane.
(e) Difference between measured data and MC
simulations in the X plane.
(f) Difference between measured data and MC
simulations in the Z plane.
Fig. 3.31 β+ emission activity (as the sum of 11C,15O and 13N) of a PMMA eye phantom calculated in Geant4
10.1. The error bars a determined by the 2-D resolution of the MicroPET scanner.
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(a) Eye phantom with 3 mm offset in the X plane. (b) The obtained PET activity in the X plane.
Fig. 3.32 PET activity at different beam positions using the 3-D printed eye phantom. The dotted lines in 3.32b
show the beam centre position obtained from the peak β+ activity.
SOBP. The phantom was scanned using the microPET scanner at the UBC hospital 11 to
13 minutes after EOB. Simulations with FLUKA and Geant4 version 9.6, and version 10.1
were carried out and compared with experiments. The experimental and simulation results
for energy deposition in water agreed well within experimental uncertainty. The agreement
for time decay of isotopes in PMMA cylinder was adequate between measurement, FLUKA
and Geant4 9.6. Geant4 10.1 showed a large discrepancy due to an overproduction of 13N
which lead to a faster exponential decay of PET activity. This overproduction resulted in
a shift in the axial PET activity deeper into the PMMA phantom thus leading to a greater
proton range discrepancy. However, for a SOBP, Geant4 10.1 had the smallest discrepancy
of the Monte Carlo codes. It must be mentioned that Geant4 9.6 and 10.1 did not have any
13N production discrepancies when using the Bertini High Precision model. Overall, when
compared to measurements, Geant4 10.1 performed better than 9.6 for energy deposition
whereas 9.6 was better for PET isotopes than 10.1. Finally a procedure was also developed to
compensate or correct for the discrepant TENDL cross section for the 16O(p,x)13N reaction.
Using this procedure the overproduction of 13N could be attenuated in post processing of
the Monte Carlo data. The results obtained with through this process in Geant4 10.1 had
excellent agreement with FLUKA and Geant4 9.6, but deviated more from experiments.
The feasibility of using 3-D printed eye phantomwas investigated. Current phantoms are
limited as they lack anatomical details present in patients. 3-D printing offers the possibility
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to produce phantoms with a great level of geometric details such as air gaps or even density
gradients. The 3-D printed eye phantom was irradiated with a broad RBP and discrepancy
between measurements and simulations in the 1-D projection was minor. Despite the good
agreement between simulation and measurement, the experiment can be further improved by
using a 3-D model of the PET scanner and a more realistic scanner resolution, using fiducial
markers during irradiation and having phantom alignment identical during both irradiation
and PET scan. This would allow systematic errors to be accounted for. For calculating
misalignments in the axial direction, there is a strong correlation between the dose and PET
activity. Dose misalignments in the Geant4 simulation as small as 1 mm were detected
from the PET activity. Future investigations could include resultant β+ activity changes
when using non symmetric patient collimators, the presence of soft tissue and skull material
around the eye. By placing radiographic films inside the 3-D printed phantom, the dose
distribution can also be measured.

Chapter 4
Validating Production of PET
Radionuclides in Solid and Liquid
Targets.
This chapter reports on the final project of the second topic of this thesis. It was conducted
at TRIUMF under the supervision of Dr. Cornelia Hoehr. The Monte Carlo (MC) toolkit
Geant4 was used to simulate the production of several PET isotopes. The experimental
results presented here are from a collection of work carried out at TRIUMF over many years
and referenced later in the chapter. FLUKA calculations were performed by A. Infantino,
the Geant4 model was developed and data analysis was conducted by myself. Publications
from this work are available in [96] and [173].
4.1. Introduction
Radioisotopes play a critical role in medicine, enabling diagnostic and therapeutic tech-
niques with 60 million procedures performed worldwide every year. 99mTc is the most
common radioisotope used in nuclear imaging. Everyday in the United States alone, greater
than 30,000 scans are performed using this radioisotope with worldwide usage exceeding
40 million [174]. 99mTc is typically obtained from the decay of its parent isotope 99Mo
which is currently produced in nuclear reactors by the fission and recovery from 235U. The
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vulnerability of the supply of 99Mo has been found when two of the major reactors, the
National Research Universal (NRU) reactor and High Flux Reactor (HFR) in Canada and
Netherlands, both experienced unplanned shutdowns together. At the time, the both reactors
were responsible for 65% of the world’s radioisotope supply. During this time the medical
community had responded by adopting mitigating strategies, such as rescheduling patients
around the availability of 99mTc, using other imaging modalities such as PET, computed
tomography (CT) scans and magnetic resonance imaging (MRI). Numerous other isotope-
producing nuclear reactors are due to end their operation in upcoming years, creating a risk
for loss of a long-term, stable supply of 99Mo and other radioisotopes for medical purposes.
This uncertainty in radioisotope supply is compounded by the effects of the transition from
highly enriched uranium (HEU) to low enriched uranium (LEU) targets for 99Mo production
due to the Global Threat Reduction Initiative [175]. Aside from the shift of using LEU (i.e.
235U content <20%) in existing reactors, these supply disruptions have prompted several
governments (including Canada) to fund the development of alternative methods for the
production of 99Mo or the direct production of 99mTc itself. Proton-induced reactions have
attracted significant interest from the scientific community after cyclotrons proved to be a
feasible alternative to reactor produced radioisotopes [174, 176]. A comparison between the
two approaches are presented in Table 4.1.
Nuclearmedicine uses radiotracers, which aremoleculeswith a radioactive atom emitting
gammas (or other particles), to integrate themselves in the biological mechanisms of a cell,
tissue or organ, giving knowledge about how such tissue works. Medical use of radioactive
isotopes dates back almost to the discovery of radioactivity itself. The first clinical studywith
a radioactive tracer, Radium C (later found to be 214Bi), was carried out in 1925 to measure
the blood flow from one arm into the opposite arm [177]. Nowadays, 99mTc, the world’s most
prevalent medical isotope, is used to monitor blood flow in the hearts of patients suspected
of reduced blood flow. Radioisotopes have also been used in neurology to understand
the inner workings of our brains, especially in cases of neurogeneration. In oncology,
radiotracers, or radiopharmaceuticals, are used to identify cancerous growth and metastases.
Overall, numerous tracers have been developed that help the medical research or clinical
communities understand the metabolic aspects behind the symptoms and the development
of disease. Different tracers will also be able to indicate if a treatment is working or if it has
a high probability of working, thus opening a complete new era in personalized medicine.
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Replacing the radioactive isotope in a radiotracer or radiopharmaceutical with an α or β
emitter can transform a diagnostic tracer into a very efficient and selective therapeutic tool
in killing the cancer cells.
Table 4.1 Comparison between the production of radioisotopes using reactors and cyclotrons.
Nuclear Reactors Cyclotrons
Principle of -Target material irradiation -Target material irradiation
production by charged particle beams. by charged particle beams.
-Inducing nuclear reactions that transmute -Inducing nuclear reactions that transmute
the material into radionuclide of interest. the material into radionuclide of interest.
Particle used Neutrons p, d,3He, α or heavy ion beams
Advantages -Production of neutron rich radionuclides, -Production of proton rich elements used
mostly for therapeutic use. as β+ emitters for PET scans.
-High production efficiency. -Decentralized production allows for back-ups.
-Centralized production: one research -High uptime.
reactor is able to supply to large -High specific activity in most cases.
regions or in some cases globally. -Small investment in comparison to reactor.
-Little long-lived radioactive waste.
Limitations -Extremely high investment cost. -Regional network of cyclotrons and complex
-High operational costs. logistics needed for short-lived produced.
-Large amounts of long-lived radioactive -Radionuclide production limited depending
waste. on installed beam energy.
-Long out-of-service periods.
-Trouble to back-up in case of unforeseen
downtime.
-Often requiring air transport.
-Public safety concerns.
-Non-proliferation treaty concerns.
The Life Sciences division at TRIUMF has three cyclotrons at their disposal. They all
accelerate negatively charged hydrogen ions and use thin carbon foils to extract protons. The
TR13 cyclotron accelerates protons to 13 MeV and is dedicated to the production of PET
isotopes for the Life Sciences division and its collaborators (UBC hospital and the BCCA).
The 30 MeV cyclotron TR30 is owned by Nordion Inc. and operated by TRIUMF for the
production of several medical isotopes for commercial use. This cyclotron is mostly used
for researching into the production of SPECT isotope 99mTc at 24 MeV. The third and final
cyclotron is the 520 MeV machine previously mentioned in Section 3.1, serving several
experimental beam lines simultaneously. α-emitters for the Life Sciences division have been
produced in the target stations of the ISAC facility. The program started in 1980s with TR13
starting production in 1995. Further information can be found in [178].
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4.2. Literature Review
Historically radionuclides were produced using nuclear physics research accelerators. How-
ever in the past several decades industry has responded by designing accelerators solely for
commercial isotope production. Many of these are installed in hospitals, academic research
institutions and commercial facilities specializing in the production/selling of radioisotopes
[179]. Cyclotrons used for biomedical research isotopes production are usually compact,
they accelerate light ions such as protons or in rare cases deuterons or helium. They produce
short lived, proton-rich radioisotopes used for diagnosis and therapy in biomedicine. In
1941 the first cyclotron dedicated to isotope production was at Washington University, St
Louis. It was used to produce 32P, 59Fe, 74As, and 35S. In nuclear medicine radioactive
isotopes are used for diagnosis and therapy. PET, PET/CT and SPECT are the main diag-
nostic techniques in nuclear medicine. For PET imaging important isotopes are 11C, 13N,
15O and 18F. Carbon, nitrogen and oxygen are elemental building blocks of organic matter
which permits the labelling of a variety of radiopharmaceuticals. On the other hand SPECT
uses medium lived radionuclides that are single photon emitters. In this technique a gamma
camera rotates around the patient taking images and creating a cross sectional tomographic
image. A significant advantage of accelerator produced radionuclides is the high specific
activity that can be generated using nuclear interactions between the accelerated ion and the
target material, presented in [180]. Also a smaller amount of radioactive waste is created
using accelerators as opposed to using research reactors. In [180], the saturation yields of
64Cu and 68Ga has been increased from typical values of 5 GBq and 6 GBq to 25 GBq and
40 GBq respectively. This was done by choosing the appropriate energy of the proton beam
and by using enriched liquid solution targets.
In 2012, it was estimated by the IAEA that there were approximately 700 cyclotrons used
primarily for radionuclide production [181]. Nearly 50% were in the 10-20 MeV energy
range and about 75% were being used for the production of 18F for FDG [182]. While the
use of radioisotopes continues to grow worldwide, the number of isotope producing facilities
has not grown at the same rate and the list of radionuclides along with the applications has
not changed significantly over the past decades [183]. Proton accelerating cyclotrons can be
categorized into three broad energies:
• Cyclotrons with less than 20 MeV are mainly used for producing positron emitting
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radionuclides. These isotopes have short half lives and thus the distance between the
cyclotron and the patient is minimized as much as possible. Many cyclotrons have self
shielding using steel thus reducing the need for a shielded bunker. Due to patient dose
requirements, in addition to the number of patients per day, many cyclotrons provide
up to 50 µA of beam current onto the target with the capability of using multiple
targets simultaneously. Typical examples are 82Rb, 18F, 13N, and 11C.
• Cyclotrons with proton energies between 20 to 35 MeV are primarily used to produce
many of the SPECT radioisotopes as well as the several PET isotopes. SPECT isotopes
have medium half-lives and are generated in dedicated facilities. Isotopes with longer
half lives allow delivery to more distant locations thus leading to the use of high
power targets and higher production throughput. Examples of isotopes produced at
this energy range are 201Tl, 123I, 99mTc, and 67Ga.
• Cyclotrons with proton energies greater than 35 MeV are used for the production of
radiotherapy isotopes. Required beam current can be in the 1 mA range. Examples of
SPECT isotopes are 77Br, 103Pd, and 186Re.
Production of various radionuclides is now routine. Nevertheless, there is a lack of both
expert skills in targetry and of a good understanding of the interplay between the cyclotron,
the target and subsequent labeling chemistry. These factors are crucial for continued devel-
opment and use of PET isotopes. The Monte Carlo codes such FLUKA, Geant4, MCNPX
toolkit have long been essential tools in accelerator design and shielding studies; their appli-
cation at lower energies for medical application is gaining in popularity, and it is therefore
important to explore their strengths and limitations in this energy regime. The accuracy
relies on the quality of reaction cross section data used by the Monte Carlo codes. Monte
Carlo codes can be used to simulate the production yields of various isotopes from different
targets, thus allowing for the optimization of the target design to maximize the isotope to
contaminant ratio. The irradiated target can be in solid, liquid or gaseous form and may
be required to satisfy strict design constraints. For example, a target may have material
composition restrictions to achieve a desired specific activity, proton energy constraints to
avoid unwanted isotope production, or a requirement to survive several hours of proton irra-
diation without any thermal issues. As a result, cyclotron targets and materials can be very
expensive. MC simulations can be used to assess the expected yield and for the optimization
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of target design and materials to maximize yield of the isotope of interest without increasing
the production of contaminants [184–187]. The success in using MC for yield assessment
depends strongly on the cross section data used for the simulation. Despite a large number
of experiments carried out with proton activation, the data available are often inconsistent
and at times data from different experiments conflict each other.
In this work, the MC package Geant4 has been used to simulate the yields of the
following PET isotopes: 13N, 18F, 44Sc, 52Mn, 55Co 61Cu, 68Ga, 86Y, 89Zr and 94mTc. The
results have been compared to results from another MC package, FLUKA, and experiments
[188]. Recently, there has been a new development in Geant4 allowing the use of TENDL
cross sections instead of the traditional nuclear data files such as the ENDF/B-VII library.
We set out to test different physics models in Geant4 to find the best approximator of isotopic
yield to experiments.
4.3. Materials and methods
4.3.1. Experiments
The experimental details have been described and, where appropriate, referenced in [188].
The TR13 cyclotron is located at TRIUMF, Vancouver, Canada and used for routine produc-
tion of medical isotopes. It is self shielded and accelerates negative hydrogen ions to 13MeV
energy with currents of routinely up to 25 µA. Extraction occurs with the use of a carbon foil
which strips off the two electrons thus reversing the charge and bending trajectory of the ion
in the magnetic field. The cyclotron has two extraction ports with a target selector, which
can move the target into the proton beam. Further details of the cyclotron are provided in
[189, 190].
The selector has four positions, allowing eight different targets to be installed at a time.
Two target assemblies were simulated in Geant4. Figures 4.1 and 4.2 illustrate the liquid and
solid target assemblies respectively with each component labelled numerically. The proton
beam enters the assembly though the baffle (1) and collimator rings (2). The beam is then
collimated further with a four quadrant conical collimator (3) contained within an insulator
flange (4). Each quadrant of the collimator is capable of measuring beam current separately
and the four readings can be used to deduce the position of the proton beam. The beam then
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enters the target assembly through a 25 µm thick aluminium foil (5), which separates the
cyclotron vacuum from the target assembly. Due to the power deposition in the foil, helium
cooling (6) is applied to the foil in the helium window (7).
Fig. 4.1 Liquid target assembly. Fig. 4.2 Solid target assembly.
The liquid target (9) is a closed volume of 0.9 ml capacity, with 8 mm depth and 12 mm
diameter. The liquid target is separated from the helium cooling (6) by a HAVAR foil (8).
HAVAR is a cobalt based metal alloy with high tensile strength. It is composed of 42.5%
cobalt, 13.0% nickel, 20.0% chromium, 2.0% molybdenum, 0.2% carbon, 0.04% beryllium,
1.6%manganese, 2.8% tungsten and remainder iron [191]. The target body (10) is composed
of standard niobium. Target loading and unloading is performed using an automated loading
system [192].
In the solid target assembly, the foil target (11) is in the place of the HAVAR with helium
jets for cooling on both sides (6) and (12). Due to the use of thin foils, the proton beam
traverses through the target and is finally stopped by the water cooled aluminium block (13)
which acts as the beam dump. The geometries were modelled as accurately as possible by
using dimensions from technical drawings.
The nuclear and chemical properties of the liquid and solid target materials are listed in
Table 4.2. After the irradiation, isotopic yield measurements were performed using gamma-
ray spectrometry analysis or ionization chamber measurements. All measured yields were
decay-corrected to the end of bombardment (EOB). When multiple irradiations took place
for the same isotope, the yield was normalized to the beam current prior to calculating the
average saturation yield. For more details see [188].
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4.3.2. Monte Carlo Simulations
4.3.2.1. Geant4
Geant4 has also been previously discussed in Section 3.5.1. Details about the model devel-
oped for this investigation, such as material definitions, physics lists and cross sections used
are presented later in Sections 4.3.2.4, 4.3.2.5, 4.3.2.6, and 4.3.2.7.
4.3.2.2. Saturation Yields
In Geant4, the calculation of induced activity relies on the cross section library used for the
inelastic nuclear reactions. These cross sections are included in the TENDL1.3 package and
can directly calculate the number of isotopes produced. The production rate for each isotope
is simulated taking into account primary proton impact, secondary interactions and decay of
other isotopes produced in these interactions.
Geant4 calculates the isotope production from the primary particle induced production
and also the full Bateman solution considering the breeding of radioactive decay products.
The production rate for a radioisotope is given by:
dN
dt
=
nI
npp
(4.1)
where N is the number of isotopes produced, n is the number of isotopes produced per
unit mass and unit time (a function of the proton flux, the target density, and the nuclear
cross section), I is the proton beam current from the accelerator, np is the number of incident
protons, and p is the proton electric charge, see [193]. After the production, the radioisotopes
will decay exponentially over time. During the beam on duration, the time-evolution can be
described by:
dN(t)
dt
=
nI
npp
−λN(t) (4.2)
where λ is the decay constant of the isotope. Considering the boundary condition, at t=0
secs there was no radioactive material in the target. The solution of Equation 4.2 gives the
120 Validating Production of PET Radionuclides in Solid and Liquid Targets.
number of isotopes at any given time t during the irradiation:
N(t) = nI
nppλ
[1− e(−λt)] (4.3)
this equation reaches a saturation level for long irradiation, Nsat , where Nsat = nInppλ .
Using Asat = Nsatλ, the saturation yield Ysat in Bq/µA is given by:
Ysat =
Asat
I
(4.4)
4.3.2.3. Error Propagation
The yield ratio, r, is defined as YMCYE . When calculating ratios, the experimental and MC
uncertainties add in quadrature. Therefore the uncertainty for yield ratio was calculated
using Equation 4.5.
σr
r
=
√(
σMC
YMC
)2
+
(
σE
YE
)2
(4.5)
where σr is the uncertainty of the yield ratio, YMC and σMC are the Monte Carlo yield
and uncertainty respectively and YE and σE are the experimental yield and uncertainty
respectively.
4.3.2.4. Target geometry and material definition
The solid and liquid targets have been represented in Geant4 using the two geometries shown
in Figures 4.1 and 4.2. Geant4 provides a wide range of simple solid geometries that can be
used. More complex geometries such as the conical collimator can be generated by combin-
ing existing shapes with Boolean operators such as G4UnionSolid and G4SubtractionSolid.
The target materials have been divided into two categories: liquid target, containing water
solution of salts, and solid targets. While it is possible to use the natural isotopic composition
of elements from the NIST15 database, user defined isotopic compositions were used in order
to match material definitions in the FLUKA model in [188]. For solid and liquid targets, the
mass fractions were calculated for each element and used in the definition of materials.
In this section, the targets’ material composition, as defined inGeant4, are presented. The
15NIST: National Institute of Standards and Technology
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individual material compositions were defined instead of using internal definitions to know
the exact atomic content and ensure consistency between experiments and simulations. The
liquid targets are water solutions of several salts. Although Geant4 has internal definitions
of all elements, the composition of isotopes were manually setup from [194] to know the
exact atomic content.
18O
The target solution had a density of 1 g/cm3 with mass fractions ω18O = 0.96 and ωwat=0.04.
The definition of 18O is listed in Table 4.3.
natO
The target was composed of deionized water in a volume of hydrogen peroxide (H2O2). The
mass fractions were ωwat=0.994 and ωper=0.006 with a density of 1 g/cm3. The natural
isotopic abundance of oxygen is reported in Table 4.3.
Table 4.3 The composition of liquid target solutions investigated [188].
Element Isotope Fraction% Density [g/cm3]
18O 18 100 1
natO
16 99.757
117 0.038
18 0.205
natMo
92 14.84
2.498
94 9.25
95 15.92
96 16.68
97 9.55
98 24.13
100 9.63
natSr
84 0.56
2.6486 9.8687 7.00
88 82.58
89Y 89 100 4.4
natMo
The salt ammonium tetrahydrate (NH4)nat6 Mo7O24 · 4H2O was used as target. 19.9 g of salt
was dissolved in 12 ml water and 1.2 ml hydrogen peroxide (H2O2). The salt density was
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2.498 g/cm3 and the final solution density was 0.995 g/cm3. The mass fractions calculated
were respectivelyωsalt= 0.599,ωwat=0.361 andωper= 0.040. The natural isotopic abundance
of molybdenum is reported in Table 4.4.
natCa
Two different targets have been simulated: a liquid target (a salt of calcium dissolved inwater)
and a solid target. The salt used as target was calcium nitrate tetrahydrate natCa(NO3)2·4H2O.
54 g of salt were dissolved 25 ml water. The salt density was 1.82 g/cm3 and the solution
was 1.55 g/cm3. The mass fractions used were ωsalt= 0.684 and ωwat= 0.316. The solid Ca
target was a foil of 1.26 m2 surface area and 2.5 mm thick, of 99.99% purity. An aluminium
foil of thickness 0.0125 mm thick is placed in front of the foil to protect the cyclotron from
vaporized Calcium [195]. The natural isotopic abundance of calcium used is listed in Table
4.4.
natZn
A liquid and a solid zinc target has been a simulated. The liquid target consisted of 75 g
zinc nitrate hexahydrate salt, natZn(NO3)2·6H2O , dissolved in 22.7 ml of water and 2.3 ml
of HNO3 1M. The salt density was 2.065 g/cm3 and the solution density was 1.56 g/cm3.
The mass fractions of salt, water and acid were ωsalt= 0.743, ωwat= 0.225 and ωacid= 0.032
respectively. The solid target was a foil of 32 mm diameter and 0.1 mm thickness of Cr
99.95% pure. The isotopic abundance of zinc is listed in Table 4.4.
natSr
The salt used was strontium nitrate natSr(NO3)2. 43.6 g of salt was dissolved in 25 ml of
water. The salt density was 2.98 g/cm3 and the final solution was 1.43 g/cm3. The mass
fractions of the salt and water were ωsalt= 0.636, ωwat= 0.364 respectively. The natural
isotopic abundance of strontium is listed in Table 4.4.
natY
The salt used as target was yttrium (III) nitrate hexahydrate natY(NO3)3·6H2O. 37.46g of
salt was dissolved in 33.735 ml of water and 2.265 ml of HNO3 1M. The salt density was
2.682 g/cm3 while the final solution and the final solution density was 1.43 g/cm3. The mass
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fractions of the salt and water were ωsalt= 0.504, ωwat= 0.043 respectively. The natural
isotopic abundance of Yttrium is listed in Table 4.4.
natCr
The target was a foil, 32 mm in diameter and 0.5 mm thick, of Cr 99.99%. The density and
isotopic abundance is listed in Table 4.4
natNi
The target was a foil, 32 mm in diameter and 0.25 mm thick, of Ni 99.98% pure. The density
of nickel and its natural isotopic abundance is listed in Table 4.4
Table 4.4 The composition of solid foil targets investigated [188].
Element Isotope Fraction % Diameter [mm] Thickness [mm] Density [g/cm3]
Ca
40 96.94
32 2.5 1.55
42 0.647
43 0.135
44 2.086
46 0.004
48 0.187
Zn
64 48.63
32 0.1 7.133
66 27.90
67 4.1
68 18.75
70 0.62
Cr
50 4.4
32 0.5 7.1850 83.853 9.5
54 2.4
Ni
58 68.07
32 0.25 8.902
60 26.22
61 1.114
62 3.63
64 0.93
4.3.2.5. Physics models
Geant4 provides multiple (data-driven, parametrized and theory-driven) physics models,
each applicable for different particle interactions at different energy levels. In this study in
order to model proton (and neutron) inelastic hadronic interactions in the relevant energy
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range, three physics lists were considered: Bertini Intranuclear Cascade High Precision
(QGSP-BERT-HP) model, Binary Intranuclear Cascade High Precision (QGSP-BIC-HP)
model and Binary Intranuclear Cascade All High Precision (QGSP-BIC-AllHP) model.
In Geant4 QGSP-BERT-HP and QGSP-BIC-HP are well established physics lists for low
energy applications, they use the ENDF/B-VII library but were not developed for predicting
radionuclide production. The reasons why QGSP-BIC-AllHP used with TENDL cross
section is suited for yield calculations have been discussed in Section 3.5.1.5.
Various options are available in Geant4 to describe electromagnetic interactions of
charged particles, gammas and optical photons for energies between 1 keV to 10 PeV.
They are called electromagnetic options 1, 2 and 3; each vary in terms of accuracy and
computation time taken. They were all tested and electromagnetic option 1 proved to
produce comparable results with the benefit of reduced computation time. Inside the target
volume no secondaries with a range of less than 1 mm are tracked. This has been done by
setting production thresholds at 1 mm for all particles inside the target volume.
4.3.2.6. Proton beam and Scoring
In this work, isotopic yields have been normalized to beam current on the target. Since col-
limated protons do not contribute to yields, but consume simulation time, a idealized pencil
beam was used in simulations. The parameters scored in the simulation were secondary nu-
cleons produced due to inelastic protons interactions, N and the number of protons incident
on the solid or liquid target, np. For isotopes with excitation states, the yield is presented as
the sum of the metastable and ground states. Inside the target volume, 100 µm and 1 µm
binning was used for the liquid and solid target respectively. To achieve yield uncertainties
of less than 1%, for the isotopic yield of interest, the number of primaries simulated was
between 109 to 1010.
4.3.2.7. External Cross sections
As the saturation yield is a function of the nuclear reaction cross section in the energy range
between the beam entering the target to the beam exiting the target or being stopped, see
[188], comparing the area under the cross section in this energy range between experimental
and TENDL cross sections is a good measure of the expected yield difference. Experimental
Nuclear Reaction Data cross sections were taken from EXFOR [151]. For reactions with
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multiple available sources, selections were performed taking into account error margins
and the number of data points available for the energy range concerned. The source(s) of
experimental reaction cross sections for every isotope investigated are listed in Table 4.7
under the reference column. After selecting appropriate cross sections, a curve was fitted
through the cross sections, and the area under the curve was calculated for both the EXFOR
and the TENDL cross sections. Comparisons between TENDL and EXFOR cross section
areas are shown in Table 4.7.
4.3.2.8. FLUKA
FLUKA is jointly developed by the European Laboratory for Particle Physics (CERN) and the
Italian Institute for Nuclear Physics (INFN) [166]. Background information about FLUKA
has been presented in Section 3.5.3. The FLUKA MC package version 2011.2b.6 was used
for the isotope production at the medical cyclotron. Isotope production in FLUKA is handled
inside the software package and is not accessible to the user for comparison. For more details
about the FLUKA model used in this work, see [188].
4.3.3. Experimental Data
18F, 52Mn, 55Co, 61Cu, 68Ga, 89Zr, and 94Tc
18F (t1/2= 110 mins, Eβ= 250 keV, 97% positron yield) is the most commonly used ra-
dioisotope in PET and the method of choice for its production is the 18O(p,n)18F reaction.
Measurements for 18F were taken during regular operation of the cyclotron, nine irradiations
varied between 10 to 21 mins with beam currents of 18 to 20 µA. The sample was measured
using an ionization chamber.
52Mn (t1/2= 5.6 days, Eβ= 244.6 keV, 26.9% positron yield) was produced by proton
irradiation of natural Cr foil target to induce the 52Cr(p,x)52Mn reaction. To prevent melting
a lower beam current of 2 µA was used for 5 hours. The foil was dissolved in concentrated
HCl. Gamma energy spectra of the dissolved foil was acquired to determine irradiation and
radiochemical yields [196].
55Co (t1/2= 17.5 hr, Eavg,β= 570 keV, 77% positron yield) was produced by proton
bombardment of natural nickel foils. Irradiations were typically 5 µA for 1 hour. The
purity of radio-cobalt was confirmed by gamma spectroscopy on a calibrated high purity
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germanium (HPGe) detector by observation of the characteristic peaks of 55Co (931.2 keV)
[197].
61Cu (t1/2= 3.4 hr, Eβ= 1.2 MeV, 61% positron yield) was produced by irradiated Zn
foil for 1 hour to induce the 64Zn(p,n)61Cu reaction. The beam current on the foil was
kept between 9.8 to 10.1 µA. The isotopic composition was measured via gamma-ray
spectroscopy.
68Ga (t1/2= 68 mins, Eβ= 836 keV, 88% positron yield) was produced by irradiated liquid
solution of zinc nitrate (natZn(NO3)2 ·6H2O) to induce natZn(p,x) reaction. The isotope has
fast target localization and blood clearance.
89Zr (t1/2= 78 hr, Eβ= 395.5 keV, 22.7% positron yield) is a long lived positron emitter
with a half life of 78 hours. It can be used for high resolution PET/CT imaging and can be
easily produced using 89Y as a target material. The three isotopes were diluted in water and
the radionuclide compositions measured with gamma-ray spectrometry[198].
To produce 94mTc (t1/2= 52 mins, Eβ= 2.438 MeV, 70.2% positron yield), natural-
abundance ammonium heptamolybdate tetrahydrate solution (((NH4)6-natMo7O24)·4H2O)
was irradiated for 1 hour. 94mTc was produced via the 94Mo(p,n)94mTc reaction [199]. It can
be used for PET imaging as a direct substitute for 99mTc [200].
13N, 44Sc, and 86Y
While 13N (t1/2= 10 mins, Eβ= 492 keV, 100% positron yield) can be produced using solid,
liquid or gaseous target [200], in TR13 it was produced via the 16O(p,α)13N reaction from
deionized water. The twelve irradiations were between 10 to 21 mins with beam currents of
10 to 20 µA. The sample was measured using an ionization chamber.
44Sc (t1/2= 3.97 hr , Eavg,β= 1.47 MeV, 94.3% positron yield) has been produced via the
44Ca(p,n)44Sc reaction with natural calcium metal by irradiation of the liquid target. The
final solutions were analyzed for elemental composition using an inductively-coupled plasma
mass-spectrometer (ICP-MS) [192]. This isotope has been produced using enriched calcium
in a 44CaCO3 solid target, however using a liquid target eliminates the need to dissolve the
solid target.
86Y (t1/2= 14.74 hr, Eβ= 660 keV, 31.9% positron yield) was produced via the natSr(p,x)
reaction. Beam currents used were between 5.9 µA and 8 µA for 68Ga and between 4.4 and
4.9 µA for 86Y, both isotopes were produced after 1 hour irradiation.
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4.4. Results
Experimental yields including the reference source, and Monte Carlo values used for com-
parison are listed in Tables 4.5 and 4.7. The yield has been decay corrected to EOB and
normalized for a beam current of 1 µA incident on the target for a 1 hr irradiation. From
the three physics lists investigated, QGSP-BIC-AllHP proved to be the best approximator for
our investigation. The QGSP-BERT-HP list failed to calculate any yield for 13N and 61Cu.
QGSP-BIC-HP did not calculate any 13N yield. This is because the following reactions are
missing from these physics lists: natO(p,x)13N and natZn(p,x)61Cu.
4.4.1. Assessment from Geant4
The calculated yields from Geant4 are compared with experimental yields in Table 4.5. The
performance of all three of the physics lists are assessed. The experiments were performed
multiple times with some performed particularly for this investigation ensuring experimental
errors were minimized.
As described in Table 4.5, QGSP-BIC-HP yield ratios were within limits for all isotopes
except 13N, 18F, 44Sc and 61Cu. The worst estimation was for 61Cu with 5.1 ± 0.2. QGSP-
BERT-HP yield ratios were within limits for all except 13N, 18F, 55Co, 61Cu and 94Tc. The
worst estimation was for 55Co with 0.07 ± 0.1. Overall the mean absolute deviation for
Binary Cascade and Bertini Cascade physics lists was 1.1 ± 1.2 and 0.6 ± 0.4 respectively
whereas for QGSP-BIC-AllHP, it was 0.7 ± 0.5, as shown in Table 4.6. From the table
it can be easily deduced that QGSP-BIC-HP performed the worst; while QGSP-BERT-HP
had the lowest error. However, its inability to take into account particular reactions made
it less reliable. Therefore QGSP-BIC-AllHP represented the best compromise between
accuracy and reliability for this investigation. Section 4.4.2 compares the performance of
QGSP-BIC-AllHP to FLUKA and experiments on an isotopic level.
4.4.2. Assessment of TENDL Cross Sections
The isotopic yields calculated in Geant4 are compared with measurements in Table 4.7. YF
refers to yield from FLUKA, YAllHP refers to Geant4 yields using TENDL libraries. Table
4.7 compares the simulated and experimental yields. The table also lists cross section ratios
obtained from Figure 4.3, where the TENDL and EXFOR cross sections (XT , XE ) have been
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Table 4.5 Isotopic yield ratio from different physics lists in Geant4.
Isotope Yexp [MBq/µA] No. of irrad. YAllHP/Yexp YBIC/Yexp YBERT/Yexp
13N 259±3 [188] 12 2.73 ± 0.01 0 0
18F 4920±60 [188] 9 0.53 ± 0.01 0.17 ± 0.01 0.28 ± 0.01
44Sc 4.9±0.3 [192] 3 2.1 ± 0.1 3.2 ± 0.1 0.8 ± 0.1
52Mn 900±100 [196] 5 1.1 ± 0.1 2.2 ± 0.1 0.6 ± 0.1
55Co 180±20 [197] 4 0.7 ± 0.1 1.05 ± 0.1 0.07 ± 0.1
61Cu 130±20 [188] 3 0.6 ± 0.2 5.1 ± 0.2 0
68Ga 138±2 [188] 3 0.84 ± 0.02 1.05 ± 0.03 1.06 ± 0.02
86Y 40±50 [188] 3 2.5 ± 1 1.7 ± 1 1.8 ± 1.0
89Zr 346±2 [188] 6 0.69 ± 0.01 0.98 ± 0.02 1.35 ± 0.01
94Tc 49±6 [199] 3 1.7 ± 0.1 1.8 ± 0.1 2.3 ± 0.1
Table 4.6 Estimation comparison between different physics lists in Geant4.
QGSP-BIC-AllHP QGSP-BIC-HP QGSP-BERT-HP
Mean absolute deviation 0.7 ± 0.5 1.1 ± 1.2 0.6± 0.4
expressed as ratios of each other. This has been referred to as cross section ratio later in
the chapter. The cross section ratio can be used to get an approximation of the theoretical
yields that can be expected when using the TENDL library. In Figure 4.3 the red shaded area
indicates the energy range of the proton beam inside the target and only the most probable
nuclear reaction cross section was taken into account. However, inMC code incident protons
and all secondaries are taken into account. For the reaction natSr(p,x)86Y, the cross section
for only the 86Sr(p,n)86Y reaction was taken into account as it was the majority contributor to
86Y yield. Contributions from other reactions are assumed to be insignificant to the overall
yield and hence not taken into account.
During experiments or routine isotope production, there are losses in the transfer system
and in vials prior to measurement for liquid targets and dissolved solid targets respectively.
There is also complex thermal and fluid dynamics of the liquid target during irradiation.
Monte Carlo codes do not take into account these aspects. Thus a factor of 2 seems to be
an acceptable limit for the ratio of saturation yield. The comparison between Geant4 and
experiment for the isotopes 18F, 44Sc, 52Mn, 55Co, 61Cu, 68Ga, 89Zr, and 94Tc fulfils this
criteria. Only for 13N and 86Y is the ratio between Geant4 and experiment larger than 2, and
none is smaller than 0.5.
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Table 4.7 Comparison between experimental (Yexp) to Geant4 (YAllHP) and FLUKA (YF ) saturation yields
and TENDL (XT ) with EXFOR (XE ) cross sections. Results from BIC-AllHP have been repeated again for
the convenience of the reader.
Isotope YF/Yexp YAllHP/Yexp XT/XE Ref.
13N 5.92 ± 0.01 2.73 ± 0.01 2.34 [149]
18F 1.66 ± 0.01 0.53 ± 0.01 0.94 [201]
44Sc 2.35 ± 0.06 2.1 ± 0.1 1.0 [202, 203]
52Mn 4.62 ± 0.11 1.1 ± 0.1 0.93 [204]
55Co 0.3 ± 0.01 0.7 ± 0.1 0.88 [205]
61Cu 3.13 ± 0.15 0.6 ± 0.2 0.55 [202]
68Ga 1.03 ± 0.02 0.84 ± 0.02 0.75 [206–209]
86Y 0.9 ± 1.3 2.5 ± 1 1.0 [210]
89Zr 0.87 ± 0.01 0.69 ± 0.01 1.22 [211–216]
94Tc 1.5 ± 0.1 1.7 ± 0.1 1.16 [202, 217]
4.4.2.1. 18F, 52Mn, 55Co, 61Cu, 68Ga, 89Zr, and 94Tc
Overall in this section, Geant4 is less than a factor of two away from the experimental yield.
It is also closer to the experimental yield than FLUKA for four isotopes (18F, 52Mn, 55Co,
61Cu, 68Ga), while FLUKA is closer for three isotopes (68Ga, 89Zr, 94Tc). In general the
comparison of the EXFOR cross sections with the TENDL cross sections used in Geant4
are within 25% except for 61Cu (0.55).
While the yield of 18F is under-calculated by a factor of 0.53 using Geant4, FLUKA
over-estimates it by a factor of 1.66. The EXFOR database [201] takes into account multiple
sources to provide a single unified table of cross sections that has been used. The 18O(p,n)18F
reaction has multiple resonances between 2 to 10 MeV with each experiment reporting
slightly different peaks. The phenomenon can be observed in Figure 4.3b.
For 52Mn, 55Co and 61Cu Geant4 performed better than FLUKA with ratios of 1.1, 0.7
and 0.6 (Figures 4.3d, e, f) against FLUKA’s 4.62, 0.3 and 3.13 respectively. For these
solid targets FLUKA appears to be less reliable than Geant4, with all yield ratios outside
acceptable limits. For these three isotopes, the yield ratios of Geant4 to experimental values
correlate very well to the cross section ratios between TENDL and EXFOR. For 52Mn the
yield ratio is 1.1 while the cross section ratio is 0.93, for 55Co, the yield and cross section
ratios are 0.7 and 0.88 respectively. 61Cu has a yield ratio and a cross section ratio of 0.6
and 0.55 respectively. The excellent level of agreement between the yield ratio and cross
section ratio indicates that while the Geant4 yield might be different from experiments, it is
a consequence of mismatching TENDL and EXFOR cross sections.
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For 68Ga the FLUKA performed better with a ratio of 1.03 against Geant4’s 0.84.
The cross section of 68Zn(p,n)68Ga reaction currently has significant discrepancies, hence
multiple sources were taken and a spline fit was used to make comparisons, see Figure 4.3g.
The TENDL library underestimates yields over the concerned energy range compared to
fitted EXFOR with a ratio of 0.75.
The yield for 89Zr was calculated more accurately using FLUKA than Geant4, the
respective yield ratios are 0.87 and 0.69 respectively. BothMonte Carlo codes under-estimate
the yield, with Geant4’s performance disagreeingwith theoretical expectations. The TENDL
cross section is higher thanmost EXFOR tabulated cross sections. This indicates that Geant4
should calculate a yield higher than experiments, however, the yield from both Monte Carlo
codes is lower than that of experiments. At this moment no explanation has been found why
the MC results challenge the cross sections shown in 4.3i.
Due toGeant4 and FLUKA’s inability to calculatemetastable isotopes, 94mTc is presented
as the sum of metastable and ground state. For this isotope, Geant4 calculates the yield with
a factor of 1.7 whereas FLUKA ratio is 1.53 and the cross section ratio is 1.16. Both MC
codes are able to calculate accurately the 94Tc yield, with FLUKA performing slightly better.
EXFOR and TENDL cross sections are compared in Figure 4.3j.
4.4.2.2. 13N, 44Sc, and 86Y
For these isotopes the deviation from the experiment is larger than a factor of two. For 13N
and 44Sc the deviation in the Geant4 simulation is smaller than for FLUKA, while only for
86Y is the deviation for Geant4 larger than for FLUKA. The EXFOR cross section area is the
same as the TENDL cross section area, except for 13N which has a very large cross section
ratio of 2.34.
13N yield was overestimated by a factor of 2.72 compared to a factor of 5.9 from FLUKA.
The yield between Geant4 and experiments of 13N results are not comparable at TR13 energy
levels as TENDLdoes not account for the resonance at 7.9MeV for the natO(p,x)13N reaction.
For energies above 8.5 MeV, the TENDL cross section vastly overestimates the yield and has
large disagreements with EXFOR. This is illustrated by Figure 4.3a. This phenomenon was
also observed when 13N was created inside a PMMA target under proton therapy conditions
in [173].
For 44Sc FLUKA performed worse with a ratio of 2.35 against Geant4’s 2.1. When
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comparing with experimental cross sections, the ratio for 44Sc is 1.05. While the agreement
between ratios is acceptable, EXFOR lacks sufficient good quality cross sections for the
reaction of interest at these low energy levels. The contribution of 44mSc to the total
production of 44Sc in Monte Carlo calculations is negligible for TR13 energy ranges.
Geant4 overestimates the yield of 86Y by a factor of 2.5 whereas the FLUKA yield ratio
is a very good 0.9. The yield of 86Y has been represented here as the sum of metastable
and ground states of 86Y. As a result, a minor overestimation from Geant4 is expected when
comparing simulated yields with experimental yields. The fitted tabulated cross sections
for 86Sr(p,x)86Y reaction were provided by the IAEA. The fit was performed using data
from [218] and [211], where the former had significant error bars contributing to a slightly
inaccurate smoothing of the fit, see Figure 4.3h. Compared to EXFOR, the TENDL data
had a marginally larger overall yield in the energy ranges relevant to this work. Despite
the discrepancy between the Monte Carlo codes, the ratio of Geant4 to experimental yields
agrees well with the ratio of cross sections for 86Y, as shown is Table 4.7 and Figure 4.3h.
4.4.3. Effects of Losses in the Transfer System
This section mentions how losses can occur during radioisotope production process. The
results presented so far does not include the thermal and fluid dynamic effects as they are
dependent on numerous factors such as target material, beam energy, beam current, and even
beam shape. The explanation of the interplay between these factors and the saturation yield
are beyond the scope of work for this thesis. Hence it is attempted to quantify the losses in
the transfer system and make adjustments to the yield calculations obtained in the previous
section. During experiments for producing 86Y, the hotcell was loaded with approximately
6.2 ml of salt solution and after irradiation 4 ml to 5 ml. This represented a loss of 27 ± 8%
when using liquid targets. On the other hand, for solid targets, a loss of 28% for solid targets
was reported in [219]. If these values are taken to be typical losses for their respective target
types, the saturation yield before extraction, i.e. the compensated experimental yield (YCE ),
can be calculated by adding the estimated losses to the yields presented previously, Yexp.
Table 4.8 compares the compensated experimental yield with the predicted Monte Carlo
yields. It can be observed that after the compensation, for FLUKA the following isotopic
yields are now outside of acceptable limits: 13N, 52Mn, 55Co, 61Cu. For Geant4 only the
yields for 18F and 61Cu were outside limits, the remaining eight isotopes were within limits.
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Fig. 4.3 Comparison of EXFOR and TENDL reaction cross sections for investigated isotopes. The proton
energies inside the target are indicated by the shaded regions. Sources of EXFOR cross sections are presented
in the reference column of Table 4.7.
4.5 Conclusions 133
Table 4.8 Comparison between compensated experimental (YCE ) to Geant4 (YAllHP) and FLUKA (YF )
saturation yields and TENDL (XT ) with EXFOR (XE ) cross sections. Results from XT/XE have been
repeated so that easier comparisons can be made.
Isotope YCE YF/YCE YAllHP/YCE XT/XE
13N 355 ± 3 4.32 ± 0.01 2.0 ± 0.01 2.34
18F 6740 ± 60 1.22 ± 0.01 0.4 ± 0.01 0.94
44Sc 7 ± 0.3 1.71 ± 0.1 1.5 ± 0.1 1.0
52Mn 1250 ± 100 3.3 ± 0.01 0.8 ± 0.1 0.93
55Co 250 ± 20 0.2 ± 0.01 0.5 ± 0.1 0.88
61Cu 181 ± 20 2.3 ± 0.2 0.4 ± 0.2 0.55
68Ga 189 ± 2 0.75 ± 0.02 0.6 ± 0.02 0.75
86Y 55 ± 50 1.0 ± 1.3 1.8 ± 1 1.0
89Zr 474 ± 2 0.63 ± 0.01 0.5 ± 0.01 1.22
94Tc 67 ± 6 1.1 ± 0.1 1.2 ± 0.1 1.16
4.5. Conclusions
A Geant4 simulation to model the liquid and solid target assembly for the TR13 medical
cyclotron at TRIUMF has been developed. The agreement between Monte Carlo simulation
and experimental yield measurements varies depending on the isotope considered. The
physics list QGSP-BIC-AllHP in Geant4 was investigated in this study, a new physics
option recently released with version 10.1. Its performance depends almost entirely on
the accuracy of the TENDL cross sections utilized by the user. In our work, TENDL has
proven to provide accurate cross sections for certain reactions, whereas for example the
16O(p,x)13N cross section currently is incorrect. For certain isotopes such as 68Ga, 86Y,
89Zr and 94Tc FLUKA was better able to calculate the yield. For 13N, 18F, 44Sc, 52Mn,
55Co and 61Cu Geant4 performed better, despite the MC models not accounting for thermal
effects or density changes in the liquid target or loss in the transfer system. Overall, in
our situation using Geant4 10.1 with the physics list QGSP-BIC-AllHP produced the best
compromised estimation for yield, with the mean absolute deviation for all targets of 0.7 ±
0.5 compared to 1.4 ± 1.6 for FLUKA. In addition, QGSP-BERT-HP and QGSP-BIC-HP
in Geant4 were also investigated. The QGSP-BERT-HP list managed to produce a slightly
lower mean absolute deviation of 0.6 ± 0.4, but failed to calculate any yield for 13N and
61Cu. QGSP-BIC-HP had a mean absolute deviation of 1.1 ± 1.2, failing to calculate any
13N yield. Due to these limitations, neither were further considered. When transfer loss is
taken into account, the mean absolute deviation for all targets using Geant4 10.1 with the
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physics list QGSP-BIC-AllHP was 0.5 ± 0.2 compared to 1.0 ± 0.9 for FLUKA. These final
findings are summarized in Table 4.9. For some isotopes differences are still large. A wider
range of isotopes needs to be examined for a better assessment.
Table 4.9 Comparison of mean absolute deviation
Mean absolute deviation Geant4 FLUKA
With transfer losses 0.7 ± 0.5 1.1 ± 1.2
Without transfer losses 0.5 ± 0.2 1.0 ± 0.9
Chapter 5
Conclusions
This thesis investigates two distinct topics of research, both with the common theme of im-
proving HT. First, by undertaking feasibility studies towards an ion beam facility at CERN
that could provide the necessary beam-time for needed radio biological experiments, pre-
sented in Chapter 2. The second part was investigating uncertainties present in Monte Carlo
packages when calculating radioisotope production both during patient treatment, Chapter
3, and for diagnostic purposes using medical cyclotrons in Chapter 4. Both contribute to
better patient care through better understanding of clinical effectiveness of HT and more
accurate treatment depth-dose verification. This chapter briefly summarizes the key findings
of this thesis and their contribution towards HT.
5.1. Design for the BioLEIR Beam Transport System
Today HT is becoming increasingly popular and despite the need for more clinical research
to reduce radiobiological uncertainties associated with such modality of treatment, available
beam-time for radio-biological has remained limited. A ion beam facility dedicated to
research could provide the much needed beamtime. Without the pressure of having to treat
patients, large systematic experiments could be carried out under controlled environments
such as studies of RBE for different LET conditions and on a large number of human cell types
with ion beams. The fact that such a facility is feasible with additions to the already existing
LEIR synchrotron facility at CERN allows for great savings in terms of infrastructure.
Designs for a common beam transport line from SS30 in LEIR to the adjacent South
Hall area, as well as for beamlines to vertical and horizontal experimental endstations were
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developed. The setup consists of 20 quadrupoles and 4 bending magnets. Based on start
parameters estimated from single particle tracking of the extraction process, the design
achieves pencil beam sizes FWHM of (5 ± .1) mm in the vertical beamline, and (5 ± .1) mm
in the horizontal beamlines. Both beamlines allow for broad beam irradiation with intensity
inhomogeneities less than ±2% across a sample area of 5 cm × 5 cm. Broad beam delivery is
based on non linear optics. This design has been presented in the yellow report, however the
council has decided that no funding shall be allocated to implement it. If the council’s stand
changes in the future and work is carried out, it should be focused in reducing the maximum
beam envelope in the transport system to reduce the aperture required and the beam losses
along the transfer line. Radioprotection/activation studies due to beam loss from different
ions along the lines must also be carried out. The facility would be limited to the irradiation
of cells, and never incorporate the treatment of patients. This limitation can be overcome
through collaboration with other treatment centres capable of carrying out patients trials.
5.2. PET Scanning of Ocular Melanoma
In Chapter 3 the proton therapy facility at TRIUMF (Vancouver, CA) was simulated using
Monte Carlo codes Geant4 (versions 9.6 and 10.1) and FLUKA (version 2011.2c.4). The
feasibility of using positron emitting isotopes from small tumour sites, such as ocular
melanoma, to determine the deposition of the proton dose was investigated. In our findings,
the range value extracted from the distal falloff at the 80% level and the 90% level were
found to agree within 1 mm with the measurement, fulfilling the clinical requirement.
A minor disagreement between the predictions of the two simulation codes and the
measurement was observed in the shape of the distal region. In particular, FLUKA tends
to underestimate the distal dose up to ≈6%, as opposed to an overestimation of Geant4 up
to ≈4% and 5% for version 9.6 and 10.1 respectively. The deviation from the measurement
may include effects of the ionization chamber response in the steep dose falloff region.
The discrepancies between the two Monte Carlo calculations are attributed to differences
in particle tracking and physics implementation between the two codes which are beyond
the purposes of this study. The deviation involves a spatial region of no relevance for PET
monitoring, i.e., at a penetration depth where positron emitters are no longer produced
because of the beam energy falling below the thresholds for nuclear reactions. We found the
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16O(p,x)13N reaction cross sections in TENDL to mismatch EXFOR, this caused an over
estimation of 13N activity at the end of range. We have proposed a possible solution to
take into account the energy spectrum of the proton beam and compensate for the excessive
PET activity. This technique has produced results that are consistent with FLUKA and
other physics in Geant4 for both RBP and SOBP. Even though QGSP-BIC-AllHP was able
to calculate energy deposition less accurately than QGSP-BERT-HP, its use of the TENDL
cross sections combined with the compensation technique resulted in the most accurate
prediction of PET isotope production inside the PMMA phantom.
Investigation with 3-D printed phantom revealed that Geant4 was able to accurately
predict β+ activity within error margins of the scanner. Beam misalignments of 1 mm could
also be accurately calculated from the detected β+ activity in the phantom. Future work
should be done with non symmetric or irregularly shaped collimators.
5.3. PET isotopes from a medical cyclotron
In Chapter 4 Geant4 was applied to the production of a number of established and emerging
positron emitting radionuclides such as 13N, 18F, 44Sc, 52Mn, 55Co 61Cu, 68Ga, 86Y, 89Zr and
94mTc, at TRIUMF. The Geant4 results have been compared with a secondMonte Carlo code
FLUKA as well as with experiments using the TR13 cyclotron with liquid and solid targets.
Saturation yield of the isotopes was assessed directly using Geant4 and compared with
other experimental and theoretical production cross sections. Direct assessment provided
an average saturation yield deviation of 0.7 ± 0.5 compared to FLUKA’s 1.4 ± 1.6. There is
reasonably good agreement between the simulated and the experimental data when QGSP-
BIC-AllHP was used, despite Monte Carlo not accounting for thermal effects, changes in
target density or loss in transfer system. By comparing TENDL and EXFOR cross sections,
it can be seen that the availability of accurate cross sections greatly affects the isotopic yield
calculations. The exception to this is 13N as the cross section of the 16O(p,x)13N in the
TENDL library is incorrect. Therefore, in order to improve the accuracy of calculations,
the cross sections available should be well known and widely accepted by the community.
Our findings support that the use of TENDL cross sections in Geant4 allows for best
approximation of saturation yield from the limited range of isotopes investigated. More
isotopes have to be investigated for a better assessment.
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